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ABSTRACT
I he Inlcrlcukin-2 Receptor a  chain (IL-2R a or CD25) plays an important role in B cell 
activation since it allows formation o f  the high affinity IL-2 Receptor and thus permits 
the B cell to respond to physiological concentrations o f  IL-2, IL-4 appears to be the sole 
cytokine which can induce IL-2R a in human tonsillar B ceils. In addition, polyvalent 
anti-Immunoglobulin antibodies and anti-CD40 antibodies can cause up-rcgulation o f  IL- 
2 R a  (Buiiinson c( a! 1995). However, although anti-Ig, anti-CD40 and IL-4 can increase 
IL-2R(x expression, this elevation in IL-2Ra levels does not necessarily facilitate 
subsequent B cell proliferation in the presence o f  IL-2. O f  the three, only anti-Ig 
antibodies, in combination with IL-2, could cause resting B cells to proliferate to a 
significant level.
Stimulation o f  human tonsillar B cells with polyvalent anti-Ig antibodies resulted in more 
than 80% o f  them acquiring an 11 v-2Ra-positive phenotype. IL-2Ra expression on 
different subsets o f  B cells present within the tonsillar population was studied by 
stimulating the cells with isotype-specific antibodies; anti-jii, anti-b or anti-y antibodies. 
Low concentrations o f  anti-p antibodies up-regulated expression o f  IL-2Ra, as did all 
concentrations o f  anti-y antibodies. However, high doses o f  anti-p antibodies and any 
dose o f  anti-b antibodies failed to up-regulate IL-2Ra. It is possible that the failure o f  B 
cells to respond to high doses o f  anti-p antibodies or to anti-b antibodies by increasing
IL-2R(x expression may cause these cells to become tolerised and thus prevent them from 
causing an auto-immunc response.
Expression o f  IL-2Ra on the cell surface can be related to events taking place at the 
promoter region o f  the IL-2Ra gene. There are at least three positive regulatory regions 
(PRR,-PRRiii) and two negative regulatory regions (NRE I and NRE II) within the 
promoter region and we chose to study PRR, and NREI because these regions are 
believed to be involved in the induction o f  IL-2Ra. It was found that an, as yet, 
unidentified protein, NRE-BP, which binds to NRE I plays a major role in controlling IL- 
2 R a  transcription when cells are stimulated via their slgM receptors. NRE-BP appears to 
be involved in the silencing o f  the IL-2Ra gene and remains bound to the promoter when 
the B cells arc stimulated with high concentrations o f  anti-p antibodies. At low 
concentration o f  anti-p antibodies, binding o f  NRE-BP to NRE I is attenuated. Although 
anti-y antibodies up-regulate expression o f  IL-2R a on the cell surface, anti-y antibodies 
have no effect on the binding o f  NRE-BP to the promoter. Previous studies have 
discovered differences in signalling through the slgM and sIgG complexes (Roifman el al 
1987; Law d  aJ 1992; Shu e! al 1994). Now we have determined that slgM and sIgG 
appear to act differently in the regulation o f  IL-2Ra and that the binding o f  NRE-BP to 
NR 17 I is important in this variation.
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Chapter One 
Introduction
1.1 B Cell Development
1.1.1 The Differentiation Pathway o f  B Lymphocytes.
B lymphocytes are derived from the pliiripotent stem cells that give rise to the 
crythroid, myeloid and lymphoid lineages o f  blood cells (Smith ef al 1991). During 
embryogenesis, B cell development occurs in waves, firstly in the placenta and 
embryonic blood, later in the foetal liver and finally in the spleen and bone marrow 
(Mclchers 1979). Millions o f  newly formed lymphocytes leave the bone marrow daily 
(Osmond 1993). Each o f  these cells either multiplies and differentiates or dies 
depending on the nature, timing and location o f  interactions with other cells o f  the 
immune system (Liu ei al 1992; Parker 1993).
B lymphocyte development has traditionally been divided into two phases (Figure 
1.1). The first phase is thought to be independent o f  foreign antigen and takes place in 
the bone marrow. The first descendent o f  the pliiripotent stem cell that is committed to 
the B lineage is termed a pro-B cell. These do not express B lineage specific markers 
and have not yet begun to rearrange the Immunoglobulin (Ig) genes (Davidson et al 
1984, 1988; Muller-Sieberg el a l 1986). The next stage is the development o f  the pre- 
B cell. 'Fhese express the pre-B cell Receptor (pBCR) (Reth 1992; Melchers el al 
1995) which contains the Immunoglobulin (Ig) heavy chains like a mature B cell 
Receptor but with the light chains replaced by “surrogate” chains, and V pre-B 
(Sakaguchi and Melchers 1986; Kudo and Melchers 1987; Schiff c/ al 1992). The 
Antigen -Independent phase terminates when Ig is expressed from rearranged Heavy
(H) and Light (L) chain genes on the surface o f  immature B cells and occurs in the 
periphery. At this point B cells with Ig specific for self-antigens are either deleted 
(Nemazee and Burki 1989) or anergised (Goodnow el al 1988).
Figure 1,1 The B Cell Development Pathway.
Reproduced from Cush ley and Harnett (1993).
4u
>DAQTQfDDINNS3Ow
•SfDDa
S
In Ihe second, A ntigen-Dependent phase, the remaining surface Ig ' cells can be 
positively selected in the peripheral circulation and colonise the secondary organs. 
Depending upon the nature o f  the antigen encountered, these cells can be stim ulated 
cither independently o f  T cells or with the co-operation o f helper T cells ( reviewed by 
M clchcrs 1989).
The first B cell which has the opportunity to encounter antigen is the mlglVf 
“ Immature"’ B cell. This has stable expression o f  IgM at the B cell surface.
S tim ulation o f the antigen receptor (AgR) on immature B cells results either in anergy 
or deletion o f the clone (Scott el a l 1987; G oodnow el al 1988; Nem azee and Burki 
1989; Alez-M artinez el al 1991). Thus B cells which produce AgRs which bind to se lf 
tissue com ponents are removed, avoiding the secretion o f  self-reactive antibodies 
which could lead to auto-im m une disease.
The next stage in developm ent is that the immature B cell expresses mIgD. This 
m lgM ' /m IgD " B cell is regarded as “m ature” and can react positively to activation 
via the AgR. In the case o f  thym us-dependent antigen, the response o f  the B cell is 
determ ined not only by antigen but also by T cell-derived cytokines. There are a 
num ber o f  possibilities. Firstly the activated B cell may become a plasm a cell; these 
express no m ig and are solely devoted to the production o f  the secretory form o f  IgM. 
Alternatively, the B cell may become a m em ory B cell. These cells form a m inor 
subset o f  B cells and can be distinguished by their somatically m utated antibodies, 
lack o f  surface IgD and characteristic surface markers. They are m ostly resting, long- 
lived and recirculating and m any have switched isotype from IgM to IgG, IgA or IgE.
Recent evidence suggests that these cells may home preferentially to mucosal tissues 
(Liu e/ a! 1995) where they can rapidly respond to incoming pathogens.
1.1.2 Clonal Selection
I’hc Clonal Selection Theory (Burnet 1959) postulates that B cells express their 
antibody as a surface receptor and can thus be selected by antigen. Each B lym phocyte 
expresses a receptor o f  a single antigen specificity; i.e. antigen receptors are clonally 
distributed. In mice and humans, different B cells express different receptors at the 
beginning o f  their developm ent. This is unlike the situation which occurs in chicken B 
cell developm ent. Here, all cells initially express the same or sim ilar receptors and 
diversity is generated through subsequent rounds o f gene conversion during 
proliferation (Reynaud el al 1994).
In all vertebrates the genes encoding antibody variable (V) regions are assem bled 
during B cell developm ent from gene segments termed V, D and J (for the Igh locus) 
or K or X (for the Igk and Igl loci) through a process o f site-specific recom bination.
( fonegaw a 1983; A lt el al 1987). This involves the introduction o f  double-strand 
breaks at specific recognition signal sequences adjacent to the V, D and J elem ents by 
the recom bination-activating genes RAG-1 and RAG-2 (Oettinger el al 1990;
M cBlane el al 1995), followed by double strand repair (Roth el a l 1995). N um erous 
V, D and .1 gene segments are present in both the Igh and the two Igk and Igl loci.
Each cell jo ins a different set o f  segm ents so that different cells express dilièrent 
receptors from the beginning. To increase diversity further, there is variation in the
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recom bination breakpoints and nucleotide deletions and insertions at those points (Alt 
and Baltimore 1982).
1.1.3 The Antibody Response
Im m ature B cells expressing conventional surface IgM receptors exit the bone m arrow 
and m igrate to the periphery. Here they can become mature (i.e. are positively 
selected) or undergo apoptosis or anergy. Three-quarters o f  the peripheral B cell pool 
are IgM 7 IgD ' mature B cells, the main cells involved in primary imm une responses. 
The rem aining cells are m emory cells and B-1 cells (Hayakawa ef al 1983). B-1 cells 
possess characteristic cell surface m arkers such as CD5 and Mac-1 (Hardy ei a l 1994). 
Early in ontogeny, they dom inate the B cell population but later are confined to 
participation in local gut and lung-associated immune responses. The origin o f  the 
cells is controversial; there is evidence that they represent an ancient separate cell 
lineage (H erzenberg e( al 1986) and are involved in “natural defence” against 
com m on pathogens in the environm ent (Herzenberg e( al 1986; Kocks and Rajewsky
1989).
Induction o f  antibody responses in B-1 and conventional B cells (B-2 cells) requires 
presentation o f  antigen in im m unogenic form. M ultimeric antigens can cause B cells 
to proliferate and differentiate into antibody secreting plasm a cells by efficient cross 
linking o f  the antigen receptor (M ond el al 1995). Both B-1 and conventional B cells 
participate in these T-cell-independent responses (Forster and Rajewsky 1987), 
producing mainly IgM and lgG3 antibodies.
T -cdl-dependent responses (Clark and Ledbetter 1994) are elicited by protein 
antigens which cannot them selves trigger an antibody response. The antigen is first 
com plexed by natural antibodies and com ponents o f  the com plem ent system  and 
presented to B cells on antigen presenting cells (APC). It is taken up by the B cell 
through its B cell Receptor Com plex (BCR) and processed; i.e. fragm ented into 
peptides inside the cells. These are then presented to T helper cells by class II 
m olecules o f  the M ajor H istocom patibility Com plex (M HC), triggering the T cell 
response. 1 -cell-dependent responses generally involve conventional B cells and it is 
in these responses that such B cells generate immunological m em ory and a new 
antibody repertoire by somatic hyperm utation o f  their antibody genes.
1.1,4 The G erm inal Centre Reaction
Affinity m aturation and memory generation take place in a specialised 
m icroenvironm ent known as germinal centres (M acLennan 1994). These arise inside 
follicles composed o f  naive B cells, on imm unisation with T-cel 1-dependent antigens, 
fhcrc is rapid expansion o f  an oligoclonal population o f  antigen-activated B cells in a 
highly organised environm ent whose main other components are antigen-specinc 
helper T cells (Fuller et al 1993; Zheng e( al 1994) and Follicular Dendritic Cells 
(FDC). FDCs are long lived cells o f  indeterm inate origin (Hum phrey and Sundaram 
1985). They carry antigen complexed to antibodies and com ponents o f  the 
com plem ent system  on their surface. Antigen can be retained in its native form on 
FDCs for at least one year. This form o f  antigen presentation, with signals delivered 
by the 'F helper cells is thought to be critical for the selection and m aturation o f  high
affinity memory cells. Interaction o f  B cells and FDCs leads to the formation o f  a 
finely structured germinal centre. Initially, rapid B cell proliferation gives rise to a 
“dark zone” which is relatively devoid o f T cells; these proliferating B cells are 
known as centroblasts. The m aturing B cells then migrate to the “ light zone” which is 
abundant in FDCs with some T cells and become known as centrocytes. Som atic 
hyperm utation is set in m otion w ithin the dark zone and high affinity “m utants” are 
selected within the light zone (Mol 1er 1992). This process occurs only during 
germinal centre developm ent and at this point there is evidence o f m assive cell death 
by apoptosis. B cells with high affinity receptors for antigen are subsequently 
“selected” and switch from producing IgM to another Ig class.
Unlike naive, resting and memory B cells (Pascual et al 1994), proliferating germinal 
centre cells express low levels o f  Bcl-2 and are programmed to die unless rescued by 
signals involving antigen and antigen-specific T cells (M acLennan 1994). Thus cells 
expressing high affinity antibodies can be positively selected in the m icroenvironm ent 
o f the germinal centre. Germinal centre B cells can also be negatively selected by 
ligands binding to their BCR. They undergo rapid apoptosis on encountering antigen 
in the absence o f  T cell help (Linton et al 1991 ; Rathmell et al 1995; Pulendran ei al 
1995; Flan et al 1995). This m echanism  may further minimise the risk o f  autoreactive 
m utants. Following this selection process, further centrocyte m aturation occurs and 
the cells will either become plasm a-blast cell type cells secreting antibody or become 
long-lived memory cells, ready to perform the functions for which they have been 
selected.
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1.2 B Lym phocyte Antigen Receptor Com plex
The B cell antigen Receptor Com plex (BCR) consists o f  a m em brane-bound 
im m unoglobulin m olecule non-covalentiy associated with 2 accessory m olecules, Ig- 
a  and Ig-p, which occur as disulphide linked heterodimers. The BCR belongs to a 
class o f  receptors which includes the T-cell Receptor (TCR) and receptors for the Fc 
regions o f  IgE (FceRI) and IgG (FcRyllla) (reviewed by Cam bier and .lensen 1993). 
These receptors possess a com plex hetero-oligom eric structure where ligand binding 
and signal transduction are com partm entalised into distinct receptor subunits. In the 
BCR, antigen is bound via m em brane bound Im m unoglobulin (mIg) m olecules and 
the m ig-associated “transducer” structure is comprised o f Ig -a  and Ig-f3 (recently 
designated CD79a and CD79b, respectively).
d1ie m ig m olecules are expressed on normal peripheral B cells at lO'-lO^ copies per 
cell. They differ from secreted antibody molecules in their heavy (FI) chain carboxy 
term inus which contains spacer, transm em brane and cytoplasmic sequences not found 
in the secreted m olecules (Rogers et al 1980; Alt e! al 1980). All im m unoglobulin 
isotypes can occur as receptors but on the vast m ajority o f  peripheral B cells (-90% ) 
only m lgM  and m IgD are found (Abney el al 1978). In resting high density B cells 
mIgD molecules are expressed at a 3-10 fold higher level than m lgM  m olecules 
(Havran e( al 1984).
Much effort has been made to define the structure o f  m ig but the size o f  the 
cytoplasm ic dom ains rem ains unclear. The m em brane form o f  the p  heavy chain (p,„) 
was predicted to have 25-26 hydrophobic amino acids, which traverse the bilayer in a 
helical fashion, and a charged cytoplasm ic tail o f  only 3 residues (I,y s-V al-fys) (Kytc 
and Doolittle 1982). This small cytoplasm ic tail was thought to be present for stable 
m em brane insertion, being too small to express any intrinsic catalytic activity. In 
contrast, the Klein, Kanehisa and Delisi algorithm (Klein ci a/ 1985) predicts that the 
cytoplasm ic tail may consist o f  1 1 amino acids. If correct, these m ig  heavy chains 
have potential sites for interaction with cytoplasm ic molecules; however there has 
been little evidence o f  this to date and it is generally accepted that the cytoplasm ic tail 
o f  pm is only three residues long.
1.2.1 The Detection o f New Com ponents o f the BCR
Since m ig m olecules have such limited cytoplasm ie structures it was proposed that 
the BCR must transduce signals via associated molecules. The first indication that the 
B cell antigen receptor needed accessory molecules came from transfection 
experim ents using m yelom a cell lines (Hornbach ei al 1988a, b, 1990). These cell 
lines do not express m RNA encoding the m em brane-bound form o f  im m unoglobulin. 
A m yelom a M chain loss variant cell line, .I558L, was transfected with vectors 
containing the secreted (ps) and m em brane (pm ) forms o f the p  heavy chain and the 
resultant transfectants analysed. .I558Lps cells produced and secreted large amounts 
o f  IgM antibodies whereas the ,I558Lpm transfectants produced m lgM  in the
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cy toplasm  but not on the cell surface, thus indicating that the cells lack a factor for the 
surface expression o f  m lgM  (S itia ei al 1987; Hombach e! al 1988a, b). Further 
studies isolated a spontaneous surface m lgM ' variant (,I558Lpm3) o f  the J558Lpm  
transfectant. Analysis o f  these two lines revealed that surface m lgM  in J558Lpm 3 
cells, but not in J558Lpm  cells, was associated with a disulphide linked heterodim er. 
This heterodim er consisted o f  two glycoproteins with m olecular m asses o f 
approxim ately 34kDa and 39kDa and were called Ig -a  and Ig-p, respectively.
A different approach to the subject was taken by Campbell and Cam bier (1990). They 
observed that ligation o f  a small proportion o f mlgM  or mIgD leads to the inactivation 
o f  the signalling ability o f  the rem aining receptors. In other system s such 
desensitisation is m ediated by receptor phosphorylation. However, the cytoplasm ic 
tails o f  m lgM  and m lgD do not contain such potential phosphorylation sites. Thus, an 
hypothesis was formed that m ig desensitisation is mediated by phosphorylation o f  its 
transducer complex. This was investigated by stimulating [^ ‘Pj-A TP-Ioaded B cells 
with anti-IgM , anti-IgD, PM A and Alum inium  Fluoride. The cells were lysed and m ig 
and its associated m olecules im m unoprecipitated. A complex o f  three inducibly 
tyrosine-phosphorylated glycoproteins was co-purified with m lgM . This com plex 
consisted predom inantly o f  a disulphide-linked heterodim er o f  32 and 37kD a proteins 
and, at lower proportion (-10% ), a disulphide-linked dimer o f  34 and 37kDa proteins. 
The 32kDa protein was found to be identical to Ig -a  and the 37kDa protein was found 
to be identical to Ig-p.
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Subsequently, experim ents were perform ed to identify which genes encoded Ig -a  and 
Ig-p. Am ino-term inal sequences were obtained from the Ig -a /Ig -p  hetero-dim er 
expressed in m lgM ' J558L|.im3 cells (Hom bach el al 1990) as well as from pp32, 
pp34 and pp37 co-purified with m lgM  isolated from normal spleen cells (Campbell el 
al 1991). pp32 and Ig -a  were found to have an identical am ino-term inus to the 
deduced protein sequence o f  the mb-1 gene. pp34, pp37 and Ig-p share an identical 
am ino-term inus with the deduced protein sequence o f  the B29 gene. Further evidence 
was obtained from W estern blots; antibodies produced against 3 peptides determ ined 
from the sequence o f m/?-/ reacted specifically with pp32. S im ilar experim ents with 
B29, pp34 and pp37 provided strong evidence that pp34 and pp37 are products o f  the 
B29 gene. Thus, the data indicate that pp32 and Ig -a  are identical and are products o f 
the mh-1 gene. Also, pp37 and Ig-P are identical and are products o f the B29 gene. 
pp34 also has extensive hom ology to the B29 gene product and has been designated 
Ig-y. The difference in m olecular weight between pp34 and Ig-P is not a function o f  
phosphorylation or glycosyiation (Reth el al 1991). Ig-y is a truncated form o f Ig-P 
lacking the C-terminus. It is expressed on low density splenic B cells and bone 
m arrow cells.
W hile all classes o f  sig associate w ith apparently identical heterodim ers, there are 
some differences in the glycosyiation status o f  the Ig -a  chain. The stoichiom etry o f 
the com plex formed between sIg and the Ig -a/Ig -p  heterodim er is unknown. 
However, the requirem ent o f  Ig -a  and Ig-P expression for sig transport indicates the 
ratio is at least 1:1 and the bilateral symm etry o f  sig would suggest a ratio o f  2 :1.
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Recent studies have investigated the role o f  m ig in receptor assem bly, signal 
transduction and internalisation, m ig associates with Ig -a  and Ig-P via the pm  chain 
Cl 13 and/or CH4 dom ains as well as the transm em brane spanning region (W illiam s et 
al 1990; Hombach el al 1990). There is a polar patch (residues TTA ST) in the 
transm em brane region o f pm  which signals retention o f  m lgM  within the endoplasm ic 
reticulum (ER) unless Ig -a  and Ig~p are also expressed (W illiam s et al 1990). This 
indicates that Ig -a  and Ig-p may engage this site, facilitating transport o f the receptor 
through the ER. The C term inus o f the pm  chain is not necessary for the assem bly and 
transport o f the receptor (Parekh e{ al 1992). However, it has been implicated in 
receptor-m ediated signal transduction. Point m utations in the C-term inus o f pm  do not 
affect association with Ig -a  and Ig-p but do ablate antigen-induced signalling 
(Pleim an et al 1994b). The core o f  this region (residues YSTTVT within the 
transm em brane region) was defined as being o f  particular importance. This sequence 
is predicted by the Klein, K anehsisa and Delisi algorithm as being cytoplasm ic and 
therefore is capable o f  interaction with a cytoplasm ic effector. This suggests that the 
function o f m ig extends beyond antigen binding and that the C-term inus o f  the pm  
chain could play a critical role in signal transduction.
The two most likely functions for Ig -a  and Ig-p are assembly and transport o f  the B 
cell antigen receptor complex and signal transduction. As stated previously, 
transfection studies with the .I558L cell line showed that Ig -a  was m andatory for 
surface expression o f  all Ig isotypes (Sitia et al 1987; Hombach ei a l 1988a, b). This 
is true for m lgM  but subsequent experim ents have shown that IgD and some 
subclasses o f IgG can be expressed at the cell surface without Ig -a  (Venkitaram an e!
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al 1991). There has been much interest in the structure and function o f  the m ig 
associated proteins. Both have extracellular dom ains and are structurally very sim ilar 
to CD3y, Ô and e. Each contains the single extracellular Ig-like dom ain, a single 
transm em brane region and cytoplasm ic tails o f  48 (p) and 61 (a )  amino acids and are 
m em bers o f  the Ig superfam ily (Herm anson el al 1988; Sakaguchi el al 1988). The 
site o f  interaction between the Ig-a/Ig-P  hetero-dim er and pm  is unclear. The 
transm em brane dom ains o f  Ig -a  and Ig-p contain a glutamic acid residue and a 
glutam ine residue, respectively. These residues may interact either with each other or 
with the polar patch m otif (TTAST) which is present in the pm  chain transm em brane 
region. As stated earlier, expression o f  this TTA ST m otif appears to signal 
intracellular retention o f m ig unless associated with the Ig-a/Ig-p  hetero-dim er 
(W illiam s e! al 1990).
Studies have shown that the cytoplasm ic tails o f  Ig -a  and Ig-p possess independent 
signalling functions. They differ quantitatively in their ability to activate specific 
signalling events; thus signalling events are compartm entalised into different chains. 
It was recognised initially by Reth (1989) that Ig -a  and Ig-p each contain a sequence 
m otif o f  about 26 amino acids which is com m on to the cytoplasm ic tails o f  other 
transducer chains including TCR(^, TC R q, CD3c, CD3y, CD35, FceRl p, FccRIy, 
human FcyRIIa and potentially CD22 (LePrince el al 1993). This moti f has variously 
been called the Antigen Receptor Flomology M otif 1 (A R H -I) (Clark 1993), the 
Antigen Recognition Activation M otif (ARAM ) (W eiss 1993), and the Tyrosine- 
based Activation M otif (ITAM ) (Klausner and Same Ison 1991). The m otif is 
characterised by the presence o f  6 conserved amino acids in the sequence (where X is 
an unconserved amino acid):
1 6
0 /E—X," D/E—X2 »- y—X, -- L/I— X j y—X^ "L/A
1 1 1  is m otif can activate signal transduction events such as protein tyrosine kinase 
activation, Ca"' m obilisation and/or lL-2 production (reviewed in W eiss and Liltman 
1994). Also, the m otif exhibits binding activity for enzymes including m em bers o f  the 
src family o f tyrosine kinases (Clark el al 1992).
1.2.2 Are There O ther Receptor Com ponents?
Ig -a and Ig-p are the most easily recognised proteins associated with m ig. However 
other receptor com ponents may exist. As noted previously, there is a second gene 
product, Ig-y which is sim ilar to Ig-p but with a truncated cytoplasm ic tail (Friedrich 
e( al 1993). M ost o f  the ARH-1 m otif is m issing from this m olecule, a fact which may 
have a significant effect on receptor function. This m olecule replaces Ig-p on 
developing B cell such as bone m arrow cells.
CD22, a 135kDa B cell restricted glycoprotein, is a possible com ponent o f  the 
A ntigen Receptor Com plex (Clark 1993). Am ong normal B cells, only those that are 
CD22 positive can m obilise Ca^ in response to Ig cross linking and m ig-m ediated 
signalling can be enhanced by ligation o f  CD22 (Pezutto e( al 1988, 1987). Follow ing 
cross-linking o f  m ig CD22 becomes rapidly phosphorylated. CD22 can also be 
coim m unoprecipitated with m ig under certain circumstances (Schulte e( al 1992; 
LePrince ei al 1993). Finally there are a num ber o f  YXXL sequences that are
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rem iniscent o f the ARH-1 m otif (Stam enkovic and Seed 1990; Torres e( al 1992). 
However, although CD22 obviously plays a role in BCR function, evidence o f  its 
association with the complex rem ains circumstantial.
it has been suggested that CD45, the m ajor lymphocyte m em brane protein tyrosine 
phosphate phosphatase, is a com ponent o f  the B cell antigen receptor complex. 
Expression o f this surface protein is essential for m lg-m ediated signalling leading to 
calcium  m obilisation, p 2 1 activation and proliferation (Justem ent ei al 1991;
Kishihara ei al 1993). CD45 knockout mice do not respond to ligation o f  the BCR ( 
K ishihara ei al 1993). In vilro CD45 dephosphorylates Ig -a  and Ig-p and in vivo 
cross-linking o f  m ig and CD45 enhances dephosphorylation o f  Ig -a  and Ig-p 
(Justem ent ei al 1991). Finally, extensive cross-linking o f CD45 alone causes 
enhanced phosphorylation o f  Ig -a  and Ig-p (Lin ei al 1992). However it seems most 
likely that CD45 is not a part o f  the BCR com plex but is present at a high 
concentration in the plasm a m em brane to maintain equilibrium between 
phosphorylated and non-phosphorylated substrates.
There has been a report by Y ellen-Shaw and colleagues o f a 56kDa protein associated 
with m lgM  in mature, but not immature B cells (Yellen-Shaw and M onroe 1992). It 
occurs as a disulphide-linked hom odim er, p56-p56, associating with m lgM  in a non- 
covalent manner. It does not appear to associate with mlgD. Other ~50-60kD a species 
have been recorded, although all seem to vary in some way from p56 described by 
Yellen-Shaw (Gold ei al 1991; Petrini ei al 1983; Koch and H au stein 1983). The 
function o f  these proteins is unknown.
1.2.3 Co-Reccptors o f the BCR.
It is clear that, as with T cells, the response o f  B cells to antigen will be m odified by 
co-receptor molecules. Three o f  these m olecules are important: the hum an FcyRIIb, 
the CD19/CD21 (CR2) complex and CD22. The involvement o f  these m olecules can 
be negative in some cases and positive in others. As discussed earlier, CD22 may be a 
com ponent o f  the BCR complex. However, since CD22 also exhibits ligand binding 
specificity, its function could also be described as that o f  a co-receptor. The hum an 
FcyRIIb is preferentially expressed on B cells and is a 40kDa m em ber o f  the Ig 
superfam ily. It has two extracellular Ig-like domains, a single transm em brane 
spanning region and a 44-76 amino acid cytoplasm ic tail ( reviewed in Ravetch and 
K ind  1991 ). Experim ents have determined that when FcyRIIb is co-ligated in antigen 
receptor signalling there is prem ature term ination o f  extracellular calcium  influx. This 
is as a consequence o f a term ination o f  IP^ generation (Bi jsterbosch and Klaus 1984) 
due to the ending o f  sustained Phospholipase C (PEC) activation (W ilson ei al 1987). 
Since PEC is regulated by tyrosine phosphorylation it is likely that the action o f  
FcyRIIb is mediated by an alteration either in protein tyrosine kinase or protein 
tyrosine phosphatase activity.
Ligation o f  the CD19/CD21 complex has the opposite effect to that o f  FcyRIIb 
ligation. CD21, also known as Com plem ent Receptor 2 (CR2), is a 140kDa protein, 
'fhe  extracellular dom ain o f  this protein is made up o f 15 short consensus repeats 
com m on in com plem ent receptor families (M atsumoto ei al 1991 ; Tanner ei al 1987;
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M oore ef a! 1987). There is a single Iransmem brane region and a 34 amino acid 
cytoplasm ic tail. Am ong the natural ligands for CD21 are iC3b, C3dg, CD23, IFN -a 
and the Epstein-Barr virus (EBV) (Bohnsack and Cooper 1988; Dosch ef al 1990; 
Aubry ei al 1992; Delcayre ei al 1991).CD21 exists as part o f  an oligom eric com plex 
made up o f  CD 19 which is a 95kDa glycoprotein mem ber o f  the Ig superfam ily, Leu- 
13, which is a 16kDa cell surface protein and TAPA-1, a 20kDa serpentine m olecule 
containing 4 transm em brane regions (Bohnsack and Cooper 1988; Andria ei al 1991 ; 
Bradbury ei al 1992; Zhou ei a l 1991). Both L eu-13 and TAPA-1 are expressed 
ubiquitously whereas CD19 and CD21 are found on B cells only (M oore ei al 1987; 
Tedder ei a l 1983; Oren ei al 1990; Jaffe ei al 1989; Chen ei al 1984; Evans ei al
1990). Involvem ent o f  this co-receptor com plex in BCR-mediated signalling causes 
enhancem ent in B cell activation (Carter ei a l 1991; Carter and Fearon 1992) and the 
m echanism  by which the co-receptor signals is well understood. TAPA-1 and CD19 
have extended cytoplasm ic structures and are proposed to be the signal transducing 
subunits (M atsum oto ei al 1991). CD19, which binds to the tyrosine kinase lyn, is 
strongly phosphorylated on BCR cross linking (van Noesel ei al 1993; Tuveson ei al 
1993). There are six tyrosine residues flanked by acidic amino acids in the 
cytoplasm ic tail o f  CD19; it is likely that these are the tyrosine kinase substrate sites. 
These sequences, if  phosphorylated, are consensus binding sites for SH2 dom ain 
containing cytoplasm ic efiectors. Antigen receptor ligation phosphorylates these sites 
leading to binding o f Phosphoinositide-3-K inase (PI-3-Kinase) (Songyang ei al 1993). 
Previous studies suggest that binding o f  phosphorylated CD19 by PI-3-Kinasc may 
lead to enzyme activation (Shoelson ei al 1993; M yers ei al 1992). C D 19’s 
cytoplasm ic tail is necessary for CD 19 enhancem ent o f  antigen receptor-m ediated
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calcium m obilisation. However, some CD 19 signalling is independent o f  its 
cytoplasm ic tail. For example, hom otypic adhesion and growth inhibition are 
dependent on the transm em brane dom ain which determines the interaction with 
TAPA-1 (Bradbury ei al 1993). As stated previously, CD 19 is o f  particular im portance 
in antigen receptor-mediated signalling because coligation o f  CD 19 and BCR reduces 
by 2 orders o f m agnitude the num bers o f  antigen receptors that must be ligated to 
induce B cell proliferation (Carter and Fearon 1992), Thus, antigen in the form o f 
com plexes containing com plem ent com ponents may hyperstim ulate B cells by virtue 
o f  m Ig-CR2 cross-linking.
1.2.4 BCR M ediated Signal Transduction
The earliest detectable event following cross-linking o f the BCR is an increase in 
protein tyrosine phosphorylation. This is due to the activation o f  m ultiple protein 
tyrosine kinases. These include m em bers o f  the src  family including blk, fyn, lyn and 
Ick (Burkhardt ei al 1991; Yam anishi ei al 1992) and the m ore distantly related syk 
(previously denoted Ptk72) (Hutchcroft el al 1991, 1992; Taniguchi ei al 1991; 
Yam ada ei al 1993). The .vrc-family kinases interact with the resting BCR prim arily 
via the Ig -a  chain (Clark ei al 1992) which associates with the first 10 N-term inal 
residues o f  the kinase (Pleiman ei al 1994a). The difference in the abilities o f  Ig -a  and 
Ig-[3 to bind the .svr-family kinases is due to a sequence o f 4 amino acids, DCSM , 
within the ARH-1 m otif o f  Ig -a  ( the equivalent sequence in lg-{3 is QTAT) (Clark ei 
al 1994). Exchanging these sequences can switch the binding ability o f  Ig -a  and Ig-fJ.
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Therefore DCSM seems to determ ine the ARH-1-m ediated binding o f .src-family 
kinases to the resting receptor.
Imm ediately following BCR ligation the Ig -a  and Ig-p ARH-1 motifs are 
phosphorylated on tyrosine residues in the amino acid sequences YEGLN and YEDI. 
On phosphorylation o f these residues, there is an approximately 20 fold increase in 
binding o f  .v/r-family kinases which triggers kinase activation (Clark e! al 1994). The 
enhanced association is due to the binding o f  .src-family kinase SH2 dom ain regions 
to the phosphorylated tyrosine residues in the ARH-1 m otif and the concom itant loss 
o f  binding to the 10 N-terminal residues (Pleim an e( al 1994a). Thus, there is 
apparently a spatial reorientation o f  the receptor-associated .src-family kinases so that 
binding o f  the kinases changes from N-term inal mediated to SH2 dom ain mediated.
The protein tyrosine kinase syk is also associated with the resting receptor complex 
and is immediately phosphorylated following receptor ligation. Originally it was 
thought that syk associated w ith sIgM (Hutchcroft ef al 1992). However, syk binds 
strongly to phosphorylated Ig -a  and Ig-p A R H -l m otif peptides. Recent findings 
showed that a phosphorylated Y-X-X-L/I sequence is the predicted binding site for the 
syk SH2 dom ains (Songyang ei al 1994) and that the related T cell kinase ZAP-70 
binds to the corresponding tyrosine-phosphorylated ARH-1 m otifs in the cytoplasm ic 
tails o f  the TCR eomplex (W ange ei al 1993). Therefore syk may be involved in BCR 
signal transduction at 2 levels; firstly, it binds to the resting receptor via sig 
transm em brane/cytoplasm ic regions and, secondly, it binds via its SH2 dom ains to 
phosphorylated Ig -a  and Ig-P and becomes activated.
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S tudies on the phosphorylation o f  cellular substrates (Yamanishi ef al 1992; 
Hutchcroft ef al 1991,1992; Brunswick et al 1991; Campbell and Sefton 1990,1992, 
Gold ef al 1990) and in vilro assays on the activity o f kinases (Burkhardt ei al 1991 ; 
Yamanishi el al 1992; Yamada ef al 1993) have shown that maximal kinase activity is 
achieved 15-60 seconds after BCR stim ulation. Experim ents using kinase inhibitors 
indicate that all downstream  signalling events and the subsequent biological responses 
are dependent on tyrosine kinase activity (Cambier ef al 1991 ; Padeh ef a l 1991 ; Pure 
and 'iardelli 1992). A lthough the m echanism  by which the BCR signals is finally 
em erging, it is unclear whether the m ultiple activated tyrosine kinases act in parallel 
or as a cascade. It rem ains uncertain as to how the initial ARH-1 m otif 
phosphorylation is triggered. Initially Hutchcroft et c// (1991) im plicated syk as the 
first kinase to be activated following ligation o f  the BCR. Several other lines o f 
evidence have supported this hypothesis. Firstly, in T cells, on cross linking chim eric 
receptors containing syk cytoplasm ic dom ains but not Ick or ZA P-70, there is 
inducible tyrosine phosphorylation and calcium m obilisation (Kolanus et al 1993). In 
addition, syk associates with sig in the absence o f  Ig -a  and Ig-p (Hutchcroft ei al
1992) and a B cell lym phom a with a knockout syk gene results in a virtual cessation 
o f  BCR signalling (1'akata ei al 1994). .vrc-family kinases have been found to bind 
phosphorylated syk through their SFI-2 domains. This is an event that requires syk to 
be activated (Cam bier ei al 1994). Finally, syk is activated by TCR ligation o f  the Ick 
deficient .I.CaMl .6 cell line. I ’his occurs in the absence o f .vrc-family or ZAP-70 
kinase activation (Couture ei al 1994).
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lowevcr, there is also evidence that .sv'c-family kinases are phosphorylated prior to
syk (Kurosaki ef al 1994). This would be consistent with studies on the TCR (Chan ef 
a! 1991, 1992a,b) which showed that the syk-related protein, ZAP-70, bound to TC R ^ 
only after phosphorylation by Ick. I ’hus the identity o f  the kinases initiating BCR 
signalling and the m echanism s by which they are activated are unclear.
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The most interesting feature o f  BCR signalling is the num ber o f  tyrosine kinases 
utilised. Recent evidence suggests that different kinases can bind to distinct 
downstream  effectors (Pleiman et ai 1993) and have different substrate peptide 
preferences (Goldman ei al 1994). This raises the possibility that these kinases 
activate di fferent downstream  pathways. After the initial activation o f  protein tyrosine 
kinases the signalling pathway diverges into at least three biochemical cascades. The 
best known ol these is the activation o f  the phosphatidyl inositol-4,5,-bisphosphate 
(PIP 2 ) specific phospholipase C (PTC) pathway by tyrosine phosphorylation
(Coggeshall and Cam bier 1984; Coggeshall ei a l 1992; Carter ei al 1991; Bijsterbosch
■
.and Klaus 1985). Although PLCyl is present, PLCy2 is the predom inant isoform in B 
cells (Coggeshall ei al 1992). PLCy2 activation leads to the hydrolysis o f 
phospholipid producing Inositol-1,4,5-trisphosphate (IPO and Diacylglycerol (DAG)
(reviewed in Nishizuki 1992). These m ediate the activation o f  various isoforms o f 
protein kinase C (PKC); the PKC isoforms expressed in B cells are a ,  (3, 5, Ç and r\
(M ischak ei al 1991) and o f  these a ,  p and 5 are DAG regulated. IP^ m ediates calcium
'
influx and the release o f  calcium  from stores in the Endoplasm ic Reticulum  is caused 
.by IP, binding to receptors on the plasm a m em brane and on the ER m em brane (Khan 
ei al 1992). The m obilisation o f calcium  also activates Calcium  Calm odulin kinase II.
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The biological effects o f  this are unknown. However nuclear CaM kinase II has been 
shown to phosphorylate the els-1 DNA binding protein (Valentine e! al 1995; Fisher 
ef al 1991), perhaps altering its transcription regulating activity. PKC m odifies the 
transcriptional activity o f the AP-1 complex, possibly by activating an intermediary 
phosphatase (Boyle ei al 1991).
The second tyrosine kinase regulated signalling pathway is activated by many 
receptors, including the BCR, and involves the p lK '’" oncoprotein (ras) (Harwood and 
Cam bier 1993; Lazarus ei ol 1993; Downward 1992). Ras is a key m ediator o f 
tyrosine kinase action and a potent regulator o f  cell growth and differentiation. M any 
o f  the effects o f  ras appear to be m ediated by a protein kinase cascade controlled by 
ras. Activated ras associates with the Raf-1 serine/threonine kinase (Koide ei a l 1993) 
and is required for the activation o f  Raf-1 in vivo (Cook and M cCorm ick 1993). In 
turn Raf-1 phosphorylates and activates M EK (Kyriakis ei al 1993) which 
phosphorylates and activates the m itogen activated protein (M AP) kinases (Davis 
1993). These may regulate gene expression since they can phosphorylate a num ber o f 
transcription factors in viiro including e-Jun., e-fos and c-myc, Ras is a m em brane- 
associated guanine nucleotide-binding protein that exists in an active G TP-bound state 
and in an inactive GDP-bound state. In B cells ras is regulated by GTPase-activating 
protein (GAP) which stim ulates the GTPase activity o f ras favouring the inactive 
GD P-bound form o f  ras (Gold ei al 1992). In contrast, guanine nucleotide exchange 
factors (GNEFs) stim ulate the release o f GDP from ras allowing GTP to bind. In B 
cells ras appears to be regulated primarily by the GNEF, vav (Bustelo el al 1992; 
Gulbins ei al 1993). Vav is tyrosine phosphorylated and presum ably activated
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follow ing BCR cross-linking (Bustelo and Barbacid 1992). Several GN EFs have been 
described in m am m alian systems. These include hom ologues o f  the Drosophila  “son 
o f  sevenless” protein (m SO Sl and m S 0S 2  in m ouse) (Bowtell el al 1992). Cellular 
ras activity reflects a balance between GNEF activity and GAP activity. mSOS-1 
translocates from the cytosol to the m em brane where ras is located (Buday and 
Downward 1993). This is m ediated by the adaptor protein Grb-2 which binds mSOS-1 
by means o f  its .svc-homology 3 (SH3) dom ains (Rozakis-Adcock ei al 1993). In 
addition, products o f  the she gene, p46" '^‘' and p52"'’7 have been im plicated as upstream  
regulators o f ras. The G rb-2/m SO S-l eom plex binds to tyrosine phosphorylated she 
via the SH2 dom ain o f  Grb-2 (Rozakis-Adcock ei al 1992). Recent studies have 
shown that ligation o f  the BCR stim ulates phosphorylation o f  she and mSOS-1 
(Saxton ei al 1994). This correlated with the formation o f  com plexes containing she, 
m SO S-E  Grb-2 and an unidentified 145kDa tyrosine phosphorylated protein.
The third cascade activated following BCR cross-linking involves the activation o f  PI- 
3-kinase (Burkhardt ei al 1991; Gold ei al 1992; reviewed in Cantley ei al 1991). This 
produces inositol lipids which activate a unique PKC isoform PKC<!  ^(Nakanishi ei al 
1993). The role o f .svc-family kinases in the regulation o f downstream  signalling is 
indicated by the discovery that BCR activation leads to kinase association with 
effectors including PLC-y-2, GAP, M APK and Pl-3-kinase (Burkhardt ei al 1991 ; 
Pleiman ei al 1993). PLC-y-2, GAP and M APK associate with the N-term inal 10 
residues o f  the .v/r-family kinases. However PI-3-kinase binding occurs through an 
interaction with the SH3 dom ain o f  the kinases lyn and fyn but not blk (Pleim an ei al
1993). The region within PI-3-kinase responsible for this binding is a pro line rich area
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found in the regulatory p85 subunit (Pleiman e( al 1994c). Since BCR mediated 
tyrosine phosphorylation has not been shown, it may be that the binding o f  the .svr- 
family kinase SH3 dom ain regulates PI-3-kinase directly.
In summ ary, a model o f  the im m ediate events in BCR mediated signal transduction
was proposed (Cam bier el al 1994) and Figure 1.2 indicates the early and late
signalling events occurring when the BCR is stimulated with antigen. Stim ulation o f
the BCR leads to the activation o f  a tyrosine kinase; candidates for this may be found
in the resting receptor complex. The first substrates to be phosphorylated are the
ARH-1 m otif tyrosines o f  Ig -a  and Ig-p. It was hypothesised that phosphorylation o f
these m otifs leads to the reorientation o f  associated .src-family kinases so that SH2
dom ains may now bind. Binding o f  these SH2 domains to the tyrosine phosphorylated 
.ARH-1 motifs activates the .vrc-family kinases. The reorientation o f  the kinases may
allow  focusing o f effectors such as GAP, PLC-y-2 or M APK via binding to the
kinase’s newly available unique region. The activity o f  these effectors can be 
m ediated by subsequent phosphorylation. Reorientation o f  the Ig-a/.src family kinase 
com plex leads to SH3 dom ain binding to PI-3-kinase and thus its activation. In 
addition, phosphorylation o f  Ig -a  and Ig-p may also lead to syk binding to the ARH-1 
m otifs and to syk activation. Precisely how coreceptors like CD22, FcyRII and the 
CD21/CD19/TAPA-1 complex may modify BCR signalling rem ains unclear.
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Figure 1.2 M odel o f Signal Transduction through the B Cell R eceptor Com plex  
(BCR)
'Phe B Cell Antigen Receptor is a  complex o f  antigen-binding sig w ith the m em brane- 
spanning signal transducing heterodim ers Ig-a/Ig-p . Signal transduction by the BCR 
is triggered by receptor cross-linking and depends upon an ARH-1 in Ig -a  and Ig-P 
which transm its signals from the BCR to the illustrated signalling com ponents. These 
act in concert with the cytoplasm ic and m em brane m olecules shown.
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1.3 The Interleukin-! Receptor
B lymphocyte growth and activation are regulated by signals transm itted at'ter the 
binding o f  antigen to sig and o f  cytokines to their specific receptors. Cytokines are a 
set o f  small proteins whose expression, secretion, or both, is induced as a result o f  
antigen-stim ulated cellular activation. These proteins act by binding to high affinity 
receptors expressed on target cells and by inducing biochem ical signals within those 
cells that profoundly affect their behaviour. The binding o f  antigen to the BCR is the 
initial event in B lymphocyte activation. The second signal that has been most 
thoroughly investigated is that provided by contact with helper T cells and the 
cytokines secreted by these cells.
One such cytokine, Interleukin-2 (IL-2), has pleiotropic effects on lym phocytes, 
including T, B and Natural Killer cells (Smith 1988a;b; Taniguchi e( a/ 1986; 
Robertson and Ritz 1992) as well as other hematopoietic cells (Benveniste and Merrill 
1984; M alkovsky e/ aJ 1987; Espinoza-Delgado e/ al 1990, DJeu d  a! 1993). lL-2 was 
found to be a potent proliferation and differentiation-inducing agent o f  B lymphocytes 
after cross-linking o f  their sigs (Nakagaw a et al 1985; Defiance e( al 1988). The 
effects o f  IL-2 on these various cells are mediated through cell surface receptors. Over 
the past few years, our understanding o f  the IL-2 Receptor com plex (IL-2R) has 
increased substantially. It is now known that the IL-2R comprises at least three 
subunits, the a ,  [3 and y chains, encoded by distinct genes. These subunits can be 
expressed individually or in various com binations resulting in receptors that bind IL-2 
with very different affinities. The IL-2R comes in three different forms; the high
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affinity IL-2R (ICd = 10'"M ) contains the three distinct subunits, the interm ediate 
affinity receptor (Kd = is m ade up o f  the p and y chains and the low affinity
receptor (Kd = 1 consi st s o f  the a  chain alone (Smith 1989).
1,3.1 The IL“2 Receptor a  chain (lL -2R a)
1 he first 1L-2R com ponent to be identified was the a  chain, (variously known as 
CD25, Tac antigen or IL-2R a). It is a 55kDa m embrane glycoprotein (p55) capable o f 
binding IL-2 (Leonard e( al 1983; Robb and Greene 1983). The deduced amino acid 
sequence o f the hum an IL -2R a predicts a mature protein o f  251 amino acids with a 
signal peptide o f  21 amino acids in length (Leonard ei al 1984; N ikaido et al 1984; 
Cosm an et al 1984), The receptor has a short (13 amino acids) cytoplasm ic dom ain 
that is positively charged and presum ably serves an anchoring function. The protein 
contains a hydrophobic 19 residue m em brane spanning region and the m ajority o f  the 
protein (219 amino acids) is extracytoplasm ic. There are two N-linked carbohydrate 
addition sites and m ultiple O-linked carbohydrate addition sites.
The a  chain is a non-signalling subunit and was thought to be the only cytokine 
m em ber o f a large family o f binding proteins whose members include the com plem ent 
receptor proteins (Davie et al 1986; Perkins et al 1988). However, Giri et al (1995) 
recently identified and cloned a novel IL -I5 binding protein that is structurally related 
to the a  chain o f the IL-2R. Together, the a  chains o f the IL-2 and IL-15Rs define a 
new cytokine receptor family. Both proteins contain a short consensus repeat called a 
“sushi dom ain” . Proteins containing this motif, such as Cls, Clr C4BP, Factor XIII,
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Factor B and Factor FI, are proteins that bind to other proteins. In these proteins, the 
sushi dom ains are often found repeated m ultiple times; com plem ent factor I I, for 
exam ple, consists entirely o f  20 sushi dom ains (Perkins el al 1988). The IL- 
2 R a  contains two sushi dom ains; several residues in the first sushi dom ain have been 
identified as being directly involved in IL-2 binding (Moreau et al 1987; Robb et al
1988). Therefore, the a  chains o f  the IL-2R and IL-15R define a new family o f  
binding proteins for helical cytokines. It remains to be discovered if  this fam ily o f  
m olecules plays a role in other cytokine receptors.
IL -2R a has been found to be expressed on CD4‘ CD8'(double negative) thym ocytes 
and activated T and B cells (Uchiyam a et al 1981 ; Ceredig et al 1985; Lowenthal et a l 
1986; M euer et al 1983; W aldmann et al 1984) and has been im plicated in thym ocyte 
differentiation (Nishi et a l 1988; Tentori et al 1988, Zuniga-Pflucker and Kruisbeek 
1990; Carding et al 1991) and lymphocyte proliferation (W aldman 1989; M inami et 
al 1993; Taniguchi and M inami 1993). IL -2R a is also expressed on pre-B and 
im m ature B cells in the bone m arrow (Chen et al 1994) suggesting a potential role for 
the IL-2R in early B cell differentiation. IL -2R a is not constitutively expressed in 
resting T and B lymphocytes and is upregulated by distinct groups o f  cytokines in 
both T  and B lym phocytes (Greene et al 1989, Butcher et al 1990; Butcher and 
Cush ley 1991 ; Tom izaw a ei al 1991; Zola et al 1991 ; Clipstone and Crabtree 1994). 
As lL -2R a has no overt signal transducing capacity its main role appears to be in the 
generation o f  a specific high affinity receptor for IL-2.
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t .3.2 The IL-2 Receptor p chain (ÏL-2RP)
A second com ponent o f  the IL-2R was subsequently identified (Sharon el al 1986; 
Tsudo ei ai 1986; Teshigaw ara el al 1987; Dukovich el a l 1987) and was denoted the 
P chain. lL-2R p is a 75kDa protein that is constitutively expressed on lymphocytes. 
1L-2RP cDNA encodes a protein consisting o f  551 amino acids (H atakeyam a ei al
1989). The N f f  terminal 265 amino acids apparently com prise the signal sequence, 
leaving 525 amino acids to m ake up the m ature form o f IL-2Rp. W ithin this, regions 
o f  214, 25 and 286 amino acids in length com prise the extracellular, m em brane- 
spanning and cytoplasm ic regions, respectively. Several unique amino acid m otifs are 
found in the extracellular region o f  IL-2Rp; their resem blance to sequences found in 
other cytokine receptors is discussed later. The cytoplasmic region o f IL-2RP is larger 
than that o f  IL -2R a but does not contain any apparent catalytic m otifs such as kinase 
consensus sequences (Hanks ei al 1988). It can be divided into 3 sub-regions based 
upon their amino acid com positions. These have been designated as the “serine rich” 
region, the “acidic” region and the “ pro line rich” region.
1.3.3 The IL-2 Receptor y chain (lL-2Ry)
The third and m ost recently identified IL-2R component, IL-2Ry, is a 64kDa protein 
that also has structural hom ology to these cytokine receptors (Takeshita ei al 1992; 
Kamio ei al 1992). IL-2Ry has a very low affinity for IL-2 by itse lf (Voss ef al 1993). 
However, when expressed with lL-2R p, these two chains form an interm ediate
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affinity receptor for IL-2. In addition, the p and y chains o f  the IL-2R are utilised by 
the IL-15R (Giri ef al 1994). M oreover, the y chain has been shown recently to be 
shared by receptors for several other cytokines (lL-4, IL-7, lL-9) (Kondo ef al 
1993,1994; Noguchi ef al 1993a, Russell ef a l 1993, 1994) and is thus designated the 
com m on y chain, yc.
A central role for the y chain is supported by the fact that X-linked severe combined 
im m unodeficiency (XSCID) occurs as a direct result o f  y chain m utations (Noguchi ef 
al 1993b; Voss ef al 1994). Patients with XSCID were shown to have m utations in 
their lL-2Ry gene resulting in prem ature term ination o f the protein, XSCID is a rare 
congenital disease in man and is characterised by a marked decrease in circulating T 
cells while B cells are present but poorly functional (Conley 1992). O ther 
haem atopoietic cell lineages appear unaffected. Therefore the IL-2Ry chain plays a 
critical role in immune system  functioning.
The protein structure o f IL-2Ry has been deduced; the NFL term inal 22 amino acids 
com prise the signal sequence with the rem aining 347 amino acids m aking up the 
mature form o f  the protein (Takeshita ef al 1992). W ithin this chain, regions o f  232,
29 and 86 amino acids constitute the extracellular, m em brane-spanning and 
cytoplasm ic regions, respectively. The cytoplasmic region o f  lL-2Ry is considerably 
shorter than that o f  IL-2RP; it contains a sequence that appears hom ologous to an SFI2 
dom ain but with no apparent catalytic motifs. Both IL-2RP and yc chains appear to 
participate in signal transduction (Arim a ef al 1992; Kishimoto ef al 1994).
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1.3.4 The Cytokine Receptor Superfamily
Both IL-2Rp and yc are m em bers o f  the cytokine receptor siiperfamily (Bazan 1990a). 
This is a large family o f  receptors for cytokines which regulate the immune and 
haem atopoietic system. It is characterised by an extracellular 200 amino acid region o f  
structural homology. This haem atopoietic cytokine receptor fam ily includes such 
receptors as IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-9R, IL-15R, the erythropoietin 
receptor (EPOR), G-CSFR, GM -CSFR and LIFR, in addition to the IL-2R ({3 and y 
chains) (Bazan 1990a; M iyajim ae/ al 1992; T agaand  Kishim oto 1992). The family 
also includes receptor proteins for factors which normally function outside the 
immune system , for example, growth hormone and prolactin (Bazan 1990a, Davis ef 
al 1991). The hom ologous region com m on to all members o f  this family is 
characterised by four conserved cysteine residues in the N F f terminal hal f  o f  this 
region and a Trp-Ser-X -Trp-Ser m otif (where X is a non-conserved am ino acid) at its 
carboxy-term inal end. The region is composed o f  2 ftbronectin type III m olecules 
(Patthy 1990). Each consists o f  about 100 am ino acids and contains 7 (3 strands folded 
to form a barrel-like structure located within the hinge region connecting the two type 
III modules and this is predicted to function as the ligand interaction site (Bazan 
1990a). Concurrent with finding structural sim ilarities within this receptor 
superfam ily, the respective ligands appear to possess a comm on architecture 
consisting o f  four a  helices interconnected by peptide loops (Bazan 1990b).
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1.3.5 IL-2 Receptor-Mediated Signal Transduction
IL-2Rp plays a critical role in transducing mitotic signal(s) in haem atopoietic cell 
lines. From studies with lymphoid lineage BAF-B03 cells expressing m utant IL-2Rp 
proteins with deletions in the intracytoplasm ic domain, it was shown that the 
cytoplasm ic dom ain o f 1L-2RP harbours two functional domains. One is the 
mem brane-proxim al serine-rich region which is important in the transduction o f  the 
lL-2 induced proliferative signals and the other is a more m em brane-distal acidic 
region with which tyrosine kinases are physically associated (Shibuya ef al 1992). It 
should be noted that the serine -rich region contains a conserved stretch o f 
hydrophobic amino acids. Replacem ent o f  leucine in this stretch with a proline may 
induce a conform ational change in IL-2Rp because the resultant receptor is no longer 
capable o f  transm itting the IL-2-induced m itotic signal (Mori ef al 1991).
1.3.6. Signalling by the Cytokine Receptor Superfamily: JAK s
Tyrosine phosphorylation o f  cellular substrates is believed to play a crucial role in the 
intracellular signal transduction pathways that regulate cellular activation and 
differentiation (Hunter and Cooper 1985, 1986). Recently, a num ber o f  studies 
showed that cytokine receptors associate with and activate m em bers o f  the JAK 
family o f  protein kinases. JAK was originally an acronym for “ju st another kinase” ; it 
has also been proposed as an acronym  for Janus kinase, Janus being the Rom an god o f 
gates and doorways who is depicted with two faces looking in opposite directions.
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This refers to the structure o f  m em bers o f  the JAK family whose most striking feature 
is the presence o f  two kinase domains. The dom ain proximal to the carboxy-term inal 
contains all the consensus sequences associated with tyrosine kinases (Hanks el al 
1988). Immediately amino-term inal to this is a second kinase-like domain. This lacks 
several residues essential for kinase activity in other kinases and the function o f  this 
dom ain is, as y e t , undetermined. Interestingly, there is a lack o f  readily detectable 
SH2 or SH3 dom ains in the sequences amino terminal to the kinase domains. There 
are at least four JAK family members with identifiable blocks o f  hom ology between 
them (Pawson and Gish 1992). These hom ologous regions may define the dom ains 
responsible for the association o f JAKs with members o f  the cytokine receptor 
supcrfamily.
Various studies defined the importance o f  the JAK family in signalling through 
cytokine receptors (Reviewed in Ihle el al 1993). These studies linked JAKs with 
specific cytokine receptors. In the case o f the IL-2R, IL-2 induces the tyrosine 
phosphorylation o f  JAK 1 and JAK3. (Kawam ura ei al 1994; W itthuhn et al 1994; 
Johnston el al 1994). In fact, JA K l associates with IL-2R|3 and JAK3 associates with 
lL-2Ry (Russell el al 1994). This differential association o f  JA K l and JAK3 with IL- 
2R(3 and yc is required to transduce an IL-2 signal. Russell ei al (1994) also predicted 
that defective yc-JAK3 association would be found in many XSCID patients. In 
addition, the activation o f  JAK3 by all y^  cytokine receptors is logical since yc 
physically associates with JAK3. However, the activation o f  JA K l by IL-2, IL-4, IL-7 
and IL-9 suggests that 1L-4R, 1L-7R and IL-9R, like IL-2R, all associate with JAK-1. 
Because the IL-15R also contains j3 and yc (Giri e( al 1994), it seem s reasonable to
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assum e that IL-15 will also activate JA K l and JAK3. Further study determined that 
JA K l and JAK3 were selectively associated with the serine-rich region oflL -2R |3  and 
the carboxy-term inal o fyc , respectively. Both regions were essential for lL-2 
signalling. However, it is clear that the different signals induced by different cytokines 
whose receptors contain yc cannot solely be explained by the involvem ent o f  JA K l 
and JAK3.
These findings show that IL-2 signalling is o f  a complex nature. In addition to JA K l, 
1L-2R(3 can recruit m ultiple protein tyrosine kinases (PTKs), such as src  family
kinases (Hatakeyam a et al 1991 ; Kobayashi et al 1993; M inami et al 1993) and syk 
.PTK (M inami and Taniguchi 1995). There is direct evidence for a physical interaction 
between lL-2R p and Ick (Hatakeyam a et al 1991). The cytoplasm ic region o f  IL-2RP 
containing the acidic region is prim arily responsible for the m olecular interaction with 
Ick. This can be separated from the additional region responsible for m itotic 
signalling, the scrine-rich region. Ick tyrosine kinase is divided into three dom ains: the 
N-term inal CD4 or CD8 binding domain, the modulatory dom ain containing the SH2 
and SH3 dom ains and the kinase domain. The N-terminal ha lf o f  the kinase dom ain is 
responsible for its association with 1L-2R|3. It seems there may be redundant and 
hierarchical associations with, or activation of, the src family PTKs in a cell lineage 
specific m anner;thus, Ick, lyn and fyn each seem to participate in IL-2 signalling in 
different cells (Hatakeyam a et al 1992; Torigoe et al 1992; Kobayashi et al 1993).
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1.3.7 Other Biochemical Events in IL-2 Signalling.
Follow ing IL-2 stim ulation, there is a rapid increase in intracellular pH as a result o f  
the activation o f  an NaVH antiport (M ills and May 1987). It is unlikely that there is 
involvem ent o f  other well-characterised biochemical pathways, such as activation o f  
PKA or PKC or calcium  m obilisation (M ills et al 1986, 1988; LeGrue 1988; Valge et 
al 1988). Various substrates, including IL-2Rp itself are phosphorylated on their 
serine and threonine residues as a result o f  stimulation with IL-2 (Ishii et al 1988).
The serine/threonine kinase involved is the ubiquitous cytoplasm ic kinase p70-75 
Raf-1. This is activated possibly as a result o f  phosphorylation on the serine, threonine 
or tyrosine residues following engagem ent o f  the IL-2R (Turner et al 1991 ; Carroll et 
al 1990; Zm uidzinas et al 1991). Raf-1 is the earliest substrate so far identified that is 
phosphorylated by tyrosine kinases upon IL-2 stimulation. Since Raf-1 rapidly 
undergoes tyrosine phosphorylation and Ick rapid activation upon engagem ent o f  the 
1L-2R, the activity o f  these two kinases may be mutually regulated.
In addition, stim ulation o f  T cells by IL-2 activates PI-3-kinase (Augustine et al 1991 ; 
Rem il lard et al 1991; M erida el al 1991). A nother possible signalling m echanism  
involves the hydrolysis o f glycosy 1-phosphatidyl inositol (GPI). Follow ing IL-2 
stim ulation, GPI is rapidly hydrolysed generating two potential signal m ediators, a 
glycosylated diacylglycerol and an inositol phosphate glycan (Eardley and Koshland 
1991; M erida et al 1990). It has also been reported that IL-2R activation may lead to 
signal transduction pathways involving cyclic AM P (W ickrem asinghe et al 1987) and
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experim ents performed within this laboratory have indicated that inducing IL -2R a 
causes cAM P levels to increase in B cells (M cKay and Cushley 1997)
1.3.8 M ultiple Signalling Pathways elicited by a Single Receptor.
Cytokines induce the expression o f  several genes including nuclear proto-oncogenes 
in T lym phocytes (Cleveland ei al 1987; Reed et al 1985a, b) and B lym phocytes 
(Kelly el al 1983). On IL-2 stim ulation, there is a rapid and transient increase in the 
num ber o f  c-fos transcripts, as well as the more stable accum ulation o f  c-myc  and c- 
myh transcripts (Stern and Smith 1986; Pauza 1987; Trouche el al 1991; Hatakeyam a 
el al 1992). IL-2R[3 is involved in at least two distinct intracellular signalling 
pathways m ediating nuclear proto-oncogene induction (Shibuya el al 1992). One 
pathway involves tyrosine phosphorylation events mediated by the .svc-family PTKs 
and leads to induction o f  the c~fbs, c-Jun and other genes o f this family (M inami el al 
1993). There is also a kinase independent pathway which appears linked to c-myc 
induction. From studies (previously m entioned in Section 1.3.5) with lym phoid 
lineage BAF-B03 cells expressing m utant 1L-2R(3 proteins with deletions in the 
intracytoplasm ic domain, it appears that an IL-2R m utant lacking the acidic region is 
incapable o f  m ediating induction o f  c-fos. It was shown, nevertheless, to be capable o f  
delivering proliferative signals accom panied by induction o f  c-myc. In contrast, 
m utation o f  the serine-rich region o f  IL-2R(3 could neither induce cell proliferation 
nor c-myc induction (Shibuya el al 1992). Hence the serine-rich region may elicit an 
as yet unidentified signal that leads to c-myc induction. Studies with fibroblastoid
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cells containing reconstituted IL-2R com plexes have also suggested the existence o f  
two distinct pathways for c-myc and c-fos induction generated from the IL-2 Rye chain 
(Asao d  aJ 1993).
1.3.9 The ST AT Fam ily o f Transcription Factors
One o f  the important consequences o f  cytokine stimulation is the induction o f  gene 
expression. A novel group o f transcription factors known as STAT proteins (signal 
transducers and activators o f  Ranscription) has been shown to be o f  im portance in 
signalling through receptors o f the cytokine receptor superfamily. The STATs were 
originally identified as com ponents o f  the interferon (IFN) signalling system (Darnell 
d  al 1994). IFN -a/p  induces the form ation o f  a transcription com plex term ed lSGF-3 
which binds to the interferon-stim ulated response elem ent (ISRE) and activates 
transcription. The ISGF-3 complex consists o f  a 48kDa DMA binding com ponent, an 
84-91 kDa protein and a 113kDa protein, termed p48, p84, p91 and p i 13 , 
respectively; p91 and p84 are alternatively spliced products o f the same gene. For 
form ation o f  the ISGF-3 complex and its migration to the nucleus p91/p84 and pi 13 
must be tyrosine phosphorylated; it is hypothesised that this tyrosine phosphorylation 
is m ediated by a JAK kinase.
Alternatively, stim ulation o f  cells with IFN-y causes p91 only to becom e tyrosine 
phosphorylated. Following phosphorylation, p91 migrates to the nucleus and 
participates in DNA binding com plexes that recognise gam m a-activated sequences
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(GAS) in genes that are transcriptionally activated by IFN-y. These com plexes do not 
contain p48 but may contain related proteins (Pearse ei al 1993).
The p91/p84 and pi 13 com ponents o f  the ISGF-3 complex are m em bers o f  the STAT 
family. Thus, S T A T -la  is p91, STAT-lf3 is p84 and STAT-2 is p i 13. The STAT 
family is characterised by the presence o f  a carboxy-terminal SH3 dom ain followed 
by an SM2 domain. There are additional blocks o f hom ology found in the amino- 
terminal region o f  these proteins. A conserved tyrosine is found near the carboxy- 
lerm inus that is phosphorylated and essential for function (Shuai ei al 1993). STATs 
bind to specific sequences related to the GAS found in the prom oter regions o f  several 
cytokine sensitive genes. There is wide variation in the sequences bound by specific 
STATs. However, the elem ents are palindrom ic and have the general sequence T-T- 
(N)vf,-A-A (where N is a non-conserved base) (Seidel ei a l 1995).
It was dem onstrated through the use o f  m utants for IFN signalling that functional 
JAKs must be present to obtain tyrosine phosphorylation o f  STAT proteins, thus 
suggesting that STAT proteins are direct substrates o f  JAKs. JA K l and JAK2 are 
associated with the IFN-y receptor and JA K l and TYK2 are associated with the IF N -a  
receptor. S ince JA K l is activated by both IF N -a/p  and IFN-y and STAT-1 is 
phosphorylated after treatm ent with each ligand, then it can be hypothesised that 
JA K l is the kinase directly phosphorylating STAT-1. Conversely, since STAT-2 is 
only seen in response to IF N -a/p , STAT-2 could be a specific substrate for TYK2. In 
fact, STAT-1 has much broader functions than simply the IFN response.
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Recent evidence dem onstrates that ligand-receptor interactions other than those 
involving IFNs can activate JAK -STAT proteins and other STAT proteins have been 
discovered. Thus, it seems likely that JAK -STAT pathways may be o f  some 
importance in polypeptide-induced transcription (Sadowski ei a l 1993; Silvennoinen 
ei al 1993; Ruff-Jamison ei al 1993; Bonn! ei al 1993). A STA T-1-related protein has 
been identified which associates with g p l3 0  and JA K l and is rapidly tyrosine 
phosphorylated during the IL-6 response (Lutticken ei al 1994). It has been designated 
STAT-3 (Zhong ei al 1994b; Kishim oto ei al 1994)
STAT-4 was cloned (Yam am oto ei al 1994) and found to be functionally like other 
m em bers o f  the family in that it can be tyrosine phosphorylated by JA K l or JAK2 and 
acquires y-aclivated sequences (GAS) binding activity. It is prim arily expressed in 
haem atopoietic cells and in developing sperm atogonia (Zhong ei al 1994a). It was 
recently discovered that IL-12 can induce tyrosine phosphorylation o f  STAT-4 in 
hum an T lym phocytes (Jacobson ei al 1995; Quelle ei al 1995).
STAT-5 is expressed in the spleen, bone m arrow and thymus. There are two STA T-5 
proteins, STAT-5A and STAT-5B which are the products o f  distinct genes (Azam ei 
al 1995; Mui ei al 1995). Cytokine receptors which contain a com m on (3 chain such 
as lL-3, IL-5 and GM -CSF appear to be involved in signalling through the tyrosine 
phosphorylation o f  STAT-5. In the murine system, IL-3, IL-5 and GM -CSF all induce 
tyrosine phosphorylation o f  STAT-5 whereas in humans IL-2 activates STAT-5. In 
hum ans, STAT-5 is phosphorylated by JAK3, a result entirely consistent with the
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finding that the C-term inal region o f the IL-2RP chain is required for STAT-5 
activation (Fujii ei al 1995).
Finally, S fA 1-6 was discovered (Hou ei al 1994). This is an IL-4 regulated STAT 
protein; it appears that the a  chain o f  the IL-4 receptor confers specificity for STAT-6 
activation. In the case o f  lL-2 m ediated signal transduction, IL-2 does not activate 
STA T-1, 2 or 3 in T cells (Beadling ei al 1994). As previously stated, STAT-5 is 
activated by 11.-2 (Fujii ei al 1995) and STAT-6 also appears to be a substrate for IL-4 
-driven tyrosine phosphorylation in T cells (Quelle el al 1995). Therefore, since both 
IL-2 and IL-4 receptors have a comm on yc subunit that selectively associates with 
.1AK3 (M iyazaki ei al 1994), it is possible that STAT-5 and STAT-6 activation in T 
cells is mediated by .IAK3.
In conclusion, IL-2 signalling is a com plex process involving a large cast o f  m olecules 
and a schem atic diagram  outlining the pathways involved is illustrated in F igu re  1.3. 
M uch rem ains to be elucidated before we will be able to fully understand the signal 
transduction pathways that activate target genes in the nucleus in response to 
stim ulation o f  the IL-2R on the cell surface.
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Figure 1.3 Sum m ary of the Signal Transduction Pathways Through the H igh  
Affinity Interleukin-2 Receptor.
IL-2 binds to the high affinity heterotrim eric IL-2R, causing Jak-1 and Jak-3 to 
associate with specific residues within the cytoplasm ic tails o f  the receptor together 
with Raf-1, syk and .vrc-family kinases. These cause signalling via certain second 
messenger pathways and induction o f  various genes through the binding o f 
transcription factors.
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1.4 The lL ”2R a Promoter Region
One approach used to elucidate cytokine signal transduction is the identification o f  cis 
response elem ents within genes and their corresponding transcription factors which 
respond to cytokine signals. The lL -2R a gene has been w ell-characterised in T 
lymphocytes; a num ber o f  cis regulatory elem ents within the prom oter region have 
been m apped and their corresponding /ram -activating factors identified. Therefore, 
this section will deal largely with what is known in T lymphocytes and then relate this 
to what is currently being explored in B lymphocytes.
One reason why the IL -2R a gene has been so extensively studied in T lym phocytes is 
because infection o f  CD4* T lymphocytes with Type 1 Human T Cell Leukaem ic 
Virus (HTLV-1) leads to constitutive IL~2Ra gene expression and cell 
im m ortalisation (Gootenberg ei al 1981 ; D epper ei al 1984; W aldm ann ei al 1984; 
Uchiyam a ei al 1985). This pathogenic retrovirus has been implicated as the cause o f  
aggressive and often fatal adult T cell Leukaem ia (ATL) (Reviewed by W ong-Staal 
and Gallo 1985). Patients with this leukaem ia may suffer from epidermal or dermal 
leukaemic 1 cell infiltrates, hypercalcem ia, osteolytic bone lesions and infection with 
opportunistic organism s (Bunn ei al 1983). HTLV-1 encodes a 40kD a trans-acting 
regulatory protein termed Tax (or alternatively T a t-1, pX, xlor, p 4 0 f TA -I ) (Yoshida 
and Seiki 1987) which activates HTLV-1 long terminal region (LTR) and can induce 
transcription o f  various cellular genes including IL -2R a and lL-2 (Inoue ei a l 1986; 
Cross ei al 1987, M uniyam a ei al 1987; Siekivitz ei al 1987; Ballard ei al 1988 
Bohnlein ei al 1988, Lowenthal ei al 1988;).
47
Early studies o f  IL -2R a gene expression indicated a 1352 base pair (bp) fragm ent 5 ’ 
to the IL -2R a gene which was shown to possess promoter activity w hen fused to a 
CA T reporter gene (Leonard ei al 1985). In addition, 5 ’ elements required for IL -2R a 
activity in HTLV-1 transform ed T cell lines and in Jurkat cells were m apped (Cross ei 
al 1987; Greene ei al 1989). Since data obtained from tum our T cell m odels and cell 
lines are not necessarily representative o f resting T lymphocytes present in peripheral 
blood, sim ilar studies on prim ary T cells were later done (Lowenthal ei al 1989a; 
Algartc ei al 1995). These studies showed that a proximal IL -2R a prom oter/enhancer 
region (positioned -276 to -274 relative to the transcriptional initiation site) contained 
4 putative binding sites for nuclear factors that apparently positively regulate its 
transcription (NF1L-2RA, NF-icB, SRF and Sp-1). Latterly, this has been designated 
“ Positive Regulatory Region I” (PRR,) since, in all, there are now at least three 
positive regulatory regions (PRR,.,;,) w ithin the hum an lL -2R a prom oter region.
PRR,i, like PRR,, lies close to the transcription initiation site between positions -137 
and -64. This region contains binding sites for at least two DNA binding proteins, an 
ets family protein, Elf-1, (Thom pson ei al 1992) and the non-histone chrom atin- 
associated protein HM G-l(Y) (Elton and Reeves 1986; .lohnson ei al 1989; Lund ei al 
1986). PRR],I lies some distance upstream  o f  the 5’ cap site, between nucleotides - 
3780 and -3703. It contains a potential binding site for STAT-5 as well as consensus 
sequences lor Elf-1, HM G-I(Y) and a m em ber o f  the GATA family. In addition to 
these positive regulatory regions, there are two negative regulatory regions, NREI and 
NREII, located between nucleotides -400 and -368 (Smith and Greene 1989) and 
between nucleotides -317 and -342 respectively (Lowenthal ei al 1989b). Thus,
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m ultiple regulatory elem ents are involved in IL -2R a gene activation and a schem atic 
diagram  illustrating the IL -2R a prom oter region is illustrated in Figure 1.4 (page 60).
1.5 The Positive R egulatoiy Region I (PRR,) in the IL -2R a Prom oter,
1.5.1 Upstream  Elem ent 1
Upstream elem ent-1 (U E -Î, [-289 to -269]) within PRR, is the binding site for the 
poorly defined 56kDa nuclear binding factor, NF1L-2RA, which is apparently 
involved in basal transcription activity (Ballard el al 1989; Lowenthal et al 1989; 
T’olcdano e( al 1990). Deletion o f this upstream  elem ent from a fully functional IL- 
2 R a  pro motor construct produced a loss o f  both PMA and T N F -a  m ediated induction 
o f  the lL -2 R a  promotor in T cells (Ballard e( a l 1988; Lowenthal el al 1989a, b).
1.5.2 The kB Elem ent
Gel retardation studies coupled with chem ical footprinting and m éthylation assays 
(Ballard el al 1988) served to map the binding site for one or m ore inducible proteins 
to a region located between bases -267 and -256 (Bohnlein el a l 1988; Ballard el al 
1988). Com parison o f  this 12bp promoter segment with sequences o f  other known 
protein recognition sites revealed a striking sim ilarity to the binding site for the 
transcription factor N F-kB (Bohnlein el al 1988, Leung and Nabel 1988; Ruben et al 
1988, Lowenthal el al 1989b). N F-kB  is a ubiquitous transcription factor whose
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properties seem to be m ost extensively exploited in cells o f the im m une system. kB- 
like regulatory m otifs have been detected in a variety o f cellular genes involved in the 
imm une response, including those encoding k light chain Ig (Sen and Baltim ore 
1986), MHC Class I antigens (Baldwin and Sharp 1988) and lL-2 (Hoyos ei a l 1989).
Five independent genes have been identified which encode transcription activator 
proteins which recognise the kB motif; all are classified as members o f  the rel family 
o f  transcription factors. The Rel protein family has been divided into two groups 
based on differences in structure, function and mode o f  synthesis (Baeuerle and 
Henkel 1994). The first group consists o f p50 (NF-kB1) and p52 (N F-kB2) which are 
synthesised as precursor proteins o f 105kDa and 1001cDa,respectively. The mature 
proteins possess a “Rel hom ology” domain o f  300 amino acids which includes DNA 
binding and dim érisation dom ains and a nuclear localisation signal. They form 
functional dimers with other m em bers o f  the family while dimers containing 
unprocessed proteins rem ain in the cytoplasm. The second group o f  Rel proteins 
includes p65 (Rel A), Rel (c-Rel), Rel B and the drosophila  Rel proteins, dorsal and 
Dif. They are not synthesised as precursors and possess one or m ore transcriptional 
activation dom ains, in addition to the Rel hom ology domain. The subunit com position 
o f  the different com plexes defines the fine specificty o f  binding to the target 
sequences and their transactivating activity (Perkins ei al 1992; Lernbecher ei al 
1993).
In the case o f  IL -2R a gene expression, Costello ei al (1993b) reported that in resting 
T cells the kB region was bound by N F-kB  p50 hom odim ers that were constitutively
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present in the nucleus o f resting cells. On activation, there was binding by NF-kB 
p50-p65 heterodim ers and probably c-Rel homodimers. Further support for this theory 
was produced by separate experim ents which again suggested that PKC expression, 
which triggers expression o f  IL -2R a in T cells, induced NF-kB activation through the 
induction o f  p65 and c-Rel in the nucleus where they bind the lL -2R a prom oter as 
heterodim ers with p50 (Pim ental-M uinos et al 1994a). Several lines o f  evidence 
indicate that this kB site in the IL -2R a prom oter is functionally important. Deletion o f 
this site from a fully active lL -2R a prom oter construct or point m utations within the 
elem ent results in com plete abrogation o f  PMA and T N F -a  inducibility o f  lL -2R a 
(Ballard ei al 1988, Lowenthal ei al 1989a, b). Secondly , a fragment containing the 
kB elem ent conferred m itogen and cytokine inducibility to a thym idine kinase 
prom oter-CA T construct (TKCAT) (Ballard ei al 1988; Bohnlein ei al 1988,
Lowenthal ei al 1988, 1989a, b). In fact, the elem ent displayed enhancer-like 
properties since it functioned independently o f  orientation and reiteration o f  the 
binding site led to an am plification o f  the induced response. Thus, it is clear that this 
kB elem ent plays a crucial role in the induction o f the lL -2R a gene in hum an T cells.
1,5.3 The Serum  Response Elem ent
Directly downstream  from the kB elem ent is a flanking Serum Response Elem ent 
(SRE) / CArG box [-253 to -243]. SRE is a m ajor cis elem ent responsible for the 
induction o f  c-fos transcription in response to a variety o f m itogens (Treism an 1992) 
and binds a transcription factor known as the Serum Response Factor (SRF). The 
proxim ity o f  kB and the SRE /CArG box raises the possibility that both elem ents act
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in cooperation, as suggested by previous regulatory elem ent m utagenesis and gel 
retardation studies (Kuang ei al 1993). It has been proposed that c~Rel/p50 
heterodim ers synergise with SRF to give a high level o f  lL -2R a prom oter activity. In 
addition, both c-Rel and p65 can cooperate with SRF to activate gene transcription 
(Pierce e( al 1995). Thus, more than one m em ber o f  the Rel Family can cooperate with 
SRF in transcriptional activation. These studies also indicated that p50 hom odim ers 
bound strongly to the kB site but did not activate transcription. Thus, it may be that 
the binding o f  SRF, readily present in the nuclei o f  resting T cells, to the SRE / CArG 
box o f lL -2 R a  is impaired by stably bound p50 hom odim ers to the flanking kB 
element.
A nother possibility is that the SRE / CArG box could be occupied by another CArG 
box-binding protein, Y Y -1. This recognises the downstream  part o f  the CArG box 
(Natesan and Gilman 1993). YY-1 is a ubiquitously expressed zinc finger protein with 
degenerate DNA binding specificity (Hahn 1992) which affects prom oter activity 
positively or negatively by affecting prom oter structure rather than directly contacting 
the transcriptional m achinery (Natesan and Gilman 1993). However, the meijority o f  
studies favour a role for SRF in hum an IL -2R a gene regulation (Lin et al 1990; 
Rom an ei al 1990; Toledano ei al 1990; Kuang ei a l 1993; Pim ental-M uinos ei al 
1994a, b).
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1.5.4 The Downstream Element
Again directly downstream  of the kB elem ent is a GC box [-245 to -240] which binds 
the transcription factor, Sp-1. One o f the m ost striking features o f  the IL- 
2 R a  prom otor is that CArG and GC boxes overlap by three nucleotides. Site directed 
m utagenesis and transient transfeetion assays in Jurkat T cells suggest that Sp-1 acts 
as a repressor o f  IL-2Rcx expression, perhaps by competing for the binding o f  SRF- 
like nuclear factors to the overlapping SRE/ CArG box (Rom an e( a! 1990).
However, this theory remains controversial; other data suggests there is not a 
repressor role for Sp-1 by steric hindrance (Pim ental-M uinos et al 1994a, b; Ai gar te et 
al 1995).
1.6 The Positive Regulatory Region 11 (PRR„) in the lL -2 R a  Prom oter.
PRR, is a potent inducer which at least partially regulates inducible IL -2R a 
expression. However, the sequence o f this region is not well conserved in mice 
(Suzuki et a! 1987). Recently, a second regulatory region was characterised within the 
hum an IL -2R a prom oter and designated PRR„ (.lohn et al 1995). This region is 
located between nucleotides -137 and -64 relative to the transcription initiation site 
and contains binding sites for at least two DNA-binding proteins. Deletion o f  these 
sites greatly reduced lL -2R a gene transcription even when the potent PRR, region 
was intact. Unlike PRR,, PRR,, is strictly conserved between mice and humans.
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W ithin PRR,I is a GGAA purine rich m otif (-91 to -94) which is a potential Els 
binding site. In fact, the Ets binding protein, Elf-1 was found to bind PRRIl in vi/ro. 
Elf-1 is a protein specific to lymphoid tissues which is closely related to the 
Drosophila E74 protein (Thom pson el ol 1992; Wang ef a! 1992). In addition, there is 
a 19 base pair AT rich sequence (-116 to -98) which is a m ajor HM G -l(Y ) binding 
site. HM G-I(Y) proteins are low m olecular weight (10-1 IkD a) high m obility group 
proteins that bind in the m inor groove o f AT rich sequences and induce strong 
bending in the DNA helix (van de W etering and Clevers 1992; G iese el al 1992). 
There are two further potential HM G-I(Y) binding sites betwen nucleotides -128 and - 
123 and between nucleotides -90 and -84.
Both Elf-1 and HM G-l(Y) can interact with each other in the absence o f  DNA and it 
has been proposed that interaction with HM G-I(Y) may allow Elf-1 to m aintain a 
transcriptionally active confirm ation (John e( al 1995). Elf-1 can also interact with 
N F-kB p50 and c-Rel, both o f  which have been implicated in the inducible expression 
o f  the IL -2R a gene (Tan ef al 1992). M oreover, this interaction is enhanced by the 
presence o f  HM G-I(Y). Thus, FIMG-I(Y) may act as a “m olecular glue” betw een Elf- 
1 and NF-kB and its ability to bend DNA (Lehn et al 1988) could also facilitate 
protein-protein interactions promoting the formation o f an active transcription 
complex.
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1.7 The Positive Regulatory Region III (PRR,,,) in the IL -2R a Prom oter.
In mice, the IL~2Ra gene has an IL-2 Response Element located about 1.3 kilobases 
upstream o f  the 5 ' cap site (Sperisen el al 1995). A sequence sim ilar to this has 
recently been identified within the human IL -2R a prom oter (John el al 1996; Lecine 
el aJ 1996) and designated PRR,,,. It is located between -3780 and -3703 and contains
two potential binding sites for STAT family proteins (GAS motifs), a GATA site and 
two Ets binding site (EBS) motifs. The two GAS sites, GASd [TTC(N)^GAA] and
GASp [TT(N)^AA] are located between nucleotides -3181 and -3173 and between
; • {
nucleotides -3161 and -3153, respectively. GASd overlaps with an EBS m otif while 
GASp overlaps w ith a GATA site (TGATAA). There is another EBS consensus site 
located between nucleotides -3138 and -3133, designated EBSp indicating it is the 
proxim al EBS element. Both consititutive and inducible factors bind to these PRR,,, 
sites in vitro. In T cells, IL-2 is required for the maximal and prolonged expression o f  
IL -2R a (Sperisen el al 1995) and the PRR,,, has been shown to possess IL-2- 
dependent enhancer activity (John el al 1996; Lecine el al 1996). It has been 
hypothesised that STAT-5 plays a major role in controlling PRR,,, activity since 
G A Sd binds STAT-5 a and STAT-5 b proteins in vitro which are activated by IL-2.
The GASd site overlaps with an EBS m otif which binds a constitutive complex; this 
contains Elf-1 as well as Ets-1 and/or Ets-2. On induction o f  the gene with IL-2, this 
is believed to be disrupted by binding o f  the STAT-5 proteins to GASd.
There is also a putative GATA binding m otif which overlaps GASp. GATA fam ily 
proteins contain a highly conserved amino acid domain which binds the GATA
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sequence m otif (A /TGATAG/A ) through a unique C4 zinc finger structure (Orkin 
1992). Surprisingly, experim ents have suggested that GATA-1 (or possibly a related 
protein), previously thought only to be found in cells o f the erythroid lineage 
(reviewed in W eiss and Orkin 1995), bound PRR,,, as part o f  a com plex that also 
contains STAT-5 and Elf-1 proteins.
It has also been proposed that HM G-I(Y) proteins may play a role in the regulation o f 
PRR,,, activity, sim ilar to that played in the regulation o f  PRR,,. There are two 
potential HM G-I(Y) binding sites, one juxtaposed to the EBSp site, the other 
overlapping the GATA motif. Thus, HM G-I(Y) may also function to m odulate the 
architecture o f  PRR„„ facilitating interactions between the key regulatory proteins 
like Elf-1, STAT-5 and GATA-1.
1.8 The Negative Regulatory Regions
There are two negative regulatory elem ents, NRE I and NRE II, w ithin the lL -2 R a  
prom otor located between nucleotides -400 and -368 (Smith and Greene 1989) and 
betw een nucleotides -317 and -342 (Lowenthal et al 1989b) respectively. NRE I is a 
31 bp region which contains an 11 bp core elem ent (TTCATCCCAGG). This core 
elem ent is sim ilar to a binding site present in the LTR o f  the Hum an Type 1 
Im m unodeficiency Virus (HlV-1) (nine from eleven bases) that binds in vitro to a 
50kDa protein (SP50) (Sm ith and Greene 1989). This HIV-1 LTR has been im plicated 
in the negative regulation o f  HIV-1 gene expression (Rosen et al 1985). Introduction 
o f  a point m utation within this 1 Ibp core elem ent enhanced basal and PM A inducible
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activity o f  the IL -2R a prom oter in hum an T cell lines (Smith and Greene 1989). In 
addition, the m utation disrupts binding o f  SP50. Therefore, NRE I apparently acts as a 
transcriptional silencer. This mechanism  could be comparable with that seen in the 
transcriptional induction o f  the (3-IFN gene which appears to involve the displacem ent 
o f  a silencer protein from the prom oter, thus perm itting the binding o f  other 
transcription factors to adjacent or overlapping positive regulatory dom ains 
(Goodburn and M aniatis 1988), Similarly, the IL-2 gene is negatively regulated by a 
specific protein binding to an NRE. Transcriptional activation depends upon the 
inactivation or displacem ent o f  this protein (Nabel ei al 1988).
There is a second elem ent within NRE I which is hom ologous to a retinoic acid 
response elem ent (RARE). This is located immediately V  to the 1 Ibp core NRE 
elem ent (Bhatti and Sidell 1994). The identity o f  the protein binding to this RARE 
m otif rem ains to be defined. The RARE site does contain a consensus m otif for AP-2 
binding.
In fact there are several new putative binding sites in the vicinities o f  both NREs. 
These contain the consensus binding site [C(A/T)(T/G)ANN(C/T)] o f  a poorly 
characterised regulatory elem ent originally described as ay-IFN  response elem ent y- 
IRE (Yang et al 1990).
In sum m ary, there are num erous regulatory elem ents involved in IL -2R a gene 
activation and these are illustrated in Figure 1.4. There is apparently a m ajor role for 
the NF-kB transcription factors. Flowever, this ubiquitous family o f  factors lacks the
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specificity characteristics required to explain the strict IL -2R a gene transcription 
regulation. Therefore it is likely that NF-icB cooperates with SRF to induce IL -2R a 
prom otor activity. There are two further /7'r7/7,v-acting factors which may be involved, 
NFIL-2RA and Sp-1; their involvm ent in the induction remains uncertain. Together 
these four DN A-binding sites constitute PRR,. There are two further positive 
regulatory regions, PRR,, and PRR,,,. It seems likely that PRR,, is involved more in the 
control o f  basal prom oter activity with PRR, and PRR,,, contributing to the inducible 
regulation o f  the gene. In addition, there are two NRE regions upstream from the kB 
motif. Proteins binding to these regions may lead to the functional silencing o f  the 
gene.
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Figure 1.4 A Schematic Diagram Showing the IL-2Ra Promoter in T Cells.
main elem ents o f  the prom oter region o f  the IL -2R a gene are illustrated as boxes 
with distinct styles and the location o f  the elem ents relative to the transcription 
initiation site are shown as numbers along the bottom  o f  the boxes. The com plexes o f  
transcriptional regulatory factors which interact with each m otif are shown above the 
boxes.
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1.9 The lL “2R a Promoter in B Cells
hi com parison to T lymphocytes, there has been relatively little work done on the 
transcriptional events which facilitate IL -2R a gene induction in B lymphocytes.
I Experiments have been performed by this laboratory to determ ine w hether B cells 
contain DN A-binding proteins which specifically bind to any o f  these regulatory 
elem ents and which receptor-iigand interactions on the B cell surface can lead to 
induction o f  the lL -2R a gene. These studies are discussed in Chapter Five.
An IL-4 Responsive Element (TTCTAAGAA) was identified in the prom oter regions 
o f  the CD23b and Ic genes (IL-4RE) which is specifically bound by the novel IL-4 
induced transcription factor, NFIL-4 (Kohler and Richer 1993). A sequence 
hom ologous to IL-4RE is found in the IL -2R a prom oter between nucleotides -306 
and -298. The protein NFIL-4 which binds to this site appears to correspond to the 
recently identified transcription factor known as STAT-6 (alternatively known as IL-4 
STAT) (Flou ei al 1994). This is a lOOkDa protein which, when discovered, was 
found to have substantial sim ilarity to the STAT family o f  transcription factors. The 
m ost significant segments o f  sequence sim ilarity corresponded to three regions, one 
consisting o f  approxim ately 50 amino acids located to the NH^-termini o f  all STAT 
proteins and two more centrally located regions which were predicted to specify SFI2 
and SH3 domains.
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1,10 Aims of the Project
The aim s o f my project were to investigate the factors which could induce expression 
o f  IL -2R a in hum an tonsillar B lymphocytes. In particular, it was determ ined that I 
would tbcus on how signals through the antigen receptor would affect IL -2R a 
expression and thus cause the B cell to proliferate and differentiate. Finally, the role o f 
transcription factors which bound the IL -2R a promoter region were to be studied in 
order to determine which were im portant in causing IL -2R a to be up-regulated and 
which, if  any, were under the direct control o f  signals transduced by the antigen 
receptor.
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Chapter 2 
M aterials and Methods
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2.1 Materials
2.1.1 Chem icals
AH routine chem icals were o f  the highest grade available and were supplied by the S igma 
Chemical Com pany o f  Poole, Dorset, U.K., unless otherwise stated below.
2.1.2 Human Tissue
Tissue was obtained from juvenile male and female tonsillectom y patients at the Royal 
Hospital for Sick Children, Yorkhill, G lasgow (courtesy o f Mr Carachi). From these we 
obtained resting B cells. The reason for the removal o f  the tonsils was not known. However, 
the children were generally young and it is unlikely that they had been exposed to any chronic 
infections. In addition, any tissue which appeared infected was im m ediately discarded.
2.1.3 Cell Culture M aterials
The following tissue culture supplies were obtained from Gibco-BRL Life Sciences, Paisley, 
Scotland, U.K.:-
RPM I-1640 medium
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Glu tam ine
Penicillin / S treptomycin 
Foetal C alf Serum
Trypan Blue was obtained from the S igm a Chemical Company, Dorset, U.K.
2.1.4 B Cell Separation M aterials
Perçoit
FicolFFlypaque (1.077g/m l)
Sheep Red Blood Cells in AlseveUs 
Solution
2-Ami noethyIisothiouronium  brom ide 
(AET)
Sigma.
Pharmacia, Uppsala, Sweden.
SAPU, Carluke, Lanarkshire, Scotland, 
U.K.
Sigma.
2.1.5 Radiochem icals
The following radiochem icals were obtained from Amersham International pic, 
Buckingham shire, U.K.:-
(Methyl-['^H]) Thym idine 
Y“[^ ‘P]-Adenosine Triphosphate
44C i/mmol 
5000Ci/mmol
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['''C]-chloroam phenicol 50-62mCi/mmol
2.1.6 Cytokines
IL - la ,  IL-1 (3, lL-3, IL-5, IL-6 and IL-8 Geneva Biomedical Research Institute,
T N F -a
IL-1Î
IL-2
IL-4
IL-7 and IL-13
Geneva, Switzerland.
British Biotechnology, Abingdon, U.K. 
Genetics Institute, Cam bridge, M A, USA. 
Genzyme, Kent, U.K.
Imm unex, Seattle, W A, USA.
R&D Systems, Abingdon, U.K.
2.1.7 Gel Electrophoresis M aterials
40%  A crylam ide / B isacrylam ide solution (29:1) from Biorad Laboratories, CA, USA. 
A m m onium  Persulphate and TEM ED from Sigma.
2.1.8 Antibodies
Polyclonal Goat anti-hum an Im m unoglobulin Sigma
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G oat anti-hum an IgM (g  heavy chain 
specific).
Southern B iotechnology Associates Inc., 
Birmingham , AL, USA.
Goat anti-hum an IgD (8 heavy chain 
specific),
F (ab ' ) 2  fragment anti-hum an IgM (p heavy 
chain specific),
F (ab " ) 2  fragment anti-hum an IgD (5 heavy 
chain specific).
Affm ipure Goat anti-hum an IgG (H&L), Jackson Im m unoresearch Laboratories Inc.
Afflnipure F(ab ’ ) 2  fragment Goat anti-hum an PA, USA.
IgG (H&L),
A fl ini pure Fab fragm ent Goat anti-human 
IgG (H&L).
M onoclonal M ouse anti-hum an CD40 
antibody
FITC-conjligated m onoclonal m ouse anti­
hum an lL-2 Receptor,
RPFi-conJugated monoclonal m ouse anti­
human CD 19.
Serotech, Oxford, U.K.
DAKO, Denmark,
Biotinylated m ouse anti-hum an CD23 
Streptavidin-Q uantum  Red conjugate
The Binding Site, B irm ingham , U.K. 
Sigma
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2.1.9 O ligonucleotides
The following oligonucletides were obtained Irom Promega, WI, USA;
CREB Consensus O ligonucletide 5 ’ AG A GAT TGC CTG ACG TCA
GAG AGC TAG 3’
AP-1 Consensus O ligonucleotide 5 ’ CGC TTG ATG AG T CAG CCG
G A A 3 ’
N F-kB Consensus O ligonucleotide 5’ AGT TGA GGG GAG TTT CCC
A G G C 3 ’
The following oligonucletide was obtained from CRUACFIEM, Beatson Institute, Scotland, 
U.K.:
IL-4RE Consensus Oligonucleotide 5’ CAG TGC CAA GAA GTG CTT
G C T 3 ’
The following oligonucleotide was obtained courtesy o f J. W innie, Beatson Institute, Scotland, 
U.K.:
NRE Consensus Oligonucleotide 5’ TTC ATC CCA GG 3 ’
2.1.10 Plasm ids
CD25 Reporter Gene Plasm ids were constructed by Dr E. Hewitt, D ivision o f  Biochem istry 
and M olecular Biology, University o f  Glasgow, U.K. (Hewitt ei a l 1997).
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2.1.11 Enzymes
T4 Polynucleotide kinase was obtained from Promega, MA, USA.
T4 Polynucleotide kinase 10 x Buffer Stock:-
700m M  Tris-HCl, pH7.6
lOOmM M g C f
50mM  DTT
2.2 BUFFERS
170m M N aC l 
3.4mM  KCl 
lOmM Na 2 HP 0 4  
1.8 mM KH 2 PO 4
TBE Buffer
89mM  Tris-HCl, pH8.0 
89m M  Boric Acid 
20m M  EDTA
Phosphate Buffered Saline (PBS) pH7.2
68
T ris-ED TA  (TE) Buffer 
lOmM Tris-HCl, pH8.0 
I mM EDTA
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2.3 M ETHODS
2-3.1 Preparation of B Lym phocytes from Human Tonsils 
2.3.1(a) AET Treatm ent o f Sheep Red Blood Cells
5ml o f sheep erythrocytes were centrifuged and washed twice in incom plete m edium  (RPM I- 
1640 medium  containing 100 LU./ml Penicillin / Streptomycin). A t the same time, 102mg o f  
2-am inoethy 1 isothiouronium  bromide (AET) was dissolved in 10ml distilled water, adjusted to 
pH9.0 with 5M NaOH and filter sterilised. 4m 1 o f  the AET solution was added to the washed 
sheep erythrocytes and the suspension incubated at 3 7 T . After 20 m inutes, the cells were 
washed five times in incom plete medium and then resuspended in 9mls o f  incom plete m edium , 
t he AET-treated Sheep Red Blood Cells (AET-SRBC) were stored at 4"C for up to one week.
2.3.1(b) Isolation o f B Cells
Ceils were obtained by teasing apart excised tonsils followed by passage through a fine mesh 
to obtain a single cell suspension. M ononuclear cells were obtained by centrifugation over 
Ficoll (1 part Ficoll: 1 part cell suspension) at 1400rpm for 15 minutes. The m ononuclear cells 
were rem oved from the interface and then washed twice in incom plete medium. The cells were 
then resuspended in incom plete medium  (see Section 2.3.1a) and 10% (v/v) AET-SRBC was 
added. After incubating for 15 m inutes at 37^C, the suspension was centrifuged at 800g for 5
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m inutes and 10% (v/v) FCS (heat inactivated) was layered on top o f the resulting pellet. This 
was left on ice for 30 minutes. After the incubation, the pellet was gently resuspended by 
rocking, the sample layered onto Ficoll and centrifuged at 1400g for 20 m inutes. B 
lym phocytes were rem oved from the interface and washed twice in incom plete m edium . The 
cells were then resuspended in 1.5ml o f  incomplete medium.
2.3.1(c) Separation of the B Cell Populations by Percoll G radient C entrifugation
Percoll gradients were prepared as described by Ratcliffe and .lulius (1982). Percoll densities 
o f  1.09, 1.08, 1.075, 1.065 and 1.055 g/ml were prepared from an iso-osm otic stock (9 parts 
Percoll: 1 part lOxPBS) using the formula:
Vy= Vj(Pi-p)
(P -Py)
where p, == the density o f  the stock iso-osmotic percoll 
p = the density o f  the solution produced 
Vy = the volum e o f  diluting medium 
Vj = the volume o f  stock iso-osmotic percoll.
1ml o f  each density o f  Percoll solution was layered into a 15ml centrifuge tube starting with 
1.09g/ml and decreasing in density to 1.055g/ml. The B cell suspension was layered onto this 
and a covering layer o f  I ml incom plete medium was pipetted on top. The gradients were
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centrifuged at 2200rpm  for 30 m inutes. Resting B cells are small, high density cells and these 
were harvested from the 1.09/1.08 g/ml interface. After rem oving the B cells from the 
interface, the cells were washed three times in incomplete m edium  and then used im m ediately. 
An aliquot o f  cells was rem oved at this stage and analysed by FACS analysis using antibodies 
conjugated to anti-CD3 and anti-CD 19 to determ ine how pure the B cell population was. This 
m ethod routinely produced a population o f  cells that was greater than 95%  B cells (data not 
shown).
2.3.2 Cell Culture o f H um an Tonsillar B Lym phocytes
Cells were maintained in com plete medium (RPM I-1640 supplem ented with 10% (vA9 foetal 
ca lf serum , heat inactivated at 56‘C  for 30 m inutes, 2mM L-Glutam ine and 100 l.U./ml 
Penicillin/Streptom ycin). Cells were cultured for the times indicated in the text and figure 
legends and with the appropriate concentrations o f  cytokines and antibodies. Cells were 
cultured in 25cm^ flasks, 24 well or 96 well plates at 37"C in a 5% CO^ atm osphere. 
Preparation and m aintenance o f the cells was carried out in a Lam inar Flow  Cabinet.
2.3.3 Determ ination o f Cell Viability.
Cell viability was determined by mixing 1 volume o f cell suspension with 1 volum e o f  0.4%  
(u '/r) Trypan Blue. V iability was determined on the basis that dead cells take up Trypan Blue. 
The num bers o f  live and dead cells were counted using a Neubauer haem ocytom eter. The
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average num ber o f  cells per 16 square grid was multiplied by 10'' and the dilution factor taken 
into account to estim ate the num ber o f  cells per ml o f culture.
% viability = num ber o f  live cells x 100
Total Cell Num ber
2.3.4 Stim ulation o f Resting B Tonsillar Cells with Anti~lg, Anti-C D40 and IL-4
Cells were cultured in 24 well plates in com plete medium at a concentration o f  10^ ’ cells per 
well in a final volum e o f  1ml. Varying concentrations o f  anti-Ig, anti-CD 40 antibodies or lL -4 
diluted in com plete medium were added to wells either separately or in com bination. The cells 
were then incubated for 24 hours at 37"C at 5% CO 2  atm osphere and harvested for use in 
FACS analysis.
2.3.4 Flow Cytom etric Analysis 
2.3.4(a) Two Colour Flow Cytom etry
Aliquots o f  approxim ately 1x10^’ cells were rem oved from cultures, pelleted, washed tw ice in 
ice-cold PBS and resuspended in PBS to give 1x10^’ cells/50pl. Two different antibodies 
which were directly conjugated to fluorescent markers (FITC and PE) were then added to the 
cells as specified in the text and figure legends. The samples were incubated on ice for 30
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minutes. After incubation, the cells were washed twice in ice-cold PBS and finally 
resuspended in 0.5ml o f  PBS for analysis by flow cytometry. In each experim ent a control was 
included where no antibody was added and this was used to correct for the autofluorescence o f 
the cells. In addition, prior to the experiment, negative isotype control experim ents were done 
(data not shown).
Im m ediately prior to data collection, propidium  iodide (PI) was added to each sample at a final 
concentration o f  5pg/m l. Antibody staining was analysed using a FA CScan flow cytom eter 
(Bccton-Dickinson, M ountain View, California, USA) using the FACSCAN program m e. Cells 
were gated on forward and side light scatter, as well as for the PI-em itted fluorescence to 
facilitate exclusion o f  non-viable cells from the analysis. Analysis was perform ed using the 
LYSYS programme.
2.3.4(b) Three C olour Flow C ytom etiy
Preparation o f  the cells was the same as in Section 2.3.4(a) but three antibodies, which were 
directly conjugated to fluorescent m arkers (FITC and PE), or to biotin, were added 
sim ultaneously to the cells as specified in the text and figure legends. The sam ples were 
incubated on ice for 30 minutes, washed twice in ice-cold PBS and resuspended in 50|ll1 PBS. 
lOpl o f  Streptavidin-Q uantum  Red Conjugate was added to the samples and they were again 
incubated on ice for 30 minutes. The cells were then washed twice in ice-cold PBS and 
resuspended in 0.5ml PBS. They were analysed using a FACScan flow cytom eter as described
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before but were gated on forward and side light scatter only to facilitate analysis o f  live cells. 
A control sample o f  cells containing no antibody was also included, as in Section 2 .3.4(a) to 
correct for the auto fluorescence o f  the cells.
2.3.5 Cell Proliferation Studies
Cells were cultured in 96 well round bottom ed tissue culture plates at a concentration o f  10  ^
cells per well. The cells were cultured for three days in complete m edium  at 37"C at 5% CO^ 
over range o f concentration o f antibodies and cytokines as specified in the text and figure 
legends; all cultures were established in triplicate. Follow ing this, the cells were pulsed with 
0.5j.iCi o f  mcthy I - [ ' FI ] -thym id i ne in a volume o f  lOpl o f  complete medium . The tissue cu lture 
plate was then incubated for 8 hours at 37"C at 5% CO t and then the contents o f  each well 
were harvested on to filter mats using a sem i-autom atic cell harvester (Skatron Instruments 
Ltd, Suffolk, U.k.). The filter papers were dried, immersed in scintillation fluid and counted 
by a liquid scintillation counter (W allac 1209 RA CKBETA counter). [T l]-Thy midi ne 
incorporation was expressed as mean counts per m inute (cpm) + S tandard Deviation (SD).
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2.3.6 Gel Shift Assays
2.3.6(a) Preparation o f N uclear and Cytoplasm ic Cellular Extracts
Buffers
Buffer A Buffer B
lOmM HEPES, pH7.5 25mM  HEPES, pH 7.5
2m M  MgCE 400m M  NaC l
15mM KCl Im M  EDTA
0.1 mM EDTA 20% G lycerol
0.1 mM EGTA Im M  DTT
Im M  DTT 0 .1% N P40
0.5m M  PM SF 0.5mM  PMSF
2pg/m l Leupeptin 2|Lig/ml Leupeptin
2pg/m l Apro tinin 2pg/m l Aprotonin
Prim ary tonsillar B cells were cu ltured overnigh t in fresh medium prior to stim u lation for four 
hours with the appropriate concentrations o f  cytokines and antibodies as described in the text 
and figure legends. 5 x 10^ ’ cells were rem oved at time zero, and at hourly intervals thereafter, 
pelleted and washed once in PBS. The samples were then resuspended in Buffer A and left on 
ice for 30 minutes. NP-40 was added to a final concentration o f  0 .5%  {v/v) and the nuclei
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im m ediately separated by centrifuging at 10,000g. The supernatant (the cytoso lic extract) was 
rem oved and stabilised by adding 60p l o f  50% (v/v) glycerol wh ile the nuclear pellet was 
resuspended in lOOpl o f  Buffer B and gently rocked for 30 m inutes at 4‘’C. The suspension was 
centrifuged at 10,000g and the supernatant removed . This was the nuclear extract. Both nuclear 
and cytop lasm ic extracts were stored at -70"C.
2.3.6(b) N on-D enaturing Gels for Gel Shift Assay
The ce llular extracts were resolved by electrophoresis on a 7% (w/v) non-denaturing 
aery lam i de gel prepared as follows;-
17.5% acry lam ide (40% A cry lam ide /Bisacry lam ide solution, 29:1)
0.25 X TBE
0.1%  A m m onium  Persulphate 
0 .05%  TEM ED
The gels were pre-run for two hours at 150V using 0.5 x TBE as the reservoir buffer.
Prior to loading, the samples were assayed for protein using the Lowry protein assay method . 
Extracts containing 5pg o f protein were combined with binding buffer in the presence or 
absence o f  cold com petitor o ligonucleotide as required and incubated at room tem perature for 
10 minutes, Ip l o f  y -p P j-lab e lled  o ligonucleotide (0 .035-0.35pm ol) was added to the m ixture 
and incubated at room tem perature for a further 20 minutes.
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5 X Binding Buffer Stock:-
20%  (v/v) G lycerol
5mM MgCU
2 .5niM  DTT
250m M  NaC l
50mM  Tris-HC l, pH 7.5
0.25mg/m l Poly(dI-dC).poly(dI-dC)
The samples were loaded onto the gel and electrophoresed at 150V for 140 m inutes. A small 
am ount o f  dye was run parallel to the sample to allow progress o f  electrophoresis to be 
monitored . Free and protein bound o ligonucleotide was visualised by autoradiography o f  the 
dried gels.
Dye Solutioii:-
250m M  Tris-HC l, pH7.5 
0.2%  {w/v) brom opheno l blue 
0 .2%  (w/v) xylene cyanol 
40%  (v/v) G lycerol
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2.3.6(c) Radio-Labelling o f O ligonucletides for Gel Shift Assay
The sense and antisense o ligonucleotides were synthesised and annealed by m ixing equim o lar 
am ounts ol the two o ligonucleotides, heating to 80“C for 5 m inutes in a water bath and then 
allow ing them to cool slowly to room temperature. y-[^^P]-dATP labelled fragm ents were 
produced by labelling the 5’ term inus o f  the DNA using T4 po lynucleotide kinase. For each 
probe, 17.5pmol o f  the appropriate DNA was mixed with Ip l o f T4 po lynucletide kinase 10 x 
Buffer, 5-10 units o f  T4 po lynucleotide kinase, Ip l o fy -p P J-d A T P  and the volume m ade up 
to lOpl w ith distilled water. The reaction was incubated for 10 m inutes at 37"C and then 
stopped by the addition o f  Ip l 0.5M  EDTA . 89pl o f  TE Buffer was added and the radio- 
labelled probe stored at -70‘^ C until needed.
2,3.7 Transfection of Tonsillar B Cells by Electroporation
Prior to electroporation, resting tonsillar B cells were cultured for a m inim um  o f 1 hour after 
isolation. The cells were then washed and suspended in incomplete m edium  at a concentration 
o f  6.25 X 10^ ’ cells/m l. 0.8m l aliquots o f  this cell suspension were electroporated at an optim um  
vo ltage o f  0 .3-0.35kV, capacitance 960jLiFD in a 0.4cm Gene Puiser cuvette (Biorad 
Laboratories, CA, USA) w ith 40pg o f  the appropriate plasmid in 40p l o f  TE buffer (A nderson 
et a l 1991). The electroporated cells which had been transfected with the same plasm id were 
poo led and incubated for a further hour in complete medium . A liquots were then rem oved and
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stim ulated for 48 hours with the appropriate antibodies as indicated in the text and the figure 
legends.
2.3.8 Reporter G ene Assay
The transiently transfected cells were harvested and washed three tim es in sterile PBS. Cell 
extracts were prepared by resuspending the cells in lOOpl o f  Tris-HC l, pH7.8 and then lysing 
them  by imm ersing them for 5 minutes in a dry ice-ethanol bath followed by im m ersion for 5 
m inutes in a 37"C water bath. This freeze-thaw lysis was done three times. The sam p les were 
centrifuged at 250g for 10 m inutes to pellet the cellular debris and the supernatant rem oved 
and heat-inactivated by incubating at 65"C for 10 minutes, to inactivate the cellular acety lases. 
A t this point, the protein content o f  each cellular extract was determined by the Lowry protein 
assay. The reporter gene activity was m easured by incubating the cell extracts with 5mM  
Acetyl Coenzym e A and Ip l o f  [*''C]-chioroamphenicol (0 .025pCi) at 37"C for 16-20 hours.
The assay was stopped by adding 600p l o f  ethyl acetate, m ixing and centrifuging at 250g for 5 
m inutes. The upper phase o f  the ethyl acetate was removed and then lyoph ilised until no ethyl 
acetate remained . The lyophilised sample was resuspended in 20p l ethyl acetate and the 
acety lated products resolved by th in layer chrom atography (TLC) on 20 x 20cm silica p lates in 
a 95%  chloroforni:5%  methanol solvent system . Acetylated chloroam phenico l was visualised 
by autoradiography and quantitated by phosphorim age analysis. Data from the phosphorim age
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analysis was expressed as phosphorescence units minus background phosphorescence per m m ' 
(P -B /m nr) and was norm alised for cellular protein content.
2.3.9 L ow iy  Protein Assay
Solution A
2%Na2C0, 
l% C u S 0 ,.5 H ,0  
2 %  N a K  t a r t r a t e . 4 H 2 0  
2.5%  SDS 
O .lN N aO H
Solution B
16.6% Folins C iocalteu Phenol Reagent
BSA standard protein samples were prepared at concentrations o f  5-100 m g in 1ml. An equal 
volum e o f  Solution A was added to the standard samples and to the sam p les wh ich contained 
an unknown am ount o f  protein. These were then mixed and incubated at room tem perature for 
10 m inutes. Follow ing this, 0.5m l o f  Solu tion B was added to the sam p les, they were mixed 
im m ediately and incubated at room  tem perature for a further 30 minutes. The absorbance o f  
the standard samples was read at 750nm with a spectropho tom eter (tungsten ligh t setting) and 
from the values obtained a standard curve was plotted. This was used to determ ine the am ount 
o f  protein present in the cellular extracts.
Chapter 3
The Induction o f CD25 Expression in Resting Human B 
Lymphocytes by Stimulation with Anti im m unoglobulin, Anti-CD40  
and IL 4.
82
3.1 Introduction
Interleukin-2 (IL-2) plays a crucial role in both the differentiation and growth o f 
hum an B lymphocytes (Callard 1990; Cushley and Harnett 1993) and the effects o f  
the cytokine are m ediated through the interaction o f  IL-2 with the IL-2 Receptor 
com p lex (1L-2R) (Smith 1989; W aldm ann 1989). To date, three po lypeptide chains 
have been identified as com ponents o f the 1L-2R, namely the a ,  (3 and y chains. The 
hum an lL -2R a chain was originally defined by the Tac antibody and is now defined 
by the CD25 antibody cluster. It was identified as a 55kDa m em brane g lycopro tein 
(p55) capab le o f  binding IL-2 (Leonard el al 1983; Robb and Greene 1983). It was 
though t to be the only cytokine receptor o f  a large family o f  binding proteins whose 
m em bers include com p lem ent receptor proteins (Davie et al 1986; Perkins et al 1988). 
However, a novel IL-15 binding protein was recently identified and cloned that is 
structurally related to the a -cha in  o f the IL-2R (Giri et al 1995). The IL -2R a chain 
binds IL-2 with low affinity (Kd = lOnM) and is non-functional w ith respect to lL-2 
internalisation and IL-2 signalling (Hatakeyam a et al 1985; Greene et a l 1985).
The p chain o f  the IL-2R is a 75 kD a g lycoprotein which, through its cytop lasm ic 
dom ain, appears to play a critical role in receptor-m ediated signalling . The third 
com ponent o f  the 1L-2R com p lex is a 64kDa transm em brane subunit, the y^  chain. The 
P and y^  chains are required for ligand internalisation and signal transduction (Arim a 
et a l 1992; Kishim oto et al 1994) and both belong to the haem atopoietin receptor 
superfamily. M u tations in the IL-2Ry chain appear to be responsib le for the X 
chrom osom e-linked im m unodeficiency SCID X l in humans (Leonard ei al 1994). 
SC ID X l patients suffer from severe recurrent infections, fail to thrive and unless 
treated with curative bone m arrow transp lantation will die in the first years o f  life.
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The disease is characterised by a m arked decrease in circulating T cells and the 
presence o f  poorly functioning B cells (Conley 1992). The lL-2Ry chain also 
participates in the formation o f functional receptors for IL-4, IL-7, IL-9 and IL-15 
(Leonard ei al 1994; Giri et al 1994; Kim ura et al 1995).
D ifferent com binations o f  these three receptor subunits on hum an B cells give rise to 
three affinity classes o f  receptor. A high affinity IL-2R is formed through the 
com bination o f the a ,  p and y com ponents in a heterotrim eric com p lex (Kd ~IO '"M ) 
with a receptor o f  intermediate affinity form ed by a com bination o f  p and y subunits 
(lO '^M); lL -2 R a  alone binds IL-2 with relatively low affinity (Kd ~ 10'^ M) (Smith 
1989; W aldm ann 1989; Kish im oto et al 1994). The a  subunit o f  the IL-2R is not 
constitutively expressed and is up-regulated by distinct groups o f  cytokines in both T 
and B lymphocy tes (Greene et al 1989; C lipstone and Crabtree 1994; Butcher et al 
1990; Butcher and Cushley 1991; Zola et al 1991; Tom izawa et al 1991). For 
example, both IL-1 and Tum our N ecrosis Factor-a (TN F-a) can prom ote expression 
o f  the a  chain in T lymphocytes (Lowenthal et al 1986; Lee et al 1987). IL-4 and IL-5 
control expression o f  the IL-2R in m urine B cells through independent induction o f  its 
two chains. It was shown that IL-5 induces these cells to express CD25 wh ile IL-4 
induces the p chain (although not always) (Loughnan and Nossal 1989; Nakanish i et 
al 1993). This was the first exam p le o f a situation where two chains o f  a receptor are 
separately regu lated by two different cytokines to perm it a coordinated appearance o f  
functional h igh affinity receptors. By contrast, in hum an tonsillar B cells, IL-4 has 
been shown to up-regulate expression o f CD25 (Butcher et al 1990; Butcher and 
Cushley 1991 ; Zo la et a l 1991 ; Tom izawa et al 19 9 1). This effect is apparently
84
specific to IL-4 and can be inhibited by IFN-y. As the a  chain has no overt signal 
transduction capacity, its main role w ou ld appear to be in the generation o f the 
specific high affinity receptor for IL-2 (Roessler et al 1994) which is crucial for the 
growth and differentiation o f  B cells.
Initially we sought to identify, in addition to IL-4, any other receptor-ligand 
interactions on hum an B cells which would facilitate up-regu lation o f CD25. The 
growth and activation o f  B lymphocytes are regulated by signals transm itted after the 
binding o f  antigen to surface im m unog lobulin (sig) and o f cytokines to their specific 
receptors. A num ber o f  other B cell-associated surface m o lecu les are also involved. 
The binding o f  antigen to sIg is the primary event in B lym phocy te activation . Thus 
we studied the effect on CD25 induction o f  stim ulating the B cell v ia its antigen 
receptor. Anti-Ig antibodies were used as analogs o f antigen, with the assum ption that 
anti-Ig will bind to constant regions o f  m em brane Ig m o lecules on all B cells and have 
the same biological effects as antigen that binds to the hypervariab le regions o f 
m em brane Ig m o lecu les only on antigen specific B cells.
We also looked at the effect on CD25 levels on resting human B cells in response to 
CD40 ligation, as m ediated by anti-CD40 antibody . The CD40 antigen is a 45-50kD a 
glycopro tein which is expressed on B cells, T cells and dendritic cells. It is a m em ber 
o f  the TNF receptor superfamily (Banchereau et al 1994). The CD40 ligand, a 
m em ber o f  the TNF family, is a 39kDa g lycoprotein found on T cells, m ast cells and 
basophils. The levels o f  expression on T cells increase as they m ature (Gauchat et al
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1993; N onoyam a et a l 1995). CD40 activation is critical for B cell proliferation 
(Banchereau et al 1991), Ig class-sw itch ing and the rescue o f germinal centre B cells 
from apoptosis follow ing somatic m utation (Liu et ol 1989; Zhang et al 1991). 
Therefore we sought to examine the effect o f  CD40 ligation on CD25 expression . 
S timuli were also used in com bination to discover if  any synergistic effects could be 
noted.
As stated, B cells can be induced to express IL -2R a but there are conflieting reports 
as to whether such B cells can respond to IL-2 and proliferate. In the m urine system , 
unstim u lated B cells can respond to h igh concentrations o f  IL-2, and IL-5-treated B 
cells have been shown to have significantly enhanced responses to IL-2 (Nakanish i et 
al 1992). In contrast, K arasuyam a et al found no synergy between lL-5 and IL-2 in 
either B cell m aturation or growth induction (Karasuyam a et al 1988). Therefore we 
sough t to discover whether an increase in CD25 expression could induce IL-2 
responsiveness in resting human tonsillar B cells.
3.2 The Induction o f CD25 Expression in Resting Tonsillar B Lym phocytes.
Id le B lym phocy tes used in th is study were prepared from a single cell suspension o f  
freshly spilled tonsillar cells with the removal o f  T lym phocy tes by resetting with 
AET-SRBC . The non-rosetting cells were then centrifuged over a discontinuous 
Percoll gradient and B cells collected from the 1.08/1.09 g/m l interface. This m ethod 
routinely produced a popu lation o f  cells that was greater than 95% B cells. B cells 
purified from the 1.08/1.09 g/m l interface are small and putatively resting in nature.
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Fo llow ing purification and prior to cu lture only a small proportion (typically 0.5-3% ) 
o f  the B cell population expresses IL -2R a (24, 25 , data not shown ). Previous studies 
(Butcher d  al 1990; Butcher and Cushley 1991; Zo la ef al 1991; Tom izaw a ei al 
1991) have dem onstrated that IL-4 can induce expression o f  IL -2R a on human B 
cells. We sough t to extend these studies by analysing the effect o f  ligation o f surface 
Ig, CD40 and various cytokines upon IL -2R a expression in the high density resting 
popu lation o f  human tonsillar B cells.
In figure 3.1 resting tonsillar B lymphocytes were cultured with lOOu/ml IL-4 and 
then analysed after 24 hours by two-co lour flow cytometry. The dot-p lo t shows that 
wh ile only 17.8% o f  the control population (unstim u lated B Cells) express IL -2R a on 
their surface, 34%  o f the IL-4 stim ulated B cells express cell surface IL -2R a . These 
data are consistent with previous observations that lL-4 induces IL -2R a expression on 
resting tonsillar B cells. The ability o f  other cytokines to promote th is effect was then 
studied.
F irstly the effects o f  IL-IO and IL -I3 , two cytokines with po tent stim u latory effects 
tow ards B cells, were examined . IL-IO is a m ajor imm unoregulatory cytokine 
produced chiefly by T cells and m onocytes. It has been shown to enhance expression 
o f  IL -2R a on B cells which have been pre-stim u lated with anti-CD40 antibody 
(F luck iger et al 1993) and has also been shown to up-regulate IL -2R a expression on 
cloned T cells o f  various phenotypes (Cohen et al 1994). IL -I3  is a  T cell derived 
cytokine which regulates human monocyte and B cell function. IL -I3  and IL-4 share
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certain functional characteristics including the induction o f  the m acrophage-like 
dendritic cell m orphology (te Velde el al 1988) with associated CD23 expression on 
m onocytes (Vercelli ei al 1988) and stim u lation o f Ig synthesis by B cells (Van 
V lasselaar et al 1992). However Figure 3.2 shows that neither IL-IO nor IL-13 were 
capab le o f  inducing IL -2R a expression at the concentrations shown. Dose response 
titrations were also done using a range o f  concentrations o f  these cytokines (data not 
illustrated) but neither showed an increase in IL -2R a expression. The concentration 
ranges used were over at least 5 points and were o f  a range that had shown 
appreciab le effects in other types o f  cells. A range o f  other cytokines was then studied 
to see if  any o f  these were capable o f  inducing IL -2R a expression (Figure 3.3). O f 
particu lar interest was IL-5 which, as stated previously, has been shown to increase 
IL -2R a expression on resting m urine B cells. However no other cytokine examined 
could induce IL~2Ra expression in hum an tonsillar B cells either at the concentration 
range shown in the experiment or indeed across a wider concentration range as before 
(data not illustrated).
F inally, levels o f IL -2R a expression on resting B cells cultured either with polyvalent 
anti-1 g or anti~CD40 antibodies were examined (Figure 3.4). Anti-CD40 antibody 
(Figure 3.4,panel D) induced a response o f  sim ilar profile to that o f  IL-4; i.e. 28.2%  o f 
the B cell population were induced to express IL -2R a on their cell surface. Flowever 
cu lture o f  the cells with anti-lg antibodies drove a response o f  considerab ly greater 
m agnitude. As seen in Figure 3.4, panel C, 68.4% o f  the B cell population were 
induced to express IL -2R a . A lthough the absolute level o f  IL -2R a expression induced 
varied between individual tonsillar preparations, IL-4, anti-Ig and anti-CD40
consistently increased IL -2R a expression on h igh density B cells and anti-Ig routinely 
induced the greatest num ber o f  B cells to become IL -2R a positive.
3.3 The Effectiveness o f IL-4, A nti-Ig and Anti-CD40 Induction o f IL -2R a  
Expression.
The concentrations o f  IL-4, anti-Ig and anti-CD40 required to drive half-m axim al 
expression o f  lL -2R a were evaluated by testing the response o f  B cells across a wide 
concentration range o f  each stimulus; the concentration o f  each stim u lus which 
elicited half-m axim al elevation o f  IL -2R a expression (i.e. the EC 5 0  dose) was also 
determ ined (Figure 3.5). IL-4, anti-Ig and anti-CD40 all increase IL -2R a expression 
in a dose dependent manner; thus the num ber o f  B cells becom ing positive for IL -2R a 
increased in proportion to the concentration o f  lL-4, anti-Ig or anti-CD40 . For IL-4, 
the EC 5 0  was o f the order o f  40-50 units/m l IL-4 (Figure 3.5, panel A) which is in 
good agreem ent with previous data from th is and other laboratories. Dose-response 
titrations o f  the effects o f anti-Ig (Figure 3.5, panel B) and anti-CD40 (Figure3 .5, 
panel C) revealed that the EC^o values for these stimuli were approxim ately 10 pg/m l 
and 0 .2 pg/m l, respectively.
These dose-response curves were converted to molar concentrations (Figure 3.6, panel 
A) to com pare the potency o f  stimuli. This revealed that IL-4 is by far the m ost potent 
inducer o f  IL -2R a expression in resting hum an B cells. The am ounts o f anti-Ig or 
anti-CD40 stimuli required to effect half-maxim al stim ulation were 2-3 orders o f 
m agnitude greater than that observed with the cytokine. F inally, F igure 3.6, panel B
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notes the maximal IL -2R a response which could be induced by each stimulus. Anti-Ig 
consistently drives the greatest proportion o f  B lymphocytes to express IL -2R a (60- 
80%). IL-4 and anti-CD40 induced broadly sim ilar responses; they both induced 20- 
25%  o f  B cells to become IL -2R a positive.
3.4 The Effects o f IL-4, A nti-Ig and Anti-CD40 Com binations on IL -2R a  
Expression.
Treatm ent o f  resting tonsillar B cells with each o f IL-4 , anti-Ig or anti-CD40 
increased IL -2R a expression . In the follow ing studies, the effects o f  these factors in 
com bination on lL -2 R a  levels was studied. F igure 3.7, panel A show s CD25 
expression in cells cultured over a range o f  concentrations o f  anti-Ig in the presence or 
absence o f  IL-4. An lL-4 concentration o f 10 units/m l was em p loyed as th is induces 
subm axim al IL -2R a up-regulation . The data show  that IL -2R a expression is 
increased in a dose dependent manner. IL-4 recruited approxim ately 10% o f  B 
lym phocy tes to the IL -2R a response. M odest doses ( l-5pg /m l) o f  anti-Ig showed a 
m odest additive efleet in the presence o f  IL-4. However, at the maximum  
concentration o f anti-Ig (25pg/m l) IL -2R a was expressed by 60% o f  the B cell 
population and IL-4 did not enhance receptor expression. In conclusion, the 
com bination o f  submaximal levels o f IL-4 and anti-Ig increased IL -2R a in only an 
additive m anner and no synergistic effects were apparent.
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Figure 3.7, panel B show s the com bined effects o f  anti-CD40 and ÏL-4. Again there 
was an increase in IL -2R a levels in response to increasing concentrations o f anti- 
CD40. This was seen whether IL-4 was present or not. The same concentration o f IL- 
4 was used as in figure 3.7A; again 10 units/m l o f  IL-4 alone elevated IL -2R a 
expression by approxim ately 10%. In com binations o f  anti~CD40 over the 
concentration range o f  0 .1-6.4 pg/m l w ith IL-4 the levels o f  IL -2R a were enhanced 
by approxim ately 5% o f  that expected for a purely additive effect.
A th ird study was performed to assess the combined effects o f  anti-Ig and anti-CD40 
on IL -2R a expression by B cells (Figure 3.7, panel C). Anti-Ig was titrated over a 
concentration range o f 0-25 pg/m l where 1-5 pg/m l gave submaximal stim u lation o f 
lL -2R a expression . On culture o f  B cells with anti-CD40 antibody ( 0.5 pg/m l) alone 
IL -2R a expression was seen to increase by approxim ately 15%. The com bination o f 
anti-Ig and anti-CD40 antibodies gave an additive effect. A t lower concentrations o f  
anti-Ig, IL -2R a expression increased by approxim ately 15% on addition o f  anti- 
CD40. Flowever at 25 pg/m l o f  anti-Ig, addition o f  anti-CD40 increased IL -2R a 
levels by only 5%. This suggests that IL -2R a had been induced to the m axim um  level 
by anti-Ig stim u lation and that no further up-regu lation could be achieved.
3.5 The Effects o f Anti-Ig antibodies, Anti-CD40 antibodies and IL-4 in 
com bination with IL-2 on B cell proliferation.
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Resting, hum an B lymphocytes can be induced to express lL -2 R a  by cu lturing them 
with anti-lg antibodies, anti-CD40 antibodies and IL-4. For B cells to pro liferate and 
differentiate in response to physiological levels o f  IL-2 they m ust express the high 
affinity form o f  the IL-2R consisting o f  the constitutively expressed p and chains, in 
association with the inducible a  chain. lL -2 R a  expression is not only essential for th is 
but also confers specificity on the receptor for IL-2 as the p and y^  are shared with the 
IL-15R . To determ ine whether increased IL -2R a expression results in significant 
pro liferation o f  resting B cells, we stim u lated the cells with a range o f  concentrations 
o f  anti-Ig, anti-CD40 and IL-4 in the presence or absence o f  IL-2.
F igure 3.8, panel A shows that IL-2 and anti-Ig synergise to induce a strong 
pro liferative response in the resting B cell population . Anti-Ig, in the presence o f  IL-2 
increased proliferation in a dose dependent manner. Cross-linking o f  surface Ig alone 
or in the presence o f IL-4 showed a weak proliferative response. F igure 3.8, panel B 
illustrates that anti-CD40 in the presence o f  IL-2 increases proliferation in a dose 
dependent fashion at low concentrations. However the strong pro liferative response 
seen on stim u lation o f  cells with anti-Ig antibodies and IL-2 was not observed; indeed 
high concentrations ofanti~CD 40 antibodies (3 .2-6.4pg/m l) in com bination with IL-2 
exerted an anti-pro liferative effect on the cells. Antl-CD40 antibodies alone or in the 
presence o f  IL-4 were unab le to induce the cells to proliferate.
F igure 3.8 panel C shows the effects o f  IL-4 upon B cell proliferation . A range o f 
concentrations o f  IL-4 had no effect on the pro 1 iterative response o f  the resting B
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lymphocytes. In the presence o f IL-2, slight proliferation was observed at 1-10 
units/m l IL-4 but th is was neg ligib le compared to the strong pro liferative response 
seen with anti-Ig and IL-2 and did not even com pare to that seen w ith anti-CD40 
antibodies in the presence o f  IL-2.
3.6 Discussion
I  he data from this chapter support previous observations (Butcher et al 1990; Butcher 
and Cushley 1991 ; Zo la el al 1991 ; Tom izaw a et a l 1991) that IL-4 is the only 
cy tokine which appears capable o f  driving IL -2R a expression in resting hum an B 
lymphocytes. However, the data also indicate that cross-linking o f  the antigen 
receptor com p lex or o f  the CD40 antigen, structures which have a positive influence 
on B cell activation, also results in enhanced IL -2R a expression. S tim u lation o f  B 
lym phocy tes with com binations o f  anti-Ig, anti-CD40 and IL-4 resu lted in some 
additive effects at the level o f  IL -2R a expression but no striking synergistic effects 
were noted. Furthermore, the data dem onstrate that anti-Ig induces IL-2 
responsiveness. Anti-Ig and IL-2 synergised to produce a strong pro liferative 
response . A lesser response was seen when the resting B cells were treated w ith anti- 
CD40 mAh and IL-2 and there was m inimal proliferation when a com bination o f  IL-4 
and IL - 2  were used.
IL -2R a expression is inducible in both T and B lymphocytes, and availab le data 
suggest that non-overlapping groups o f  cytokines regulate expression o f  the IL -2R a 
gene in the two lym phoid subsets. The data from this chapter confirm s th is theory.
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I
rhus IL - l a ,  T N F -a  and IL - 6  are all known to promote IL -2R a expression in T 
lymphocy tes (Greene et al 1989; C lipstone and Crabtree 1994) but from experim ents 
perform ed in this laboratory, appear to have no effect on quiescent B cells; sim ilarly 
IL-4 has no effect upon IL~2Ra levels in quiescent tonsillar T lym phocy tes (Butcher 
et al 1990).
The spectrum  o f  biological activities o f  IL-13 largely overlaps those previously 
ascribed to IL-4; i.e. it enhances expression o f  CD23 and class II MFIC antigens on 
resting B cells. It also stim ulates B cell proliferation in com bination with anti-Ig and 
anti-CD40 antibodies and it induces IgE synthesis (DeFrance ei al 1994). However, 
neither lL-10 nor lL-13 could induce IL -2R a expression in resting B cells.
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Experim ents were done to investigate whether IL-IO and IL-13 were capable o f  
prom oting IL -2R a expression in quiescent B lymphocytes. IL-IO is produced ch iefly s
by T cells and monocytes. It was originally designated “cytokine synthesis inh ibitory 
factor” as it inhibits the production o f ThI type cytokines and antigen and m itogen 
specific T cell activation (Fiorentino et al 1991 ; De-W aal-M aleft ei al 1991 ; Taga and 
Tosatol 1992; Del-Prete el a l 1993), However, in the hum an system lL-10 stim u lates 
DNA synthesis o f  tonsillar B cells which have been activated either via their antigen 
receptor or via cross-linking o f  surface CD40 antigen (Rousset ei al 1992). It has also 
been reported that IL-2 and IL-IO synergise to induce the pro liferation and 
differentiation o f  normal and leukaemic B cells activated by anti-CD40 by 
upregu lating the expression o f  high affinity IL-2 receptors (F luck iger ei al 1993).
Not only is the regulation o f  IL -2R a lineage specific, it also appears to be species 
specific. In the murine system, IL -2R a is up-regulated by IL-5 (Loughnan and Nossal 
1989). W hile lL-5 has clear-cut activities as an eosinophil dilTerentiating factor in 
m ouse and man, there is some controversy concerning the role o f  IL-5 in B cell 
differentiation . A num ber o f  experimental system s have shown the effects o f  lL-5 on 
hum an B cells (Pene el al 1988) whereas others have not (C lu tterbuck et al 1987). 
How ever there is no doubt that IL-5 has no effect on the induction o f  IL -2R a in 
hum an quiescent B cells.
The data suggest that the 140kDa IL-4 receptor element (Idzerda ei al 1990) possesses 
critical structural m otifs involved in translation o f  the IL-4 binding event to activation 
o f  lL -2R a transcription . A role for the chain in this process would seem less likely 
as the IL-2 and IL-7 receptor com p lexes include y^ . and neither o f  these cytokines 
prom otes IL -2R a expression in quiescent B cells. It was o f interest to discover 
whether lL-15, a new ly discovered cytokine, would have any effect on IL -2R a 
induction. Subsequent results in this laboratory indicated that IL-15 has no effect on 
lL -2R a expression in hum an B lymphocytes. IL-15 shares biological activities with 
IL-2 and can also interact w ith the (3 and y components o f the IL-2R com p lex (Giri ei 
al 1994). The discovery o f  an IL-15 specific binding protein (Giri ei al 1995) further 
extended the analogy between IL-2 and IL-15 and their receptor system s. The 
receptor for IL-15 shares structural sim ilarities with the IL -2R a subunit. The a  chains 
o f  the IL -I5R  and the IL-2R have defined a new  family o f  binding proteins for helical 
cy tokines. It was previously though t that the sole role for CD25 was to generate the
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h igh affinity receptor for IL-2; however, it is also essential in generating the specific 
receptor for IL-2 since com p lexes o f  (3 and chains lacking the a  chain can also 
com prise the IL-15 receptor.
CD40 cross-linking induces a sim ilar num ber o f  B cells to express IL -2R a, 
approxim ately 25-30%, as observed with IL-4 stimulation. However, only a sing le 
anti-CD40 niAb was used in this series o f  experiments and is clear from a num ber o f  
studies in murine models the two rat mAbs directed against distinct CD40 epitopes 
can promote different responses. Thus, one o f the two anti-CD40 reagents caused both 
upregulation o f  various B cell surface m arkers and cellular pro liferation, while the 
other failed to do so (although this reagent could synergise with subm itogenic 
am ounts o f  anti-IgM  to promote B cell proliferation) (Heath ef al 1994). Therefore, 
while the data from th is chapter indicate that anti-CD40 mAb can prom ote IL -2R a 
expression in a small subset o f  quiescent tonsillar B cells, it is clearly possib le that 
m Abs to distinct epitopes may give a different response. Thus, Burlinson et al 
investigated whether the CD40 ligand itse lf induced expression o f  IL -2R a . Their data 
indicated that both ligation o f CD40 with either trim eric soluble CD40 or anti-CD40 
m Ab induced expression o f  IL -2R a to broadly sim ilar levels (Burlinson el al 1996).
S tim u lation o f  B lymphocytes with anti-Ig resu lted in more than 80% o f  the quiescent 
cells acquiring a lL -2R a positive phenotype. This situation has parallels with anti- 
CD3 driven IL -2R a expression in T lymphocytes or in Jurkat cells, where stim u lation 
w ith anti-CD3e or anti-TcR reagents is a potent inducer o f transcription through the
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lL -2 R a  locus ( reviewed in Greene ei al 1989; C lipstone and Crabtree 1994). This 
resu lt is entirely in keeping with the cells responding to a com m itting stim u lation with 
antigen and expressing receptors for cytokines which can shape their subsequent 
response to that antigen; in the case o f  B cells, expression o f  IL-2 receptors perm its 
the cells to display enhanced growth and/or accelerated im m unog lobulin secretion in 
response to binding lL-2.
A lthough anti-Ig, anti-CD40 and IL-4 can all up-regulate IL -2R a expression, this 
elevation in lL -2R a levels does not necessarily facilitate subsequent B cell 
proliferation in the presence o f IL-2. Th is suggests that lL -2 R a  induction under these 
circum stances either fails to form a functional high affinity IL-2R or, m ore likely, that 
the ligation o f  the high affinity heterotrim eric IL-2R by IL-2 does not fully stim u late 
mi to genic signal transduction pathways w ith in resting B cells. Cross-linking o f  sig  in 
com bination with IL-2 induces pro liferation in resting B cells. As stated cross-linking 
o f the antigen receptor also induces up to 80% o f cells to express IL -2R a . Thus, 
cross-linking o f  sig induces the form ation o f  functional high affinity IL-2Rs and 
induces the B cells to be responsive to IL-2. A com bination o f  IL-2 and anti-Ig may 
reflect some physio log ical significance; extensive cross-linking o f sig on B cells 
which are in the germinal centre is likely to occur through interaction w ith follicu lar 
dendritic cells (FDC). This response indicates a requirem ent for highly repetitive or 
po lyvalent ligands, such as antigen in immune complexes on FDC . The data are 
consistent with a general model o f  B cell activation whereby there is synergy between 
cellular interactions and cytokines.
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In contrast, anti-CD40 did not synergise with IL-2 to produce a strong pro liferative 
response. However there was an increase in proliferation seen w hen cells were 
stim u lated with a combination o f  IL-2 and anti-CD40, suggesting perhaps that a small 
population o f B cells could be induced to express IL -2R a and respond to IL-2 as a 
result o f  stim u lation with anti-CD40 .
lL-4, while inducing 25-30%  o f  cells to express IL -2R a, did not synergise with IL-2 
to produce proliferation. These data taken together suggests that the IL-4-driven 
increase in expression o f  IL -2R a may be independent o f B lym phocy te proliferation .
One o f  the m ost striking findings o f  this chapter is that on stim u lating the B cells via 
their antigen receptor, up to 80% o f them were induced to express cell surface IL- 
2 R a . The fo llow ing chapter expands upon th is finding to determ ine w hether different 
isotypes o f  anti-lg antibodies cou ld have different effects on the up-regu lation o f  IL- 
2 R a  and whether the degree o f  cross-linking o f  the antigen receptor could a lter IL- 
2 R a  expression . In addition, by using F(ab ’ ) 2  fragm ents o f  these antibodies, it was 
possib le to discover whether Fc receptor-m ediated inhibition (which is exp lained fully 
in Chapter 4) plays a role in the expression o f  IL-2 R a  in resting human B cells.
98
Figure 3.1 The Effect o f IL-4 on IL-2Ra Expression.
High density resting tonsillar B cells were cultured with 100 Units/m l IL-4 in com p lete 
medium for 24 hours. The cells were stained with FITC-anti-CD25 p lus PE-anti-CD 19 
lor 30 m inutes on ice. A fter washing, propidium  iodide was added to a  final concentration 
o f  2pg/m l to facilitate exclusion o f  dead cells and 5000 live gate events co llected . The 
two co lour dot-plots show green fluorescence (FITC) on the x-axis and red fluorescence 
(PE) on the y-axis. The percentage o f  B lymphocytes positive for CD25 was calculated as 
previously described (Butcher ei al 1990) according to the fo llow ing equation:
% CD25 ' B Cells = CD25 ' /CD19+ Cells x  100
(CD25" / CD 19' cells) + (CD25' / CD 19' cells)
Panel A: Control (17%)
Panel B: 100 U/m l lL-4 (34%)
The figures shown in brackets are the percentage o f  B cells positive for CD25 expression .
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Figure 3.2 The Effect of IL-IO and IL-13 upon IL-2Ra Expression.
High density resting tonsillar B cells were cultured w ith the appropriate cytokines and 
then stained and the percentage CD25 positive B cells determ ined as described in the 
legend to Figure 3.1. The data shown for IL-IO and IL-13 are from independent 
experiments. Panel A: Control (15.1%); Panel B 100 U/m l IL-IO (18 .4% ); Panel C; 
Control (4.5%); Panel D; 100 ng/m l IL-13 (5.4%). Again, the figures shown in brackets 
are the percentage o f  B lymphocytes positive for CD25 expression . These experim ents 
were perform ed 3 tim es; no statistical analysis was done on the resu lts as it is not possib le 
to com pare one tonsillar popu lation with another.
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Figure 3.3 The Effect of Various Recombinant Cytokines upon IL-2Ra Expression.
High density resting B cells (not all from the same tonsillar preparation) were cu ltured 
with a range o f  recom binant hum an cytokines as detailed on the bar chart. The cells were 
stained and the percentage o f  CD25 positive B cells was determ ined as described in the 
legend to Figure 3.1. 3% o f  cells cultured in medium alone will express CD25 (data not 
shown). Each cy tokine was tested at least twice on independent tonsillar preparations.
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Figure 3.4 The induction of IL-2Ra by Different Stimuli.
High density resting tonsillar B cells were cultured with the indicated stimuli for 24 hours 
in com p lete medium, stained and the percentage o f CD25 positive B cells determ ined as 
described in the legend to Figure 3.1. Panel A: Control (17 .8%); Panel B: 25 pg/m l 
Polyvalent anti-Ig (68.4%); Panel C: 1 pg/m l anti-CD40 (28 .2%). Again, the figures 
shown in brackets are the percentage o f  B lym phocy tes positive for CD25 expression .
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Figure 3.5 Dose Response Titrations for IL-4, A nti-Ig and Anti-CD40.
High density resting tonsillar B cells were cultured w ith the indicated concentrations o f  
IL-4 (A), anti-Ig (B) or anti-CD40 (C). CD25 expression was determ ined by flow  
cy tom etry as described in the legend to Figure 3.1. The data shown are representative o f  6  
independent tonsillar B cell preparations.
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Figure 3.6 Com parison o f Potency o f Stimuli.
The percentage o f  CD25 positive B cells was calculated over a range o f  IL-4, anti-Ig and 
anti-CD40 concentrations as described in the legend to Figure 3.1 and the data expressed 
in terms o f  the molar concentrations o f  each stim ulus app lied (Panel A). Panel B notes 
the maximal CD25 response induced by each stimulus.
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Figure 3.7 The Effect o f Com binations o f IL-4, Anti-Ig and Anti-C D40 upon IL -2R a  
Expression.
High density resting tonsillar B cells were cultured for 24 hours w ith either anti-Ig (A) or 
anti-CD40 (B) at the concentrations indicated in the presence and absence o f  IL-4 (10 
U/m l). In addition, anti-Ig was titrated in the presence or absence o f  anti-CD40 (0.5 
pg/m l). The percentage o f  CD25 positive B cells was assessed as described in the legend 
to Figure 3.1.
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Figure 3.8 The Effect o f anti-Ig, anti-CD40 and IL-4 in com bination w ith IL-2 on B 
Ceil Proliferation
Resting tonsillar human B cells were cultured for 72 hours in com plete m edium  w ith the 
following range o f  stimulants:
Panel A :0-25pg/m l anti-Ig alone, with 50 units/m l IL-4 or with 50 units/ml IL-2.
Panel B: 0-6.4|Lig/ml anti-CD40 alone, with 50 units/ml IL-4 or w ith 50 units/m l IL-2. 
Panel C: 0-1000 units/ml IL-4 either alone or w ith 50 units/ml IL-2.
Following this, the cells were pulsed w ith 0.5pCi o f  m ethyl-[^H]-thymidine, incubated 
for 8  hours and then harvested. [‘^ H]-thymidine incorporation is expressed as counts per 
minute (cpm ) and each well was set up in triplicate so that the standard deviation (SD) 
could be calculated.
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Chapter 4
Different Isotypes o f Anti-Immunoglobulin have Different Effects on 
the Induction o f IL-2R a in Resting Tonsillar B Cells
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4.1 Introduction
A com m on means o f  activating B cells so that they are able to respond to cytokines is 
to stim ulate them  via their surface im m unoglobulin receptors. Experim ents in Chapter 
3 showed that stim ulation o f  tonsillar B lymphocytes with polvalent anti­
im m unoglobulin resulted in m ore than 80% o f the cells acquiring a CD25* phenotype. 
This is entirely in keeping with the cells responding to a com m itting stim ulation w ith 
antigen and expressing receptors to cytokines which can shape their subsequent 
response to that antigen. The m ajority o f  cells isolated from tonsils are m IgM '
/m lgD ' ' w ith relatively low num bers o f  m lg C  B cells in the tonsillar population. 
Thus, it was im portant to determ ine whether each population o f cells could increase 
expression o f  IL -2R a on their cells and the m agnitude o f this response.
M ost m ature B lymphocytes co-express two classes o f antigen receptor, IgM and IgD. 
Differences in the signal transduction pathways between them  rem ain a m atter o f 
controversy. Both classes o f  receptor have the same short cytoplasm ic sequence 
(KVK) and are expected to com m unicate with the same intracellular m olecules. 
Several studies suggest that the engagem ent o f  mIgM  and m lgD  induce sim ilar B cell 
responses (Steckm ann 1980; M ond e/ al 1981; Brink et a! 1992). This is true for early 
biochem ical responses such as the activation o f PTK (Gold e( al 1990; Burkhardt et al
1991) and hydrolysis o f inositol phospholipids (Klaus el al 1989; Harnett et al 1989). 
O ther studies show that m IgM  but not m lgD  can induce negative responses in B cells 
such as anergy and apoptosis (Bell and Goodnow 1994; Tisch et al 1988; Ales- 
M artinez et al 1992; Kim et a l 1991, 1992; Carsetti et al 1993). Thus it was im portant
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to determ ine whether stim ulation o f  m IgM  or m lgD  could induce the B cells to 
express lL -2R a , perm itting them  to respond to IL-2 and causing them  to proliferate 
and differentiate.
M em brane IgG-bearing cells constitute a more mature memory B cell population 
(reviewed in V itetta et at 1991; M ackay 1993). It has been suggested that m em ory B 
cells are derived from a precursor subset that is distinct from precursors o f  prim ary or 
m IgM -bearing cells (Linton et al 1989). M any early second m essenger pathw ays are 
sim ilar in mIgM  and m IgG positive cells (M ittelstadt and De franco 1993; Gold el al 
1992; Tam aki et al 1992; Choquet et al 1993) but there are also significant 
differences. In addition, unlike m IgM  and m lgD , mIgG has a cytoplasm ic tail o f  28 
am ino acids. Thus, experim ents were carried out to determine w hether m em ory B 
cells were capable o f  inducing surface IL -2R a.
Receptors specifically recognising and binding to the Fc part o f  IgG (FcyR) are 
m em bers o f  the im m unoglobulin superfamily. Three main types o f  FcyR have been 
described; the FcyRl, FcyRlI and FcyRIII. O f these, FcyRII (also know n as CD32) are 
expressed on the surface o f  B cells (Ravetch and Kinet 1991). There are six different 
transcripts o f FcyRll (Van de W inkel and Capel 1993) and FcyRlIb is the m ajor 
isoform represented on hum an B cells. It is known to regulate B cell responses. In 
fact, activated B cells are subject to negative regulation by circulating antibodies 
which bind to FcyRII (Hunziker et al 1990). Binding to the FcRII sends a dom inant 
negative signal to the B lym phocyte that prevents or aborts lym phocyte activation 
(Klaus et al 1984) triggered through the A R H l motifs o f the signal transduction units.
Ig a  and IgP (M uta et al 1994). Thus, it was necessary to compare the effect o f intact 
anti-Ig antibodies with F(ab ’ ) 2  anti-Ig antibodies on IL -2R a induction. Intact 
antibodies co-cross-link the sig and the Fc receptor whereas F(ab ’ ) 2  antibodies lack 
the Fc fragment which contains the sites for binding to the Fc receptor. It was 
im portant to determine whether the IL-2 responsiveness induced on the B cell by 
crossing o f  surface Ig was subject to negative feedback regulation by Fc receptor 
binding.
W hether a sig-m ediated signal results in activation o f  a B cell has been suggested to 
depend upon several factors; the state o f  differentiation o f the B cell is important 
(Defranco et al 1982; Boyd et al 1981; Scott et al 1985; Hasbold and Klaus 1990) as 
is the presence o f  certain lym phokines (Pecanha et al 1991). In addition, the isotype o f  
the sIg delivering the signal m ay be crucial (Goodnow et al 1989; Tisch et al 1988;
A les-M artinez et al 1988) and finally, the degree o f cross-linking achieved by a 
particular ligand is also a factor (Pecanha et al 1991; Russell et al 1991). Therefore, in 
this chapter we sought to address whether the isotype o f  sig delivering the signal is 
im portant in inducing expression o f  IL -2R a and whether there is an Fc-mediated 
inhibition o f  this induction on resting B cells.
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4,2 D ifferent Isotypes o f Anti-Im m unoglobulin Antibodies Have Significantly  
Different Effects on the Induction o f IL -2R a Expression in Resting Tonsillar  
B Cells.
In Chcipter 3 we determ ined that stim ulation o f  resting B cells with polyvalent anti-Ig 
caused a m assive induction o f  IL -2R a expression on the surface o f  the cells. W e 
sought to extend this study by stim ulating populations o f  resting B cells with the 
follow ing different isotype-specific anti-Ig antibodies, anti-p, anti-ô and anti-y. In 
Figure 4.1, resting tonsillar B cells were cultured with low (0.5 pg/m l) or high (25 
pg/m l) doses o f  anti-p antibodies and then analysed for IL -2R a expression after 24 
hours by two colour flow cytometry. The dot plots show that, o f  the control 
population, only 23%  express IL -2R a on the cell surface. However, w hen the cells are 
stim ulated with a low dose o f  anti-p this percentage increases to approxim ately 35%. 
This concentration o f  antibody appears to produce the m axim um  level o f  IL -2R a 
expression and no other concentration o f  anti-p can induce higher levels o f  lL -2R a. 
Interestingly, high doses o f  anti-p  do not induce the cells to express IL -2R a and, in 
fact, in some cases the percentage o f  B cells expressing IL -2R a is slightly lower than 
that o f  the control population. The cells, w hich had been subjected to a  high dose o f  
anti-p , were not dead. V iability checks using Trypan Blue were performed (data not 
shown) and these confirm ed that there was no change in the am ount o f  dead cells 
present when com pared to a control population. These results were noted consistently 
in independent tonsillar preparations.
The results observed when resting B cells are cultured with anti-p  are in marked 
contrast to those seen when the cells are cultured with anti-ô. Figure 4.2A shows 
again that approxim ately 20%  o f the control population express cell surface IL -2R a. 
However, anti-ô was unable to increase IL -2R a expression above the level o f  the 
control either at low doses o f the antibody (data not shown) or at high doses (Panel 
B). Again, this was dem onstrated in m ultiple independent tonsil preparations.
Finally, resting B cells were cultured with anti-y antibodies (Figure 4.3) and, again, 
this showed a different result to that seen with either anti-p or anti-ô. 2 0 % o f  the 
resting B cell population expressed lL -2R a when unstimulated. However, a high 
concentration o f anti-y induced 43%  o f  these cells to express IL -2R a at the cell 
surface. This was the maximum  level o f  IL -2R a that could be induced by anti-y and 
no further up-regulation could be achieved. The data were representative o f  several 
experim ents performed on independent tonsil preparations.
To confirm  these results, extensive dose response experiments were performed using 
each antibody over a wide concentration range (Figure 4.4). Stim ulating the cells w ith 
varying concentration o f  each antibody gave distinct and separate curves. At low 
concentrations anti-p  induced lL -2R a expression to a maximum  level o f 
approxim ately 35-40%. In most cases (although not always), the concentration o f anti- 
p  which gave the m aximum  induction o f  IL -2R a expression was 0.5-1 pg/m l; 
som etim es 5 pg/m l gave the m axim um  level o f  IL -2R a expression. W hen the cells 
were cultured with a  high dose o f  anti-p (25-50 pg/m l) an increase in IL -2R a 
expression was never seen. In fact, on some occasions there was inhibition o f  IL -2R a
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expression with the percentage o f cells expressing lL -2R a falling below that o f the 
control. This distinctive profile was observed in all independent tonsil preparations. 
A nti- 6 , however, was never dem onstrated to up-regulate IL -2R a expression whether 
at high or low doses o f  the antibody. The percentage o f cells expressing IL -2R a never 
increased beyond the level seen in the control population.
W hen the cells were stim ulated with anti-y antibodies they up-regulated lL -2 R a  in a 
dose dependent manner. This was comparable to the result seen with polyvalent anti- 
Ig. However, only 50% o f  the cells at most were driven to express surface lL -2 R a  
when cultured with 25-50 pg/m l anti-y, unlike the situation observed with polyvalent 
anti-Ig when a maximum o f  80% o f  the cells were driven to express IL -2R a.
4.3 Do Different Isotypes o f Anti-Iinm unoglobulin Antibodies Have a Sim ilar  
Effect on CD23 Expression?
CD23 is the 45kDa low affinity form o f  the IgE Receptor, FcRcIl, on B cells and is 
potently induced by lL-4 (DeFrance et al 1987). Since IL-4 also induces IL -2R a on B 
cells, it was o f  interest to determ ine whether other inducers o f  IL -2R a would have an 
effect on CD23 expression. Thus, the same dose response experim ents were 
perform ed using each isotype antibody and the levels o f CD23 expression determ ined 
using three colour flow cytometry. Resting B cells already express high levels o f 
CD23 on the cell surface in com parison with IL -2R a (between 50-70%  depending on 
the tonsillar preparation). W hen cells were cultured with a wide concentration range 
o f anti-p, at low concentrations there was an approximate increase o f 5% in CD23
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expression which was not seen when the cells were cultured with high doses o f  anti-p. 
Thus, this reflects the results seen with IL -2R a expression in response to anti-p 
stim ulation, although the increase in CD23 expression is sm aller in m agnitude than 
that o f  IL -2R a expression. Culturing the cells with anti-y causes an increase in CD23 
expression in a dose-dependent fashion, again reflecting the effect seen when the cells 
are cultured with anti-y and stained for IL -2R a expression.
The only difference seen between the induction o f IL -2R a and CD23 came when the 
cells were cultured with anti-ô. In this case, there was a slight induction o f  CD23 
expression (o f 2-5%) at the higher concentrations o f anti-ô antibody. As has been 
stated previously, no concentration o f anti-ô could drive resting B cells to induce IL- 
2R a.
4.4 Does Signaling via the Fc R eceptor affect IL -2R a Expression?
The Fc receptor on B cells, FcyRIIb ((31 isoform) helps m odulate B cell activation 
triggered by the surface Ig complex (Ravetch and Kinet 1991; M ellm an 1988). 
Therefore, it was o f  interest to determine whether Fc receptor-m ediated signaling 
eould play a role in the lack o f  induction o f  lL -2R a expression seen when cells are 
cultured w ith  anti-0 or with high concentrations o f anti-p antibodies. This w as done 
by com paring the effects seen w ith intact antibodies with those seen when F(ab ’ ) 2  
fragm ents o f  antibody were used. Figure 4.6 shows a comparison o f  intact anti- 
p antibodies and F (ab ’ ) 2  anti-p antibodies. Both sets o f antibodies gave the same 
result; both could enhance expression o f  lL -2 R a  at low concentrations but high 
concentrations o f  the antibodies caused no induction o f IL -2R a.
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I ’his was in sharp contrast to the results seen w hen anti-ô antibodies were used (Figure 
4.7). Intact anti-ô antibodies failed to up-regulate IL-2R a. H ow ever F (ab ’ ) 2  fragm ents 
o f  this antibody reflected the results seen when the cells were stim ulated with anti-p  
(intact or F(ab ’ ) 2  fragments; that is, low doses o f  F(ab ’ ) 2  anti-ô antibodies up-regulated 
levels o f IL -2R a to alm ost 40%. At high concentrations however, no increase in IL- 
2 R a  expression could be detected. This indicates that Fc receptor-m ediated inhibition 
is playing a part in sIgD signaling.
Figure 4.8 shows a comparison o f  the effects o f  intact, F (ab ’ ) 2  fragm ents and Fab 
fragm ents o f  anti-y antibodies on IL -2R a expression. Both intact and F (ab ’ ) 2  
antibodies induced IL -2R a expression in a dose dependent manner. Fab fragments, 
which are unable to cross-link receptors did not up-regulate expression o f  IL -2R a at 
all. This is consistent w ith the theory that cross-linking o f any isotype o f  antigen 
receptor is necessary for signals to be transduced.
4.4 Discussion
One o f  the most interesting findings from Chapter 3 was that when B cells are 
stim ulated with polyvalent anti-Ig antibodies alm ost 80% o f  them  are induced to up- 
regulate IL -2R a. Thus, the next step was to determine what happens to IL -2R a 
expression when tonsillar B cells are stim ulated with different isotypes o f anti-Ig 
antibodies. The cells were cultured with intact anti-p, anti-ô and anti-y antibodies; 
these will stim ulate different subsets o f cells present w ithin the resting tonsillar
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population. Culturing tonsil B cells with anti-p antibodies will stim ulate two different 
populations o f  cells. Firstly, if  there are any imm ature IgM VIg D' cells present, anti-p  
will bind to the antigen receptors on these cells. In addition, m ature B cells which 
express both sIgM and sIgD will bind this antibody. Anti-ô antibodies will also bind 
to receptors on mature B cells while anti-y antibodies will bind to IgG receptors on 
m em ory B cells which are present in small num bers within the resting tonsillar 
population.
M ature B cells express two classes o f  m em brane-bound im m unoglobulin, sIgM  and 
sIgD, while imm ature B cells express only sIgM  (Goding et al 1977; V itetta and U hr 
1977). W hether the two classes o f  sig have different functions on B cells is a m atter o f  
controversy. A num ber o f  studies have suggested that cross-linking sIgM  and sIgD 
induces sim ilar B cell responses (Sieckm ann 1980; Mond et al 1981 ; Brink et al
1992). In particular, this is true for early biochem ical responses such as the activation 
o f  PTKs (Gold et al 1990; Burkhardt et a l 1991) and the hydrolysis o f  phospholipids 
(Cam bier el al 1987; Klaus el al 1987; Harnett et al 1989). However, other studies 
have revealed functional differences betw een sIgM and sIgD. sIgM , but not sIgD, 
induces negative responses in B cells such as anergy and apoptosis (Cam bier et al 
1976; V itetta et al 1976; A les-M artinez el al 1988; Tisch et al 1988; M ongini et al 
1989; Kim et al 1991, 1992; Carsetti ei al 1993). Findings from the experim ents 
performed in this chapter have shown that sIgM  and sIgD play different roles in the 
up-regulation o f  IL -2R a. Cross-linking o f  sIgM with low doses o f  anti-p  antibodies 
can induce expression o f  IL -2R a while engaging sIgD with anti-ô antibodies does not 
affect levels o f expression o f  IL -2R a at all.
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Imm ature B ceils are extrem ely sensitive to tolerance induction w hereas m ature B 
cells are more difficult to tolerise (reviewed in Nossal 1983). This has led to the 
developm ent o f  the controversial theory that antigen induced signaling through slgM  
provides a negative or tolerogenic signal. In fact, ligation o f  sIgM  has also been 
reported to inhibit the proliferation and differentiation o f  mature cells (M aruyam a 
al 1985; Kearney ei al 1978; Anderson el al 1974; Ralph 1979; Rothstein and Kolber 
1988; Kim ei a l 1992). These experim ents would initially appear to oppose this theory 
since up-regulation o f  IL -2R a allows form ation o f  the high affinity IL-2 Receptor and 
thus leaves the B cell prim ed to proliferate and differentiate in the presence o f  other 
signals. However, only low concentrations o f  anti-p  antibody cause IL -2R a to 
become up-regulated and this effect is not seen with higher doses o f  the antibody. One 
explanation for this could be that extensive cross-linking o f  sIgM could be m im icking 
the effect seen with auto-antigen within the germinal centre and cause the B cells to 
become tolerised. Put simply, the signal delivered by foreign antigens trapped on the 
surface o f  FDCs m ight be lower than that delivered by high doses o f  ubiquitous auto­
antigen. Thus, the failure o f  tonsillar B cells to up-regulate IL -2R a in response to high 
doses o f  anti-p antibodies may represent a “fail-safe” device for elim inating clones 
that exhibit auto-reactivity and that will provoke a damaging auto-im m une response.
On m ost mature B cells IgD is the dom inant antigen receptor and is expressed 2-10 
tim es m ore abundantly on the cell surface than IgM (Havran et al 1984; Carsetti et al
1993). As discussed above, studies have suggested that sIgM , but not sIgD, can 
induce negative responses in B cells and it has been hypothesised that engagem ent o f
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sIgD confers a dom inant positive signal for B cell activation. However, knockout 
mice lacking the IgD antigen receptor are not drastically im m unodeficient which 
suggests that sIgM may functionally replace sIgD in these mice (N itschke et al 1993; 
Roes and Rajewsky 1993). I f  this is true then it seems surprising that cross-linking 
slgD  does not enhance expression o f  IL -2R a and thus allow high affinity receptors for 
IL-2 to form. This suggests that additional signals would be required and that ligating 
slgD  is not enough to activate the cells.
A com parison o f  the effects o f  intact and F(ab ’ ) 2  fragments o f  antibodies on lL -2R a
expression indicated that Fc receptor-m ediated inhibition played a role in functional 
.sIgD signaling. Intact anti-5 antibodies could not induce IL -2R a expression whereas 
low concentrations o f  F(ab ’ ) 2  anti-5 antibodies could. In fact, F (ab ’ ) 2  anti-5 antibodies 
gave a result identical to that seen when cells were cultured with intact anti-p 
antibodies. In the cases o f anti-y and anti-p antibodies, F (ab’), fragm ents give sim ilar 
responses to those seen with the respective intact antibodies. W ork has been done 
which shows the Fc-dependent suppression o f  antigen-specific B cell responses can be 
overcom e by f  cells or T cell-derived lym phokines (Hoffman and Kappler 1978; Lees 
and Sinclair 1975; Kolsch et al 1980) and IL-4 has been shown to reverse Fc 
Receptor-m ediated inhibition in m ice (O ’ Garra et al 1987). It has been hypothesised 
that FcyRIIb is predom inantly responsible for protection o f  the resting state o f B cells 
preventing inadequate auto-antibody production (Sarmay et al 1995). This would 
prevent B cells from being activated in the absence o f suitable T cell help.
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Cross-linking o f  sIgG on memory B cells causes IL -2R a to be up-regulated in a dose- 
dependent fashion. This is a different result to those seen on engaging slgM  or sIgD 
but one which is o f  some significance. M emory B cells m ust be able to proliferate in 
response to lower am ounts o f  antigen than naive cells (Y efenof e/ al 1986). For them  
to do this, they would obviously need to be able to form high affinity IL-2Rs, 
requiring increased IL -2R a expression. These m emory B cells have already been 
selected against foreign antigen, not self, and therefore there is no need for IL -2R a 
levels to be decreased when high doses o f  antibody are added to prevent an auto­
im m une response.
The next chapter goes on to discuss events at the prom oter region o f  the IL -2R a gene. 
It is im portant to relate the events that are occurring at the cells surface to those 
happening at the m olecular level. In particular, there is a protein which binds to a 
negative regulatory region within the IL -2R a promoter which has the ability to 
silence expression o f this gene and it was o f  interest to discover w hether signals 
through the antigen receptor could affect the binding o f  this protein to the prom oter 
region.
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Figure 4.1 The Effect of Anti-p Antibodies upon IL-2Ra Expression.
High density resting tonsil B cells were cultured in com plete m edium  (Panel A) or w ith 
either 0.5 pg/nil anti-p  (Panel B) or with 25 pg/m l anti-p (Panel C) for 24 hours. The 
cells were stained with FITC-anti-CD25 and PE-anti-CD19 and analysed by two colour 
How cytom etry. Propidium  Iodide was added to facilitate exclusion o f  dead cells and 
5000 live gated events were collected. The two colour dot plots show  green fluorescence 
(FITC) on the x-axis and red fluorescence (PE) on the y-axis. The percentage o f  B cells 
positive for IL -2R a was calculated as previously described in the legend to F igure 3.1. 
These experim ents were repeated 4 tim es and a representative experim ent shown.
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4.2 The Effect of Anti-ô Antibodies on IL-2Ra Expression.
High density resting tonsillar B cells were cultured in either com plete m edium , Panel A, 
( 19%) or with 25 pg/m l anti-ô, Panel B,(20% ) for 24 hours. The cells were stained and 
the percentage o f  B cells positive for IL -2R a was determined as previously described in 
the legend to Figure 3.1. The figures shown in brackets are the percentage o f  B cells 
positive for IL -2R a expression. Again this was repeated four tim es and a representative 
experim ent shown.
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4.3 The Effect of Anti-y Antibodies on IL-2Ra Expression.
High density resting tonsillar B cells were cultured in either com plete m edium , Panel A, 
(21%) or with 25 pg/m l anti-y, Panel C (51%) for 24 hours. The cells were stained and 
the percentage o f  B cells positive for IL -2R a expression was determ ined as described in 
the legend to Figure 3.1. The figures shown in brackets are the percentage o f  B cells 
positive for IL -2R a expression. Again this was repeated four tim es and a representative 
experim ent shown.
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4.4 Dose Response Titrations o f Anti-p, Anti-ô and Anti-y Antibodies.
High density resting tonsillar B cells were cultured w ith the indicated concentrations o f  
anti-p, anti-ô and anti-y antibodies for 24 hours (Panel A). IL -2R a expression was 
determ ined by flow cytom etry as described in the legend to Figure 3.1. The data shown 
are representative o f  six independent tonsillar B cell preparations. Panel B shows the data 
expressed in term s o f the m olar concentrations o f  each stim ulus applied.
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4.5 The Effect of Anti-|i, Anti-0 and Anti-y Antibodies on CD23 Expression.
High density resting tonsillar B cells were cultured for 24 hours w ith the indicated 
concentrations o f  anti-pi, anti-ô or anti-y. Cells were then stained with FITC-anti-CD 25, 
PE-anti-CD19 and Biotin-conjugated anti-CD23 followed by Streptavidin Quantum  Red 
to detect the biotinylated antibody. Levels o f CD23 expression were determ ined in the 
same way as described previously for IL -2R a expression in the legend for Figure 3.1. 
Panel A shows the data expressed in term s o f  the pg/m l o f  antibody used w hereas Panel 
B shows the data expressed in term s o f  m olar concentrations. This experim ent was 
repeated 3 tim es and the results show a representative experiment.
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Figure 4.6 A Titration Curve Comparing the Effects of Intact Anti-|i with F(ab )]
Fragments of Anti-p on IL-2Ra Expression.
High density resting tonsillar B cells were cultured for 24 hours w ith the indicated 
concentrations o f  either intact anti-jx or F(ab ’ ) 2  fragm ents o f  anti-p. Levels o f  IL -2R a 
expression were determ ined as described previously in the legend to Figure 3.1 .The data 
are expressed in term s o f  the m olar concentration o f  each antibody.
137
6 0 -,00
r ?  5 0 -
Ou
<N
10 -
0 10 20 30 40 50
Anti-|a (|lg/ml)
Intact
F (a b ) ' 2
60-1
^  50
10 100 10001
*
138
Figure 4.7 A Titration Curve Comparing the Effect of Intact Anti-ô with F(ab ’)2
Fragm ents o f Anti-ô on IL -2R a Expression.
High density resting tonsillar B cells were cultured for 24 hours with the indicated 
concentrations o f either intact anti-ô or F(ab’)2 fragments o f anti-ô. Levels o f IL-2Ra 
expression were determined as shown previously in the legend to figure 3.1. The data are 
expressed in terms o f the molar concentration of each antibody.
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Figure 4.8 A Titration Curve Com paring the Effect o f Intact Anti-y, F (ab ’)2 
Fragm ents o f Anti-y and Fab Fragm ents o f Anti-y on IL -2R a Expression.
High density resting tonsillar B cells were cultured with the indicated concentrations o f  
either intact anti-y, F(ab ’ ) 2  fragm ents o f anti-y or Fab fragm ents o f  anti-y. Levels o f  IL- 
2 R a  expression were determ ined as shown previously in the legend to Figure 3.1. The 
data are expressed in terms o f the m olar concentration o f  each antibody.
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Chapter 5
Expression o f the IL-2R a Gene in Human Tonsillar B Lym phocytes
143
5.1 Introduction.
The preceding chapters have dem onstrated that IL -2R a expression can be induced in 
hum an tonsillar B lymphocytes by stim ulating the cells with either ÎL-4, anti-I g or anti- 
CD40 antibodies. In particular, the isotype o f anti-Ig which is used to stim ulate the cell is 
o f  importance; both anti-p  and anti-y cause IL -2R a to be up-regulated on the B cell 
surface, although this up-regulation is abrogated at high doses o f anti-p. By contrast, 
induction o f  expression is not seen when cells are cultured with anti-ô. In order to define 
the m olecular levels o f  control regulating the IL~2Ra promoter, a series o f  experim ents 
consisting o f  gel shift assays and transient transfection studies were perform ed to 
determ ine whether IL-4 or anti-1 g antibodies could induce IL -2R a prom oter activity.
In T lym phocytes the IL -2R a prom oter region has been well characterised and the m ajor 
cis acting sequences identified. A 1352 base pair fragment 5’ to the IL -2R a gene has 
been shown to have prom oter activity when fused to a reporter gene (Leonard et al 1985). 
Several cis regulatory elem ents within this region have been m apped and their 
corresponding /ram -activating  factors identified. There are believed to be at least 3 
positive regulatory elem ents, PRR,_,„, involved in IL~2Ra prom oter activity. W ithin 
PRRj, located -276 to -244 relative to the m ajor transcription control site, there are four 
putative binding sites for nuclear factors that positively regulate transcription (NFIL2RA , 
N FkB , SRF and Sp-1) (Bohnlein et al 1988; Leung and Nabel 1988; Ballard et al 1989; 
Cross et al 1989; Lowenthal et al 1989; Lin et al 1990; Roman et al 1990; Toledano et al
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In addition to the positive regulatory regions o f  the IL -2R a prom oter, there are two 
negative regulatory regions which lie within 400 base pairs o f  the transcription initiation 
site. N RE I is located between nucleotides -400 and -368 (Sm ith and Greene 1989) and 
N R E II is located between nucleotides -317 and -342 (Lowenthal et al 1989b). N R E I 
contains an 11 base pair core elem ent (TTCATCCCAGG) which binds in vitro to a 
50kD a protein (SP50). This is thought to m ediate the negative regulation o f  the gene; 
displacem ent or inactivation o f  SP50 is associated with transcriptional activation (Sm ith 
and Greene 1989).
Thus, the IL -2R a prom oter contains m ultiple regulatory elem ents which together 
orchestrate a coordinated response to m itogenic or growth factor stim ulation. Since IL-4
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1990; Algarte et al 1995; John et al 1995,1996). PRR„ (-137 to -64) (John et al 1995) 
contains binding sites for at least two DNA binding proteins, an Ets fam ily protein, Elf-1 
, (Thom pson et al 1992) and the non-histone chrom atin-associated protein, HM G -l(Y ) 
(Elton and Reeves 1986, Johnson et al 1989; Lund et at 1986). PRR,,, is located some 
distance upstream  o f  the 5’ cap site, between nucleotides -3780 and -3703; it has a 
binding site for STAT-5 as well as consensus sequences for Elf-1,1-IMG-I(Y) and a 
m em ber o f  the GATA fam ily o f  DNA binding proteins (John el al 1996). It seem s likely 
that PRR„ contributes towards basal prom oter activity and cell-type specificity o f 
expression o f  the gene whereas PRR, and PRR„; contribute more potently to the 
inducibility o f  the IL -2R a promoter.
and anti-Ig antibodies can induce surface lL -2 R a  expression on hum an B cells, 
experim ents were performed to determ ine whether this up-regulation was m ediated by 
interactions at sites within the prom oter region. High concentrations o f  anti-p  can inhibit 
the induction o f  lL -2R a and it was o f  particular interest to ascertain w hether anti-p  - 
driven inhibition o f  IL -2R a in B cells regulates the activity o f the protein(s) capable o f 
binding to the N RE I element.
5.2 Analysis o f DNA Binding Protein Activity Specific For the NF-kB Region o f  the 
IL"2Ra Prom oter in Resting B Cells.
NF-kB is a ubiquitous transcription factor whose properties are extensively exploited by 
cells o f  the immune system. Several lines o f  evidence have indicated that the kB site in 
the IL -2R a prom oter plays a critical role in the induction o f the IL -2R a gene in hum an T 
cells (Ballard el al 1988; Lowenthal el al 1988, 1989a, b; Bohnlein el al 1988). Thus it 
was im portant to determ ine whether B cells, like their T cell counterparts, contained 
D N A-binding protein activities which could bind to the kB motif. N uclear extracts were 
prepared from resting tonsil B cells and were found to contain a protein (or proteins) 
which recognised and retarded labelled NF-kB oligonucleotide (Figure 5.1, lanes 1 and 6) 
and which were sensitive to com petition by a 10- or 100-fold excess o f  cold NF-kB 
oligonucleotide (Figure 5.1, lanes 2 and 3 respectively). Binding was insensitive to the
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presence o f a 1 0 - or 1 0 0 -fold excess o f an non-specific oligonucleotide which 
corresponded to an AP-2 consensus binding site (Figure 5.1, lanes 4 and 5 respectively).
5.3 The Effects o f Anti-p Antibodies and IL-4 on NF-kB Specific DNA B inding  
Protein Activity in B Cell Extracts.
A range o f  concentrations o f  anti-p  gives a distinctive profile o f  IL -2R a induction; that 
is, at low concentrations o f  anti-p IL -2R a expression is induced in resting tonsil B cells 
w hereas at high concentrations this effect is com pletely abrogated. Thus, B cell extracts 
were prepared from tonsillar B cells which were cultured either with a low  concentration 
(0.5pg/m l) or a  high concentration (25pg/m l) o f  anti-p. These have been shown to induce 
or inhibit cell surface expression o fIL -2 R a , respectively (see Chapter 4). A t tim e 0 there 
w as oligonucleotide binding activity in both sets o f  extracts (Figures 5.2A and B) and this 
activity was not significantly altered on addition o f  either concentration o f  anti-IgM . NF- 
KB specific DNA binding protein activity was also studied on extracts which had been 
cultured with intermediate concentrations o f  anti-IgM  (1 and lOpg/m l) (data not shown). 
Again, there was no significant alteration in DNA-binding protein activity over a four 
hour tim e course. Similar experim ents were performed using B cell extracts cultured with 
varying concentrations o f  anti-ô and anti-y antibodies (data not shown), again with an 
identical result.
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Since IL-4 also potently induces IL -2R a expression in resting B cells, we next 
determ ined whether IL-4 exerted any effect on NF-kB protein binding activity in tonsillar 
B cells (Figure 5.2C). An identical result was obtained to those obtained w ith anti-p; that 
is, there was no alteration in protein binding activity at the kB region w hen the cells were 
stim ulated with 2nM  IL-4 (400U/nil).
5.4 The Effects o f A nti-p Antibodies and lL -4 on NEIL-4 DNA Binding Protein  
Activity in B Cell Extracts.
We have found lL-4 to be the sole cytokine that will up-regulate IL -2R a expression in 
resting tonsillar B lymphocytes. However, the m olecular m echanism s o f  IL-4 action in 
this response are still obscure. IL-4 also tightly regulates induction o f  FcsRII (CD23), the 
low affinity receptor for IgE. An IL-4 responsive elem ent was identified within the CD23 
prom oter region (DeFrance et al 1987; Vercelii et al 1988) and an lL-4 dependent nuclear 
binding factor, NFIL-4, was found to interact specifically with this novel 9 base pair 
m o tif (Kohler and Rieber 1993). NFIL-4 also interacts with a hom ologous sequence 
w ithin the prom oter o f  the germ line Is transcript. A consensus sequence for the NFIL-4 
binding site was proposed to be 5 ’ T(T/C)C(T/C)(A/G)(A /G )GAA 3 ’ and a sequence 
corresponding to this w as found in the IL -2R a prom oter in B cells (-306 to -298). Thus, 
we next determ ined whether IL-4 and/or anti-p  exerted any effects on NFIL-4 protein 
binding activity in tonsillar B cells.
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At tim e 0, NFIL-4 oligonucleotide binding activity was clearly detected in B cell extracts 
by gel shift assay (Figure 5.3A, B and C). However, both low and high concentrations o f  
an ti-p  (Figure 5.3A and B respectively ) failed to have any effect on NFIL-4 binding 
activity to the IL-4RE, as m ight have been expected. In contrast, NFIL-4 binding activity 
was increased over a four hour period following addtion o f  2nM  IL-4. Two m obility shift 
bands were evident in the analysis and both were shown to be sensitive to com petition by 
excess cold IL-4RE oligonuceotide (data not shown). Thus, binding o f  N FIL-4 to IL-4RE 
in the lL -2 R a  prom oter seems to be under the sole control o f  IL-4 and, as expected, is not 
affected by signals delivered via the IgM antigen receptor.
5.5 Does the Negative Regulatory Region Play a Role in Induction o f the IL -2R a  
Prom oter W hen Cells Are Stim ulated W ith Anti-p?
Low concentrations o f anti-p  will induce expression o f IL -2R a in hum an tonsillar B cells 
while high concentrations o f  the same antibody inhibits this effect com pletely. This 
phenom enon is seen solely when cells are stim ulated with the anti-p isotype. A possible 
explanation for this differential effect could lie in the capacity o f  anti-p  to inlluence the 
activity o f  the NRE binding protein (NRE-BP) in B cells. To test this notion, it was firstly 
investigated whether B cells, like their T cell counterparts, contained proteins which 
could bind to the 11 base pair core region o f  N RE I.
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N uclear extracts from resting tonsil B cells which had been cultured with either anti- 
p (Figure 5.4A) or IL-4 (Figure 5.4B) were found to contain protein(s) which recognised 
and retarded labelled NRE oligonucleotide (Lanes 1 and 4). This was sensitive to 
com petition by 100-fold excess o f cold NRE oligonucleotide (Figure 5.4A and B, lanes 2) 
but insenstive to the presence o f  1 0 0 -fold excess o f  an oligonucleotide corresponding to 
the AP-1 consensus binding site (Figure 5.4A and B, lanes 3). Experim ents perform ed by 
others in this laboratory confirmed that oligonucleotides corresponding to the consensus 
binding sites for Oct-1, NF-kB , CREB and TFIID were also unable to com pete for 
binding to the NRE oligonucleotide. Two sequence specific bands were evident; both 
showed sensitivity to com petition with un label led N RE oligonuceotide. The gel shift 
profile is essentially identical to that noted for Jurkat T cell Lines and to that reported 
previously (Smith and Greene 1989; Hewitt et al 1997).
Once it had been established that B cells did indeed possess protein(s) capable o f  binding 
to the 11 base pair core m otif o f  N R E I, the next step was to discover w hether culturing 
the B cells with anti-p  had any effect on the binding o f  these protein(s) to this region. 
Therefore, extracts were prepared at hourly intervals from resting tonsillar B cells 
stim ulated either with a low concentration o f  anti-p  (0.5pg/m l) or a high concentration o f 
anti-p  (25pg/m l) and the DNA binding protein activity for the NRE I analysed by gel 
shift assay (Figure 5.5A and B respectively). It was found that low concentrations o f  anti- 
p  significantly decreased NRE oligonucleotide binding activity over a  four hour period. 
However, in sharp contrast, high concentrations o f  anti-p did not affect the binding o f
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proteins to N R E oligonucleotide. This differential effect m ight partially explain the 
failure o f  high concentrations to drive IL -2R a expression in resting tonsillar B cells. 
Thus, the distinct induction and then inhibition o f IL -2R a expression seen at the surface 
o f  the cell in response to a range o f  concentrations o f  anti-p is reflected by DNA binding 
events at the NRE I region o f  the promoter.
Once this effect had been determined, studies were performed to assess the effect that 
culturing B cells with ÏL-4 w ould have on N RE binding protein activity. Extracts were 
prepared from B cells which had been cultured with 2nM  IL-4 for up to four hours. 
Follow ing addition o f  lL-4, NRE oligonucleotide binding activity (clearly detectable at 
tim e 0) was again reduced over the four period (Figure 5.5C). This was essentially an 
identical result to that obtained when the cells were cultured with low concentrations o f  
anti"p and is consistent with the hypothesis that ligands which induce IL -2R a expression 
cause loss o f  N RE-BP activity.
5.6 Do O ther Isotypes o f A iiti-Ig Antibodies Affect NRE B inding Protein Activity?
A nti-Y antibodies can also induce IL -2R a expression on the B cell surface; unlike anti-p 
this induction is not reversed at high concentrations o f  the antibody. It was therefore o f  
interest to see if  varying concentrations o f  anti-y would have any effect on the protein(s) 
binding to NRE I. Extracts were again prepared from resting B cells w hich in this case
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had been cultured w ith low and high concentrations o f  anti-IgG and gel shift assays 
perform ed (Figure 5.6A and B respectively). However this tim e there was no alteration in 
the binding o f  proteins to the NRE oligonucleotide. At time 0 there was detectable N R E 
oligonucleotide binding activity and this did not increase or decrease over the four hour 
tim e period (or indeed after 24 hours - data not shown).
Culturing resting B cells with anti-IgD antibodies had no effect on the levels o f  IL -2R a 
expression on the cell surface and, in distinct contrast to the results seen with low 
concentrations o f anti-IgM  and with IL-4, there was no change in the protein binding 
activity to NRE I (Data not shown).
5.7 Analysis o f the Activity o f IL -2R a Deletion Reporter Constructs.
A reporter plasm id (pCD25-CA T-E) had been constructed previously in this laboratory 
(H ew itt e! a! 1997). This contained a 592 base pair fragment o f the IL -2R a prom oter 
region o f  the hum an IL -2R a gene located upstream  o f the chloroam phenicol acetyl 
transferase gene. The vector also contained an SV40 enhancer sequence which facilitates 
detection o f low levels o f reporter activity in human B cells (H ew itt e( al 1997). The 592 
base pair fragm ent inserted into the plasm id comprised the m inim al prom oter/enhancer 
region o f  the IL -2R a gene which extends from -472 to +109 and contains the 11 base pair 
N RE I sequence. In addition, a deletion construct was made which lacked this 11 base
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pair region (pANRE-CAT-E). Each plasm id was transfected into tonsillar B cells and the 
reporter gene activity assessed after stim ulation with IL-4. M ock-transfected cells were 
used as a control. Reporter gene activity was assessed by TEC analysis (Figure 5.7A) and 
quantitated by phosphorim age analysis (Figure 5.7B). Figure 5.7A, lanes 1 and 2 give the 
results o f  cells m ock-transfected as a control; lane 1 shows unstim ulated cells, lane 2  
shows cells stim ulated w ith IL-4). B cells transiently transfected with the full length IL- 
2 R a  prom oter construct, pCD 25-CAT-E, resulted in a low level o f reporter gene activity 
(Figure 5.7, lane 3). Som ewhat surprisingly, there was no induction o f  activity after 
stim ulation o f  the cells w ith 2nM  IL-4 (Figure 5.7, lane 4). However, on transfecting the 
cells w ith the NRE-deletion construct, pANRE-CAT-E, the basal level o f  reporter gene 
activity was increased approxim ately 10-fold on stim ulating the cells w ith IL-4 (Lane 6 ) 
com pared to the activity seen in the unstim ulated cells (Lane 5). Figure 5.7B shows a 
phosphorim age quantitation o f the TLC data.
However, the m ost striking results came when resting B cells were either m ock- 
transfected, transfected with pCD 25-CAT-E or transfected with pANRE-CAT-E and then 
cultured for 48 hours w ith anti-p antibodies. Figure 5.8, lanes 1,2 and 3, give the results 
o f  the m ock-transfected cells which were cultured in either complete m edium , with 
0.5pg/m l anti-p  or with 25pg/m l anti-p  respectively. As expected, these lanes show  no 
acetylated forms o f  chloroam phenicol. On transfecting the cells with pCD 25-CAT-E, 
there is a 20-25 fold induction o f  reporter gene activity in cells cultured with 0.5pg/m l 
anti-p  (Figure 5.8, Lane 5) com pared to control cells cultured in com plete m edium
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(Figure 5.8, lane 4). Cells cultured with 25pg/m i anti-p show no increase in basal gene 
activity (Lane 6 ), as m ight have been predicted from the results o f  previous FACS and gel 
shift experiments.
Resting B cells were also transfected w ith the deletion construct, pANRE-CAT-E, and 
then cultured either in complete m edium  (Figure 5.8, lane 7), w ith 0.5pg/m l anti- 
p  (Figure 5.8, lane 8 ) or w ith 25pg/m l anti-p  (Figure 5.8, lane 9). Again at low 
concentrations o f  anti-p there is induction o f  reporter gene activity. However, m ost 
im portantly, high dose anti-p stim ulation does not suppress expression o f  the pANRE- 
C AT-E reporter construct; in fact, there is a significant induction o f reporter gene 
activity. Figure 5.8B shows a phosphorim age quantitation o f  the TLC data.
These data are consistent w ith the interpretation that, firstly, protein(s) binding to N R E I 
inhibits basal activity o f  the IL -2R a promoter. Secondly, expression o f  the IL -2R a 
induced by low doses o f  anti-p  correlates with attenuation o f  the N R E protein binding 
activity. Finally, inhibition o f  IL -2R a induction by high concentration o f  anti-p is caused 
(at least in part) by the binding o f  protein(s) to N R E 1, presum ably resulting in 
suppression o f  transcription o f  the gene.
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5.8 Discussion
The IL -2R a prom oter region in B ceils possesses m ultiple regulatory regions. O f these, 
w e chose to study, firstly, the positive regulatory region PRR, and, secondly, the negative 
regulatory region N RE I. The key finding to emerge from this study is that transcription 
o f  the IL -2R a gene in hum an tonsillar B lymphocytes is subject to negative regulation by 
an 11 base pair NRE which is a potent suppressor o f  transcription. In T cells, this N R E I 
is bound by a 50kDa protein (SP-50) which is, as yet, undefined. It is not known w hether 
the same protein is present in B cells. However, given that the gel shift patterns are 
sim ilar in B cells, T cells and Jurkat cells, it seems likely that the same protein is 
involved in each case. Low concentrations o f  anti-p which were found to induce 
expression o f  IL -2R a on the cell surface also caused attenuation o f  the NRE binding 
protein (NRE-BP) activity. However, at high concentrations o f  anti-p  there was no
attenuation o f  N RE-BP activity, correlating w ith the fact that high concentrations o f  anti- 
p  do not drive B cells to express surface IL -2R a.
Regulation o f  the human IL -2R a is very complex and the most extensive study o f 
prom oter regulation has been in T cells. Recent studies using band shift and DNase I 
footprinting assays (Algarte et al 1995) indicated that there is apparently a m ajor role 
played by the N F-kB transcription factor in the positive regulation o f  the IL -2R a 
prom oter. It was proposed that in resting T cells the kB elem ent is occupied by a 
constitutive N F-kB  hom odim er which impairs SRF binding to the flanking SRE/CArG
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box. On activation o f T cells, the KB elem ent is occupied by a p50-p65 heterodim er 
which is associated with an SRE/CArG box DNA binding factor. By contrast, resting B 
cells do not appear to possess such constitutive protein-DNA interactions at the IL -2R a 
locus. Again, unlike T cells, activation o f  B cells either via the antigen receptor or by IL- 
4 fails to affect the binding activity o f  proteins to the kB element. In any case the anti-p  
data represented here w ould fail to distinguish between the binding o f  p50 hom odim ers 
and p50-p65 heterodim ers to the icB motif; further gel super shift assays w ould need to be 
performed. However it is clear that other elem ents within the prom oter m ust be playing a 
significant role in IL -2R a gene regulation in B cells.
One such candidate for this m ight be the IL-4RE, located -305 to-298 to the transcription 
initiation site. Sequences in the prom oter regions o f  the CD23 and Is genes (which are 
controlled by IL-4) were found to be bound by an IL-4-activated nuclear factor NFIL-4 
(recently dem onstrated to be STA T- 6 ; H ou et al 1994; Kohler and Richer 1993). A 
sequence sim ilar to these was found in the IL -2R a prom oter in B cells; the cells also 
possess a DN A-binding protein which interacts with oligonucleotides containing an IL- 
4RE sequence. Treatm ent o f  the B cells with IL-4 resulted in an increase in activity o f  the 
protein binding to the IL-4RE. The identity o f  this protein in B cells has yet to be defined; 
early experim ents carried out by others in this laboratory indicated that IL-4RE is bound 
by a phospho-tyrosine containing protein which is sensitive to STA T - 6  oligonucleotides. 
How ever they were unable to supershift the protein-oligonucleotide complex with anti- 
STA T - 6  antibodies. This suggests that N FIL-4 m ight be m ade up o f  a  com plex
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containing STA T - 6  plus another, as yet unidentified protein. The fact that anti-p 
antibodies fail to induce binding o f  NFIL-4 to IL-4RE could mean that another regulatory 
elem ent within the IL -2R a prom oter region plays a role in the induction o f  IL -2R a by 
anti-p  antibodies.
Thus attention was focused on the role that the negative regulatory elem ents m ight play 
in controlling transcription o f  this locus. In T cells, the NRE I region o f  the prom oter is 
active and involved in suppressing transcription o f the IL -2R a gene. The 11 base pair 
elem ent is bound by SP-50 in T cells, silencing IL -2R a transcription. B cells also possess 
a protein capable o f  binding an oligonucleotide containing this 1 1  base pair region and, 
indeed, low concentrations o f  anti-p which induce IL -2R a expression were found to 
attenuate NRE binding protein activity. High concentrations o f  this antibody did not 
appear to alter binding protein activity at this region, a fact which correlates with the 
observation that high doses o f  anti-p  will not induce IL -2R a expression on the cell 
surface. Furthermore, deletion o f  the N R E from the promoter sequence increased basal 
reporter gene activity in B cells treated with both low and high doses o f  anti-p. These 
findings would seem to suggest that NRE I plays a major role in controlling IL -2R a 
transcription when cells are stim ulated via their IgM antigen receptors. The situation 
where cells are stim ulated via the IL-4 receptor seems to be m ore com plex w ith a variety 
o f  positive and negative regulatory factors all playing a part.
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It should be noted that negative regulation o f  IL -2R a transcription at N R E 1 actually 
encom passes 31 base pairs; the 11 base pair core o f NRE I already m entioned and a 
Retinoic Acid Response Element (RARE). Treatm ent o f B cells with IL-4 results in loss 
o f  DNA binding protein activity for RARE specific oligonucleotides (Hewitt el al 1997). 
However, this elem ent does not appear to be under the control o f  signals transduced via 
the IgM antigen receptor since treating the cells with a variety o f  coneentrations o f  anti-p  
failed to alter the binding activity o f  proteins to the RARE oligonucleotide (data not 
shown).
Therefore it simply remains to speculate on the nature o f the protein(s) that m ight bind to 
the N R E I 11 base pair core element. In T cells, as has been stated, SP-50 rem ains 
undefined. There are no specific hom ologies to consensus binding sequences for a range 
o f  transcription factors. A possible candidate was thought to be Y Y l, a ubiquitously 
expressed zinc finger protein which requires only a core CAT m otif for DNA binding 
(H yde-D eRuyscher el al 1995) and it has been known to act both as an activator and as a 
suppressor o f  transcription. However, recent studies in this laboratory have appeared to 
rule out Y Y l as a protein which will bind the NRE I element. Other transcription factors 
which were thought to be possible candidates included CREB, an els fam ily m em ber or 
HM G-I(Y). All have been discounted, due to com petition assays (data not shown), 
supershift assays and m olecular m ass, respectively. Thus, although it is known that the 
proteins which bind N RE I silence transcription and play a dom inant role in induction o f  
lL -2 R a  by the antigen receptor, it rem ains to be determined how signals from the antigen
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receptor are linked to a protein acting at NRE I and whether this protein belongs to an 
already defined family o f  transcription factors or in fact is a novel factor which has not 
previously been characterised.
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Figure 5.1 Identification of NF-KB-specific DNA Binding Activity in Tonsil
Resting B Ceils.
N uclear and cytoplasm ic cell extracts were prepared from the resting tonsillar B cells (5 x 
10^ ’) which had been cultured overnight in complete medium. The binding activity o f  5pg 
aliquots o f protein to y-f^^PJ-labelled N F-kB  oligonucleotide was assessed by gel shift 
assay in the absence o f  cold competitor oligonucleotide (lane 1 ) or in the presence o f  1 0 - 
fold or 100-fold excess o f  cold NF-kB oligonucleotide (lanes 2 and 3 respectively) or in 
the presence o f  10-fold or 100-fold excess o f  a non-specific oligonucleotide, AP-2 (lanes 
4 and 5 respectively). Lane 6  shows a repeat o f the binding activity o f  y-p^P]-labelled 
N F-kB oligonucleotide in the absence o f cold com petitor oligonucleotide. Specific 
binding activities are indicated with horizontal arrows.
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Figure 5.2 Effects of Anti-p and IL-4 Stimulation on NF-kB Binding in Tonsil
Resting B Cells.
N uclear and cytoplasm ic extracts were prepared from resting tonsillar B cells which had 
been cultured overnight in complete m edium  and then stim ulated w ith either 0.5pg/m l 
anti-p  (A), 25pg/m l anti-p (B) or 400 U/ml IL-4 (C) for up to four hours. 5pg o f  protein 
extract was analysed by gel shift assay for binding to y-f^P]-labelled N F-kB 
oligonucleotide. Specific binding activities are illustrated by horizontal arrows.
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Figure 5.3 Effects o f A nti-p and IL-4 Stim ulation on NFIL-4 Binding in Tonsil 
Resting B Cells.
Nuclear and cytoplasmic extracts were prepared as described in Figure 5,2, that is 
cultured overnight in complete m edium  and then stim ulated with either 0 .5pg/m l anti-p  
(A), 25pg/m l anti-p  or 400 units/ml IL-4 for up to four hours. The binding activity o f  5pg 
o f  protein to -labelled NF-IL-4 oligonucleotide was assessed by gel shift assay. 
Specific binding activities are illustrated with arrows.
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Figure 5.4 Identification of NRE specific DNA Binding Activity in Resting Tonsil
B Cells.
Nuclear and cytoplasm ic extracts were prepared from resting tonsil B cells w hich had 
been cultured overnight in complete m edium  and then stim ulated w ith 25pg/m l anti-p(A ) 
or 400 units/m l lL-4 (B). The binding activity o f  5pg aliquots o f  protein (nuclear extracts 
only shown) to y-[^^P]-labelled NRE oligonucletide was assessed by gel shift assay in the 
absence o f  cold com petitor oligonucleotide (Lane 1), or in the presence o f 100-fold 
excess o f  cold NRE oligonucleotide (Lane 2) or in the presence o f  100-fold cold non­
specific oligonucleotide (AP-1) (Lane 3). Lane 4 shows a repeat o f  the binding activity o f  
y-p^P]-labelled N R E oligonucleotide in the absence o f  cold com petitor oligonucleotide. 
Specific binding activities are indicated by horizontal arrows.
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Figure 5.5 Effects of Anti-p and IL-4 Stimulation on NRE-specific Binding
Activity in Resting Tonsil B Cells.
Nuclear and cytoplasm ic extracts were prepared as described in Figures 5.2 and 5.3. Cells 
were cultured overnight in complete m edium  and then cultured for up to 4 hours with 
either 0.5 pg/ml anti-p (A), 25 pg/m l anti-p (B) or 400 units/m l IL-4(C). The binding 
activity o f  5pg aliquots o f  protein to y -pP ]-labelled  N R E oligonucleotide w as assessed 
by gel shift assay. Specific binding activities are indicated w ith horizontal arrows. This 
experim ent is reprasentative o f  4 tonsillar preparations.
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Figure 5.6 Effects of Anti-y Stimulation on NRE Binding Activity in Resting
Tonsil B Cells.
Nuclear and cytoplasm ic extracts were prepared as described in previous figures. Cells 
were cultured overnight in complete m edium  and then cultured for up to four hours w ith 
0.5 pg/m l anti-y (A) or 25 pg/m l anti-y (B). The binding activity o f  5pg aliquots o f  
protein to y-['^^P]-labelled NRE oligonucleotide was assessed by gel shift assay. Specific 
binding activities are indicated with horizontal arrows.
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Figure 5.7 Activity of CAT Reporter Gene Constructs in Tonsil B cells cultured
with IL”4
Resting tonsil B cells were transfected with 40 pg o f  the following plasm id DNAs:
Lanes 1 and 2: No plasm id
Lanes 3 and 4 pCD25-CAT-E plasm id
Lanes 5 and 6  pANRE-CAT-E plasmid.
Follow ing this, the cells were rested for an hour and then cultured with either com plete 
medium (Lanes 1, 3 and 5) or with 400 Units/m l IL-4 (Lanes 2, 4, and 6 ) for 48 hours. 
I ’hen they were harvested and assayed for CAT activity by TLC. Panel A  shows an 
autoradiograph o f  the TLC plate and Panel B presents a  phosphorim age analysis o f  the 
TLC data. The units o f  relative reporter activity are expressed as phosphorescence units 
m inus background phosphorescence per m m ^ . Plasm ids were constructed by E. Hew itt 
(Hewitt et al 1997)
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Figure 5.8 Activity of CAT Reporter Gene Constructs in Resting Tonsil B Cells
Cultured with Anti-p.
Resting tonsil B cells were electroporated w ith 40pg o f the following plasm id DNAs; 
Lanes 1, 2 and 3 N o Plasmid
Lanes 4, 5 and 6  pCD25-CAT-E
Lanes 7, 8  and 9 pANRE-CAT-E.
They were then rested for an hour before being cultured with either com plete m edium  
(Lanes 1, 4 and 7), 0.5 pg/m l anti-p(Lanes 2, 5 and 8 ) or 25 pg/m l anti-p  (Lanes 3, 6  and 
9). Follow ing this, they were harvested and assayed for CA T activity by TLC. Panel A 
shows an atuoradiograph o f  the TLC plate and panel B presents a phosphorim age analysis 
o f  the TLC data. Plasmids were prepared by E. Hew itt (Hewitt et al 1997)
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Chapter 6 
General Discussion
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The experim ental data presented in this thesis provide new  insights into the regulation o f  
IL -2R a expression in tonsillar B lymphocytes. In sum m aiy, cross-linking o f  the antigen 
receptor in B cells can increase IL -2R a expression, although anti-Ig antibodies are not 
such potent inducers as IL-4. Engaging the antigen receptor alone cannot cause B cells to 
proliferate; additional signals are required. Furtherm ore, ligating sig  on different subsets 
o f  B cells causes variations in the expression o f  IL -2R a on these cells. Finally, cell 
surface expression can be related to events at the level o f the IL -2R a prom oter.
6.1 The Im portance o f IL -2R a in B C ell Activation.
IL -2 R a  is not thought to be involved in IL-2 receptor signalling. How ever, it is an 
im portant B cell m olecule since its presence allows the high affinity IL-2 receptor to form  
and therefore peim its the B cell to respond to physiological concentrations o f  IL-2. Thus, 
factors w hich can regulate expression o f  IL -2R a play a m ajor role in the fate o f  the B 
cell. D ata from  Chapter 3 show  that polyvalent antibodies, anti-CD40 antibodies and IL-4 
can all induce expression o f  IL -2R a in hum an tonsillar B cells. This induction appears to 
be  both  lineage and species specific. It w ould be o f  some interest to discover w hether any 
other B cell activators can increase IL -2R a expression. L igation o f  B cell M H C class II 
antigen causes signal transduction events w ithin the B cell and can cause up-regulation o f  
IL -2R a in  a hum an B cell line, although this alone cannot cause the cells to proliferate 
(E .Hewitt, personal com m unication).
178
In  the experim ents on prim ary B cells presented here, the physiological relevance o f  IL- 
2 R a  w as confirm ed. O nly B cells w hich had increased levels o f  IL -2 R a  w ere able to 
respond to IL-2 and proliferate significantly. A n additional experim ent w hich could be 
perfonned  to confm n that the presence o f  IL -2R a is crucial for B cell grow th w ould be to 
repeat the proliferation experim ents from  Chapter 3 hut also adding an an ti-IL -2R a 
antibody. I f  this inliibited proliferation, it w ould indicate that IL -2R a is indeed necessary 
for B cell proliferation. It is presim iably necessary for B cell differentiation also, although 
no experim ents were perform ed w ithin this laboratory to determ ine this.
6.2 IL -2R a Expression in D ifferent B Cell Subsets.
The data presented in Chapter 4 appear to support the theoiy that sIgD and sIgM  have 
different functions in B cell signalling, since anti-|u antibodies are capable o f  increasing 
expression o f  IL -2R a w hile anti-5 antibodies are not. It has heen suggested that sIgM  
plays a negative role in B cell signaling w hile ligation o f  sIgD provides a dom inant 
positive response. However, another m odel suggests that the critical param eter w hich 
determ ines w hether a B cell is tolerised or activated via its sIg is not w hether sIgM  or 
sIgD is engaged hut rather the m aturational stage o f  the B cell upon encounter w ith the 
antigen (Norvell and M onroe 1996). Cells isolated from tonsils w ill m ostly  be m ature, 
w ith  sm all num bers o f  im m atine or inem oiy B cells (Butcher and Cushley 1991). A dding 
anti-p  antibodies to tonsillar B cells w ill stim ulate both im m ature and m ature B cells and
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it w as found that low concentrations o f  anti-p  antibodies up-regulate IL -2 R a  expression 
w hile this effect w as not seen at high concentrations o f  the same antibody.
Previous studies in m ice have shown that stim ulation o f  germ inal centre (GC) B cells 
w ith  large amounts o f  soluble antigen can m im ic a situation w here m ature GC cells 
becom e auto-reactive and apoptose. B cells outside the follicle do not die but expand and 
differentiate into antibody secreting cells (Pulendran et al 1995 a, b). A  sim ilar argum ent 
can be used w hen studying the effects o f  anti-p antibodies on IL -2R a expression in 
resting tonsillar B cells. The m ajority o f  B cells in  the tonsil w ill be GC B cells. Cross- 
linking their sIgM  w ith large amounts o f  antibody could provide a signal w hich m im ics 
that o f  large am ounts o f  auto-antigen on FDCs. Thus, GC B lym phocytes m ay be able to 
discrim inate betw een foreign and se lf antigen simply by detennining the size o f  the signal 
received by sig. This hypothesis is supported by the finding that short tem i sig  triggering 
m ay protect GC cells from  apoptosis (Liu et al 1989) w hereas prolonged stim ulation 
leads to death (Shokat and G oodnow 1995; Pulendran et al 1995a; Galibert et a l 1996). 
Therefore, it w ould he interesting to determ ine whether the cells subjected to high doses 
o f  anti-p  antibodies were apoptosing. In addition, further w ork needs to be done to 
separate the im m ature and m ature B cells to determ ine w hether differences in  the 
expression o f  IL -2R a can be seen.
The reason that high doses o f  anti-p  antibodies fail to up-regulate IL -2R a expression has 
been explained above. However, the failure o f B cells to significantly up-regulate IL -2R a
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in  response to sIgD is less easy to explain physiologically. In the m urine system , anti-IgD 
antibodies cause a substantial decrease in the num ber o f  spleen and lym ph node B cells, 
w hen T cell help is blocked w ith anti-CDd antibodies (Finkelm an et al 1995). The loss o f  
B cells occurs slowly over a period o f  2-7 days. A  likely interpretation o f  this is that sIgD 
cross-linking in  the absence o f  additional signals inactivates and eventually deletes m ost 
auto-reactive B cells regardless o f  w hether the auto-reactivity results from  expression o f  
germ line or som atically m utated Ig genes. A ny slight increase in  IL~2Ra expression that 
could be seen as a result o f  ligating sIgD can thus he explained by  the presence o f  any T 
cells w hich m ay he contam inating the B cell preparation.
W hen differentiating into m em ory B cells, GC B lym phocytes recover the ability to 
proliferate in response to sig triggering. Thus, the discovery that anti-y antibodies can up- 
regulate expression o f  IL -2R a in  a do se-dependent m aim er is unsurprising, since these 
antibodies w ould be acting on the sig  o f  m em oiy  B cells and there w ould be no need for 
these cells to becom e tolerised on encountering large amoimts o f  antigen. M em ory B cells 
have been positively selected and are not generally involved in auto-iim nune reponses. 
Further investigations into the responses o f  different subsets o f  B cells within tonsils 
w ould  he o f  m uch interest. It is possible to separate im m ature and m ature B cells from  
each other by panning w ith anti-IgD antibodies. In addition, naive and m em oiy B cells 
can be purified according to the surface expression o f  IgD, IgG, IgA, CD38 and CD44 
(Liu and Banchereau 1996). These experim ents should give pure cultures o f  each B cell
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subset and help provide a clearer picture o f  how  each population o f  B cells responds 
w hen their sig  is ligated.
6.3 CDS^B Cells.
The 67kD a CD5 m olecule is present on B la  lymphocytes. These CD5^ cells produce low 
avidity auto-reactive antibodies (Hayakaw a et a l 1984; Casali et a l 1987; M acK enzie et 
al 1991). The function o f  C D 5 on B cells rem ains unclear but it is thought that CD5^ cells 
form  a separate subset o f  B cells. CD5^ cells express m ore sIgM  and less sIgD than 
conventional B cells. I f  w e assum e that there are two populations o f  B cells present 
w ith in  a tonsillar population (CD5^ and CDS' cells) then it w ould be interesting to 
discover w hether the cells responding to ligation o f  sIgM  by  up-regulating IL -2 R a  are 
CD5^ or not. Studies have shown that CD5^ B cells activated th iough their antigen 
receptor fail to proliferate (Zupo et al 1991) and require IL-2 to enhance their 
proliferative response (Zupo et a l I9 9 l \ Defrance et al 1992). Experim ents in  this thesis 
have show n that anti-p  antibodies fail to up-regulate IL -2R a at h igh concentrations; in 
addition anti-p  antibodies require IL-2 to cause B cells to proliferate. Therefore it w ould 
be o f  interest to determ ine w hether w e have been studying the responses o f  CD5^‘ cells. 
This could be done by  purifying C D 5^ B cells from tonsil B cells by  dual colour 
fluorescence FA CS sorting. However, two points suggest that the responses studied have 
been those o f  conventional (i.e. CDS') B cells. Firstly, any changes in  IL -2R a expression 
seen w hen the cells w ere stim ulated via sig w ere m im icked by  alterations in  CD23
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expression. B cells w hich express CD23 do not express CD5 (W ortis et al 1995) and 
therefore the fact that CD23 and IL -2R a are heing regulated in  the same m anner suggests 
that w e have heen looking at CDS' cells. In  addition, a recent paper has shown that both  
CDS^ and CDS' cells require both  anti~p antibodies and IL-2 to becom e activated and 
proliferate. Therefore, it seems likely that the population o f  B cells responding to anti-p  
antibodies by  altering their expression o f  IL -2R a are CDS' B cells.
6.4 Events at the IL “2R a  Prom oter.
K now ledge o f  the structure and regulatory properties o f  the IL -2R a prom oter region has 
increased greatly over the past few years. There are at least th iee positive regulatory 
regions and two negative regulatoiy regions, all o f  w hich are capable o f  binding large 
num bers o f  transcription factors w hich m ay (or m ay not) act cooperatively and w hich 
m ay be influenced by  various signals from  the cell surface. The experim ents w ith in  this 
thesis have focused on N R E I and PRRj since these, together w ith  PRRm, are believed to 
be involved in the induction o f  IL -2R a expression and therefore o f  greatest interest. The 
m ost clear-cut finding to em erge w as that ligating sIgM  w ith low  doses o f  antibody 
caused N R E-BP to be released from  N R E I. NRE-BP is a protein w hich appears to be 
involved in  the silencing o f  gene transcription. A t high concentrations o f  anti-p  antibody, 
N R E-B P rem ains bound to the prom oter. These experiments w ere confirm ed by  reporter 
gene assays w hich used deletion constructs o f  the IL -2R a prom oter region. Thus, it is
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possible that N R E-BP could play a role in B cell tolerance, w hen sIgM  is stim ulated by 
large am ounts o f  antigen, preventing an auto-reactive response.
A s expected, on culturing B cells w ith anti-5 antibodies, N R E-BP rem ained bound to the 
prom oter. However, it w as surprising that anti-y antibodies failed to affect N R E-BP 
activity. These antibodies m ay be acting potently upon proteins w hich are hound to 
another site w ithin the prom oter. Previous studies have com pared signaling through the 
sIgM  and sIgG  com plexes and discovered several differences. It was found that the 
com bination o f  anti-p antibodies and a phorbol ester was m itogenic in  tonsil B cells bu t 
that anti-y antibodies and phorbol ester did not elicit a proliferative response (Roifinan et 
al 1987). In addition, protein tyrosine phosphorylation patterns w ere studied in  a  variety 
o f  B cell lines representing different stages o f  B cell m aturation and there w ere distinct 
differences betw een sIgM  and sIgG  bearing cells (Law et al 1992). Finally, it w as 
discovered that anti-p  and anti-y antibodies m odulate c-fos R N A  levels differently in 
hum an B lym phocytes (Shu et al 1994). N ow  we have determ ined that sIgM  and sIgG  are 
also acting differently in  the regulation o f  IL~2Ra and have pinpointed a transcription 
factor (NRE-BP) w hich appears to p lay a role in this variation. It m ay be that sIgG  acts 
upon another factor binding to a different site w hich is able to induce IL -2R a gene 
expression even though N R E-BP rem ains bound to the prom oter.
H ow ever, there m ay he another explanation for the differences seen. B oth  sIgM  and sIgG  
are associated w ith the transm em brane proteins, Ig -a  and Ig-p/y (Reth 1992). In  addition.
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it w as discovered that sIgG can also be expressed at the cell surface in another fonn. It is 
fixed in  the m em brane by  a glycosyl phosphatidylinositol anchor instead o f  Ig -a  and Ig- 
p/y (W illiam s et a l 1993). Thus, the differences observed m ay sim ply be due to the 
configuration in w hich sIgG  exists in  these cells. It w ould be interesting to discover 
w hether sIgE+ and sIgA+ m em ory B cells behave in the same w ay as sIgG+ cells; 
how ever such behaviour w ould he difficult to assess as they are only present in the tonsil 
in  tiny num bers.
6.5 Sum m ary
The experim ents w ithin this thesis have shown that, together w ith  IL-4, anti-Ig antibodies 
and anti-CD40 antibodies are capable o f  up-regulating cell surface IL -2R a on hum an 
tonsillar B cells. W hen different subsets o f  the B cell population are stim ulated v ia  their 
respective sig receptors there are differences in  the expression o f  IL -2R a seen. In 
particular, stim ulating im m ature and m ature B cells through sIgM  up-regulates 
expression w hen low concentrations o f  antibody are used. This response is abrogated 
w hen high concentrations o f  antibody are used. It is possible that the use o f  high 
concentrations o f  anti-p antibodies is m im icking the effects seen w hen large am ounts o f  
auto-antigen is present in  the germ inal centre; the B cells becom e tolerised and w ill not 
provoke a dam aging auto-im m une response. B y studying the b inding o f  N R E-BP to N R E 
I w ith in  the IL -2R a prom oter region, w e have discovered that this transcription factor is
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under the control o f signals transduced via sIgM and therefore may he playing a crucial 
role in B cell tolerance.
There is much work remaining to be done in the area o f IL-2Ra gene regulation. 
Experiments within this laboratoiy are currently heing undertaken to determine the 
identity o f NRE-BP and the intermediate signalling events which affect the binding o f 
this factor to the promoter. However, control o f IL-2Ra expression is undoubtedly 
extremely complex and multiple elements are acting cooperatively to allow induction o f 
IL-2Ra; it may be several years before a clear pictine of the regulation o f  IL -2R a 
expression in B cells emerges.
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